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Abstract 
 
Patients with nephrotic range proteinuria have a higher risk of cardiovascular 
disease through qualitative and quantative changes in lipids and lipoproteins.  
The aim of this study was to examine the effect of omega-3 fatty acids derived 
from fish oil in this population. 
Treatment with omega-3 fatty acids in these patients was well tolerated and 
had a number of beneficial effects. They reduced small dense LDL 
concentration, remnant lipoproteins, VLDL and triglyceride levels. 
Postprandial lipaemia was improved with an improvement in chylomicron 
clearance. However, we found that treatment increased LDL-C and although 
there was a redistribution to protective HDL2 rather than HDL3, HDL-C was 
not significantly increased. Furthermore, there was no improvement in 
endothelial function or inflammatory markers. 
Thus, we do not recommend treatment with omega-3 fatty acids alone for 
dyslipidaemia in this population of patients. The combination of omega-3 fatty 
acids with a statin merits further work. 
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Summary 
Nephrotic range proteinuria is associated with increased risk from CHD. This 
is thought to be in part through qualitative and quantative change in lipids and 
lipoproteins. Among the lipid and lipoprotein abnormalities possessed by 
these patients, increased concentration of triglyceride rich lipoproteins, 
lipoprotein remnants and excess small dense LDL contribute significantly to 
this risk. Furthermore, postprandial lipaemia plays an important role in the 
development of atherosclerosis as triglyceride rich lipoproteins are mainly 
produced in the postprandial state. This suggests that abnormalities of 
postprandial lipoprotein metabolism may contribute to the increase in 
triglyceride rich lipoproteins observed in this population. Low levels of HDL are 
an important risk factor for CVD independent of other factors and increasing 
these levels have been shown to reduce this risk. Experimental and clinical 
data has shown that endothelial dysfunction and inflammation is important 
early in the development of atherosclerosis. Both epidemiological data and 
randomised controlled trials have shown that increased intake of omega-3 
fatty acids is associated with reduced CV disease. Omega-3 fatty acids act 
through a number of mechanisms. Their main effect on lipoprotein metabolism 
results in a reduction in triglyceride levels. They also have anti-thrombotic, 
anti-inflammatory and anti-arrhythmic properties contributing to their beneficial 
effect on CV disease.  
The main hypothesis of this research was that omega-3 fatty acids have the 
ability to correct the dyslipidaemia of proteinuric renal disease. First, we aimed 
to examine whether omega-3 fatty acids provided adequate triglyceride 
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lowering effects and consequent benefits on LDL phenotype and HDL 
concentration. Next, we aimed to examine whether omega-3 fatty acids 
improved postprandial lipaemia in this population and finally we aimed to 
assess their effect on endothelial function.  
We recruited 19 patients with primary glomerular disease and nephrotic range 
proteinuria and compared them with normal controls. Patients and controls 
were treated with 4g daily of omega-3 fatty acids for a period of 8 weeks. 
Treatment was generally well tolerated with only one patient withdrawing due 
to adverse gastrointestinal side effects. An additional patient withdrew prior to 
commencing the study, therefore we analysed 17 patients. 
At baseline, patients with nephrotic range proteinuria had increased 
concentration of total cholesterol, plasma triglyceride, VLDL, remnant 
lipoproteins and small dense LDL (LDL III). Omega-3 fatty acids reduced 
triglyceride rich lipoproteins, remnant lipoproteins and LDL III in the patients 
with nephrotic range proteinuria but also increased LDL-C. However, the 
increase in LDL-C was also associated with a redistribution to larger, lighter 
and potentially less atherogenic LDL.  
Postprandial lipaemic response was assessed following a fat load both pre 
and post treatment with omega-3 fatty acids. Postprandial chylomicron 
concentration was greater in the patients with nephrotic range proteinuria 
compared with the controls at baseline but postprandial VLDL1 concentration 
did not differ between the two groups. Treatment with omega-3 fatty acids 
reduced postprandial chylomicron in the patient group but not the controls. 
Postprandial VLDL1 was not affected by treatment in patients or controls, 
18 
 
however peak postprandial VLDL1 concentration was significantly lowered in 
all subjects. 
On examining the structure and composition of these chylomicrons, we found 
that patients with nephrotic range proteinuria had significantly higher levels of 
apolipoprotein CII, CIII and E per particle with greater quantities of triglyceride, 
total cholesterol, free cholesterol and phospholipid indicating that these 
particles are bigger. We did not demonstrate any difference in the structure or 
composition of VLDL1 particles between patients and controls. However, 
despite the reduction in postprandial chylomicron concentration observed post 
treatment; omega-3 fatty acids did not influence the structure or composition 
of either chylomicrons or VLDL1 in patients or controls. This suggests that any 
improvement in postprandial dyslipidaemia results from reduced chylomicron 
synthesis rather than any change in their structure.  
HDL subfractions were measured in both patients and controls at baseline 
and following treatment with omega-3 fatty acids. There was no difference in 
the concentration of these subfractions in patients compared with controls. 
Treatment had a beneficial effect on the HDL subfractions with an increase in 
protective HDL2 and a reduction in HDL3 concentration in spite of any change 
in HDL-C. 
Finally, we measured microvascular endothelial function using the technique 
of laser doppler imaging and also by analysing markers of endothelial function 
and inflammation in the patients compared with the controls. We were unable 
to demonstrate a difference in endothelial function but plasma PLA2 were 
increased in the patients at baseline. Omega-3 fatty acids did not affect 
endothelial function or markers of inflammation in patients or controls. 
19 
 
In conclusion, in this research we have shown that omega-3 fatty acids have a 
number of beneficial effects on lipids and lipoproteins in patients with 
nephrotic range proteinuria. However, any potential benefit that may result 
has to be balanced against the increase in LDL-C and so monotherapy with 
omega-3 fatty acids in this population may not be advisable. We suggest that 
the combination of omega-3 fatty acids and HMG Co A reductase inhibitor 
merits further investigation to ascertain whether this is the optimum 
therapeutic option to achieve the dual goal of reducing triglyceride rich 
atherogenic lipoproteins as well as LDL-C in this high-risk patient population. 
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Chapter 1: Introduction 
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1.1 Cardiovascular Risk and Proteinuria 
The presence of excess urinary protein is associated with increases in both 
cardiovascular disease (CVD) and coronary heart disease (CHD)(1). An 
increasing number of studies have suggested that microalbuminuria is a risk 
factor for CVD. This risk has been shown to increase as the level of 
proteinuria increases. In the „HOPE‟ (Heart Outcomes Evaluation Trial),which 
examined 3577 diabetics aged 55 or over with either one previous 
cardiovascular event or risk factor, microalbuminuria was associated with 
increased risk of the combined end-point of myocardial infarction, stroke or 
cardiovascular (CV) death in patients with and without diabetes(2). This risk 
increased as the level of proteinuria increased. In studies examining the 
general population, this risk is evident even at low levels of albuminuria, 
independent of other CV risk factors(3;4). In a population based study 
examining over 40,000 subjects, increased urinary albumin excretion was 
associated with increased CV mortality independent of other risk factors(3). 
Klausen et al found a 2 fold increase in the relative risk of CHD and a 1.9 fold 
increase in relative risk of death in subjects with low levels of 
microalbuminuria independent of age, sex, creatinine clearance (CrCl), 
diabetes mellitus, hypertension and plasma lipids(4).  This risk is higher in 
patients with persistently positive dipstick proteinuria as found in the MRFIT 
study(5). This showed that patients with 1+ of persistently positive dipstick 
proteinuria was associated with a 2 fold relative risk of death from CHD, 
increasing to 2.5 fold with 2+ proteinuria(5). Furthermore, Miettinen et al 
demonstrated that clinical proteinuria (>300mg/l) was associated with a 5 fold 
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increase in the incidence of stroke in non-diabetics(6). This risk increases 
further in patients with nephrotic range proteinuria. Ordonez et al showed that 
patients with nephrotic range proteinuria (>3g/24hrs) possessed a 3 fold 
increase in the risk of CHD death and 5.5 fold increase of myocardial 
infarction independent of hypertension and smoking (7). There are, however, 
no prospective intervention trials examining risk reduction in patients with 
nephrotic range proteinuria. 
The precise mechanism behind the association of proteinuria with CV risk is 
unknown. Glomerular capillary leaking of albumin may be a manifestation of a 
widespread vascular process caused by atherosclerosis (8;9). A link between 
microalbuminuria and endothelial dysfunction has been observed (10). Non-
diabetic hypertensive patients with microalbuminuria have been shown to 
have higher levels of von Willebrand factor (vWF) antigen than those without 
microalbuminuria(11). vWF is a glycoprotein which is secreted in larger 
amounts when there is damage to the vascular endothelium, therefore 
microalbuminuria may reflect damage to the systemic vascular endothelium.  
It is not clear whether proteinuria leads to increased CV risk or whether 
proteinuria is a marker of increased risk. However, nephrotic range proteinuria 
is associated with a number of qualitative and quantative changes in lipids 
and lipoproteins (described later), which contribute to the increased CV risk. 
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1.2 Normal Lipoprotein Metabolism 
1.2.1 Lipids 
Lipids play an important role in metabolism as they are both a source of 
energy, are essential for the structure of cell membranes and precursors to 
essential vitamins and hormones. Cholesterol and phospholipid are required 
for the formation of the cell membrane. Cholesterol also acts as a precursor 
for vitamin D, bile acids and steroid hormones. Triglycerides provide a high 
energy source. These lipids are hydrophobic neutral particles and cannot be 
transported in the circulation in their free form. As a result, they are bound to 
proteins and other lipids to form amphipathic lipoprotein particles. 
 
1.2.2 Lipoproteins 
Lipoproteins are globular particles with differing lipid and protein content. They 
can be classified by a number of different methods; size, density, flotation 
constant and electrophoretic mobility. The most widely used method of 
classification is when lipoproteins are classified by density ultracentrifugation 
(12).This divides lipoproteins into 5 main classes: chylomicrons, very-low 
density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density 
lipoprotein (LDL) and high density lipoprotein (HDL). The properties of these 
are outlined in table 1.1. 
Lipoproteins may also be classified according to their protein component 
(apolipoprotein).  Each lipoprotein contains one or more apolipoproteins. 
Individual apolipoproteins control lipoprotein metabolism in a variety of ways 
such as by binding to specific cell membrane receptors or by acting as co-
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factors for enzymes involved in lipoprotein metabolism. They are also 
essential for the structural integrity of lipoprotein particles. These properties 
are outlined in table 1.2. 
Chylomicrons are the largest lipoprotein and are also the lightest. They are 
synthesised in the intestine from dietary fat. The main apolipoprotein is apo B-
48 but acquires apo CII and E. Chylomicrons have a high triglyceride content. 
VLDL are the next step down in terms of density and size. They contain 5 –
12% protein, 50-55% triglyceride, 18 –20% phospholipid, 12 –15% cholesteryl 
ester and 8 –10% free cholesterol. They differ from chylomicrons in that they 
are synthesised in hepatocytes and their main function is the transport of 
endogenously synthesised triglyceride. Furthermore, in contrast to 
chylomicrons, the main apolipoprotein is B-100. They also contain apo CII, 
apo CIII and apo E.  VLDL can be separated into 2 subfractions by 
cumulative- gradient ultracentrifugation according to their flotation coefficients. 
VLDL1 (Sf 60-400) is larger, lighter and rich in triglyceride while VLDL2 (Sf 20-
60) is smaller, denser and more enriched in cholesteryl ester. VLDL1 and 
VLDL2 production is regulated independently. VLDL1 is associated with raised 
triglycerides (13).  It is metabolised slowly and is integral to the formation of 
small dense LDL, whereas VLDL2  is metabolised more rapidly to IDL and 
LDL. 
IDL is smaller than VLDL and more dense. It is composed of 10-12% protein, 
24- 30% triglyceride, 25-27% phospholipid, 32 –35% cholesteryl ester and 8-
10% free cholesterol. IDL is primarily derived from triglyceride hydrolysis of 
VLDL. IDL is taken up by the liver or undergoes further triglyceride hydrolysis 
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to become LDL. IDL contains both apo-B100 and apo E. Increased plasma 
IDL concentration has been associated with atherogenesis(14). 
 
LDL is smaller than IDL and more dense. LDL contains 20-22% protein, 10-
15% triglyceride, 20-28% phospholipid, 37-48% cholesteryl ester and 8-10% 
free cholesterol. LDL is the main transporter of cholesterol and cholesteryl 
esters. The main apolipoprotein of LDL is B-100 accounting for approximately 
25% of the particle mass. Excess LDL is associated with atherogenesis. LDL, 
itself, can be further subdivided by a number of different methods including 
size, density and electrophoretic mobility. This will be discussed further later. 
HDL is the smallest of the lipoproteins and the most dense. HDL contains 
approximately 55% protein, 3-15% triglyceride, 15-30% cholesteryl ester, 24-
46% phospholipid, 15-30% cholesteryl ester and 2-10% free cholesterol. The 
main function of HDL is in reverse cholesterol transport as it takes cholesterol 
from peripheral tissues to the liver. The main apolipoprotein constituents of 
HDL are AI, and II and also contain apolipoproteins CII, CIII and Apo E. HDL 
may be separated into 2 subclasses, HDL2 and HDL3.  HDL2 is larger and 
richer in lipids and HDL3 is smaller and denser. There is an important inverse 
relationship between HDL and coronary artery disease risk, which will also be 
discussed later. 
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Table 1.1: Properties of Plasma Lipoproteins 
 
________________________________________________________________________________________________________ 
 
Lipoprotein   Density   Particle Size   Flotation Coefficient  Molecular Weight  
 
      (kg/l)             (nm)               (Sf)       
________________________________________________________________________________________________________ 
 
Chylomicron   <0.94    75-1200    >400     50-1000 x 106 
 
VLDL    0.94-1.006     30-80    20-400    10-80 x 106 
 
IDL    1.006 –1.019     25-35    12-20     5-10 x 106 
 
LDL    1.019-1.063     18-25    0-12     2-3 x 106 
 
HDL    1.063-1.21      5-12      0-9*     65-386 x 103 
 
________________________________________________________________________________________________________ 
 
*at solvent density 1.20kg/l 
 
Adapted with permission (15)  
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Table 1.2: Plasma Apolipoproteins  
_______________________________________________________________________________________________________ 
 
Apolipoprotein  Particle    Main Function     Molecular Weight 
________________________________________________________________________________________________________ 
 
A-I    HDL     Accepts cholesterol     28,000 
Ligand for HDL binding 
LCAT activator 
 
AII    HDL     Ligand for HDL     17,500 
         LCAT cofactor 
 
A-IV    HDL     Ligand for HDL     46,000 
         LCAT cofactor  
 
B-48    Chylomicrons   Forms structure     264,000 
 
B-100    VLDL, IDL, LDL   Forms structure     512,000   
         Ligand for LDL receptor 
CII    Chylomicrons, VLDL  Activates LPL     9000 
 
CIII    Chylomicrons, VLDL  LPL inhibitor      9000   
  
E    Chylomicrons, VLDL, IDL,  Ligand for IDL receptor, LDL-RP   34,000 
    Lipoprotein Remnants   & VLDL Receptor 
________________________________________________________________________________________________________ 
 
LCAT=Lecithin cholesterol acyltransferase, LPL= Lipoprotein lipase, LDL-RP= LDL receptor- related protein 
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Figure 1.1 Exogenous Lipoprotein Metabolism 
 
Dietary cholesterol and fatty acids are absorbed in the intestine where triglyceride is synthesised from free fatty acids with glycerol and 
cholesterol is esterified to form cholesteryl esters. These are assembled into chylomicrons. Apo CII and E are acquired as the chylomicrons 
enter the circulation. LPL hydrolyses the core triglyceride making the chylomicrons progressively smaller and releasing free fatty acids 
which are used as an energy source, converted to triglyceride or stored in adipose tissue. The end products are chylomicron remnants, 
which are cleared from the circulation by hepatic chylomicron remnant receptor. 
(FFA = Free fatty acids, TG = Triglyceride, LPL= Lipoprotein Lipase) 
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1.2.3 Exogenous Lipid Metabolism 
Lipoprotein metabolism can be considered as either exogenous or 
endogenous pathways. The exogenous pathway involves transport of dietary 
fat from the intestine (mainly in the form of triglyceride) as chylomicrons to the 
liver (fig 1.1). This pathway begins with the intestinal absorption of dietary 
cholesterol and fatty acids. Triglyceride is synthesised from the combination of 
free fatty acids with glycerol and absorbed cholesterol is esterified to form 
cholesteryl esters within the small intestine. These are assembled to form 
chylomicrons. The main apolipoprotein is B-48 but CII and E are acquired as 
the chylomicrons enter the circulation. Apo-B48 permits lipid binding to the 
chylomicrons but does not bind to the LDL receptor thereby preventing 
premature clearance of chylomicrons from the circulation. Apo C II is a 
cofactor for lipoprotein lipase (LPL), which hydrolyses the core triglyceride 
thus making the chylomicrons progressively smaller and at the same time 
releases free fatty acids. These free fatty acids are used as an energy source, 
converted to triglyceride or stored in adipose tissue. The end product of 
chylomicron metabolism is chylomicron remnants, which are cleared from the 
circulation by hepatic chylomicron remnant receptor, for which apo E is a 
ligand. Surface components are transferred from the chylomicron remnants to 
HDL. 
 
1.2.4 Endogenous Lipid Metabolism 
The endogenous pathway involves transport of lipids, which are synthesised 
in hepatocytes to peripheral tissues. This pathway begins with the synthesis of 
VLDL particles in the liver, which are released as nascent VLDL particles 
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containing apo A-I, and B-100. Apolipoproteins CII, CIII and apoE are picked 
up from circulating HDL. As VLDL passes through the circulation, its structure 
is altered. Triglyceride is removed through the action of LPL (activated by apo 
C-II) generating either VLDL remnants or IDL. Surface components including 
the C and E apolipoproteins (originally donated from HDL) are transferred to 
HDL. In addition to this hydrolysis, a large amount of exchange takes place 
between VLDL and HDL. Cholesteryl ester is transferred from HDL to VLDL in 
an exchange reaction that concomitantly transfers triglyceride from VLDL to 
HDL. This is mediated through cholesteryl ester transfer protein (CETP). 
Therefore, VLDL particles lose triglyceride via lipolysis and become 
cholesteryl ester enriched via the action of CETP thereby forming IDL. Further 
hydrolysis of IDL is mediated via hepatic lipase allowing further depletion of 
triglyceride and loss of apoE, which in turn leads to the formation of a smaller 
particle LDL. 
 
1.2.5 HDL Metabolism 
The protective effect of HDL is largely through reverse cholesterol transport, 
which removes excess cholesterol from cells and atherosclerotic plaques.  
Small nascent HDL particles are synthesised in the liver and intestinal cells. 
These particles acquire free cholesterol from peripheral tissue via the 
adenosine triphosphate- binding cassette protein A1 receptor (ABCA1). Free 
cholesterol is esterified by lecithin cholesterol acyltransferase (LCAT) forming 
cholesteryl ester, which moves to the particle core and results in larger, 
mature HDL particles. These particles transport cholesterol to the liver by 
interaction with the scavenger receptor class B1 receptor (SRB1) which frees 
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them to recirculate and participate in another cycle of reverse transport. The 
major apolipoprotein on HDL is A-1. Apo A-1 is involved at many points 
throughout this pathway namely interaction with the ABCA1 receptor, 
activation of LCAT and recognition of the SRB1 receptor. This pathway allows 
the removal of cholesterol from peripheral sites such as arterial vessel walls. 
Both the HDL mediated reverse cholesterol transport pathway in combination 
with the endogenous lipoprotein pathway involving the apo B containing 
lipoproteins (VLDL, IDL and HDL) allow exchange of cholesterol and 
triglyceride mediated by CETP. Thus, cholesterol within HDL is exchanged 
with triglyceride within Apo B containing particles enabling transport to the 
liver and removal from the circulation by the LDL receptor(16). 
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Figure 1.2 Endogenous Lipoprotein Metabolism 
 
VLDL is synthesised in the liver and released as nascent VLDL particles containing apo A-I, and B-100. Apolipoproteins CII, 
CIII and apoE are picked up from circulating HDL. As VLDL passes through the circulation, triglyceride is removed through 
the action of LPL (activated by apo C-II) generating either VLDL remnants or IDL. Further hydrolysis of IDL is mediated via 
hepatic lipase allowing further depletion of triglyceride and loss of apoE, which in turn leads to the formation of a smaller 
particle LDL. 
(TG= Triglyceride) 
Nascent VLDL 
Apo B100 
Mature VLDL 
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1.3 Dyslipidaemia and Atherosclerosis 
1.3.1 Cholesterol and LDL-C 
The association between hypercholesterolaemia and CVD was initially based 
on epidemiological data. Studies have demonstrated a continuous graded 
correlation between cholesterol and risk of CHD (17;18). The impact of 
cholesterol lowering in both primary prevention and secondary prevention of 
CVD is now well established. 
The West of Scotland Coronary Prevention Study (WOSCOPS) is one of the 
most important studies examining the use of statins in primary prevention. 
Treatment with pravastatin significantly reduced cholesterol and LDL-C levels 
as well as CV end-points(19). A subsequent meta-analysis of primary 
prevention trials using statins also shows reductions in cholesterol and CVD 
mortality(20).  
There have been many trials examining the effect of cholesterol lowering in 
secondary prevention. A number of studies have looked at the effect of 
cholesterol lowering on the regression of atherosclerosis. These studies 
evaluated regression either through coronary angiography (21-23) or 
ultrasonic techniques (24;25). Furthermore, there have been several large 
studies assessing clinical outcome with lipid lowering. The Scandinavian 
Simvastatin Survival Study (4S) found a 25% reduction in cholesterol and 
35% reduction in LDL-C with a significant reduction in mortality in over 4000 
patients treated with simvastatin(26). More recently, in the „Treating to New 
Targets‟ (TNT) study, LDL-C levels were significantly lower (2.0 mmol/l with 
80mg of atorvastatin vs 2.6 mmol/l with 10mg). Fewer patients reached the 
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primary end-point which was a major CV event in the high dose arm (27). The 
benefit of lipid lowering in patients in the absence of substantially elevated 
lipid levels has been observed. The Cholesterol and Recurrent Events 
(CARE) study included patients with a mean total cholesterol of 5.4mmol/l, 
and LDL-C of 3.6mmol/l. Treatment with pravastatin significantly reduced the 
combined end-point of coronary death and non fatal myocardial infarction 
(28). 
 
1.3.2 HDL 
Low levels of plasma HDL-C are a significant independent predictor of 
increased risk of CHD. This has been demonstrated in several observational 
studies. The Framingham Heart study showed that, in the normal population, 
the risk for myocardial infarction increases by about 25% for every 0.13mmol/l 
reduction in HDL-C (29). This is also evident in patients already diagnosed 
with CHD. An analysis of the LIPID and CARE studies encompassing over 
13,000 patients, revealed that low HDL-C was a significantly stronger 
predictor of CHD in patients with LDL-C less than 125mg/dl (3.2mmol/l) 
compared with those with LDL-C greater than or equal to 125mg/dl (30). 
This cardioprotective effect is due to, in part, its role in reverse cholesterol 
transport. Furthermore, HDL is thought have a number of other protective 
effects. These include anti-inflammatory, anti-oxidant and pro-fibrinolytic 
effects (31). 
There are several studies examining the effect of raising HDL.  The Veterans 
Affairs High Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) 
compared treatment with gemfibrozil to placebo in over 2000 patients with 
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CHD. There was 6% increase in mean HDL concentration and significant 
reductions in nonfatal MI and CHD death in the gemfibrozil arm. This 
reduction in nonfatal MI and CHD deaths correlated with HDL and was 
independent of changes in LDL-C or triglyceride concentrations (32). The HDL 
Atherosclerosis Treatment Study examined a combination of simvastatin and 
niacin therapy. This combination reduced LDL-C by 42%, increased HDL-C by 
26%, induced regression of angiographic atherosclerosis and reduced the 
likelihood of sustaining a CV event. The magnitude of reduction in CV events 
and increase in HDL in this study was much greater than in studies which 
used statins alone, suggesting that the additional effect of raising HDL 
provides further benefits (33).  
 
1.3.3 Remnant Lipoproteins 
Remnant lipoproteins are formed from chylomicrons or VLDL particles, which 
have been partially metabolised by LPL. These particles are heterogeneous in 
size and composition and determined by plasma triglyceride concentration. 
Elevated remnant lipoproteins are associated with atherosclerosis. Patients 
with established coronary artery disease have been found to have increased 
levels of remnant lipoproteins(34;35). Karpe et al found that carotid artery 
intima-media thickness was positively related to baseline plasma remnant-like 
protein cholesterol (RLP-C) independently of plasma triglyceride and LDL 
levels (36). Two further Japanese studies have shown that elevated RLP-C 
levels were predictive of future coronary events in patients with CHD 
independent of other risk factors (37;38). 
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1.3.4 Oxidized LDL 
It is has been suggested that there is a link between lipids and inflammation in 
the development of atheroma. LDL, which is present in the lipid fraction of 
atheroma within the intima, undergoes oxidative modification. These modified 
lipids have a number of pro-atherogenic properties. They induce expression of 
adhesion molecules, chemokines, proinflammatory cytokines and other 
inflammatory mediators. They are also immunogenic and so capable of 
inciting T cell responses, which in turn can incite local responses within the 
plaque. 
The association of oxidized LDL with CHD has been observed in a number of 
studies. Elevated plasma levels of oxidized LDL has been observed in 
patients with stable CHD compared with healthy controls (39). Ehara et al 
demonstrated that oxidized LDL levels correlated with the severity of acute 
coronary syndromes (40). In addition, Toshima et al found concentrations of 
oxidized LDL in patients with angiographically proven CHD to be 1.9 times 
higher than controls (41). 
 
1.4 Postprandial Lipaemia 
Postprandial lipaemia was first suggested to be linked with atherosclerosis in 
1979 by Zilversmit (42). Triglyceride rich lipoproteins (TRLs) are mainly 
produced postprandially (43;44). The triglyceride rich particles (chylomicrons 
and VLDL) are metabolised by LPL into glycerol and free fatty acids as 
described earlier. LPL activity is the rate-limiting step in the postprandial 
phase; therefore competition for this enzyme leads to accumulation of VLDL, 
as chylomicrons are the preferred substrate for LPL. This competition is more 
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likely to occur in the presence of fasting hypertriglyceridaemia such as in type 
II diabetes.  Strong positive correlations between fasting triglyceride and 
postprandial triglyceride concentrations have been observed (45). However, 
subjects with normal fasting levels of triglyceride have also been found to 
have impaired lipoprotein clearance (46).  
Clinical studies have shown that peak and late postprandial triglyceride 
concentrations as well as retinyl palmitate (a marker of intestinally derived 
TRLs) are associated with CHD (47-52).  Simpson et al observed a prolonged 
and exaggerated period of hypertriglyceridaemia following a fat load and 
increased levels of retinyl palmitate in patients with severe CHD (51). Patients 
with CAD have also displayed a delay in the normalisation of triglyceride 
concentration and delayed clearance of retinyl esters (48). Furthermore, in a 
study by Patsch et al, both the maximal triglyceride increase and the 
magnitude of the postprandial triglyceride response following a fat load were 
higher in patients with CHD (50). Increased levels of chylomicron remnants 
have been shown to be related to the rate of progression of coronary lesion in 
post myocardial infarction males (53). Carotid intima-media thickness (IMT) is 
used as a surrogate marker for atherosclerosis. In one study of healthy males, 
following a fat load, the subsequent triglyceride response was related to IMT 
independent of other clinical risk factors (54). In summary, it is clear that there 
is a well-established relationship between postprandial lipaemia and 
atherosclerosis. Currently, the assessment of postprandial lipaemia is through 
the administration of a standard fat load followed by regular venesection for 
eight hours. However, this means of assessment cannot be applied to large 
numbers of patients in a clinical setting and so a more practical method for the 
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assessment of postprandial lipaemia would need to be developed before this 
can be applied as a useful clinical tool. 
 
 
1.5 The Atherogenic Lipoprotein Phenotype 
The Atherogenic lipoprotein phenotype (ALP) is a term used to describe a 
collection of proatherogenic lipoprotein abnormalities. It was defined by Austin 
as hypertriglyceridaemia, low HDL-C levels and a predominance of small 
dense LDL (55).  
LDL was first subdivided using gradient gel electrophoresis (56) into a discrete 
number of subfraction with differing size and density. Subjects with a 
preponderance of large LDL were labelled as having „Pattern A‟ and those 
with small LDL „Pattern B‟(57) and ALP. „Pattern B‟ has been shown to be 
associated with a three-fold increased risk of myocardial infarction (58). An 
alternative method of analysis that allows quantification of each LDL 
subfraction is through density gradient ultracentrifugation. This divides LDL 
into three main subfractions (LDL I d=1.025-1.034g/ml, LDL II d=1.034-1.044 
and LDL III d=1.045-1.060)(59).  LDL I is large and predominates in 
premenopausal women with LDL II being the most common subfraction in 
males. LDL III is the smallest and most dense subfraction and has been linked 
with CHD in number of studies(58;60-64) (Fig 1.3).It is thought that the 
generation of small dense LDL is as a result of defective clearance or 
overproduction of VLDL (65). Chylomicron metabolism is also affected with 
increased production of chylomicron and chylomicron remnants and HDL falls 
with a shift towards smaller, denser HDL3. ALP has been observed to be 
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common in a number of conditions: diabetes (66), metabolic syndrome (67), 
familial combined hyperlipidaemia (68) and patients with nephrotic range 
proteinuria (69). 
Small dense LDL particles have been associated with CHD in a number of 
studies including cross-sectional, prospective, epidemiological and 
intervention studies (70). Moreover, the National Cholesterol Education 
Program Adult Panel III has accepted small dense LDL as a cardiovascular 
risk factor (71). Whilst, most of the studies have shown that small LDL size is 
a predictor of CHD on univariate analysis only, several studies found LDL size 
to be an independent predictor on multivariate analysis. The Standard Five-
City project found that patients with myocardial infarctions had smaller LDL in 
a nested case control study independent of other factors(60). Griffin et al 
observed that LDL III concentration of > 100 mg/dl conferred a 4.5 fold 
increase in risk of CHD and 6.9 fold increase risk of myocardial infarction (61). 
The Quebec Cardiovascular Study examined 2072 men over a period of 13 
years. They observed a strong association between small dense LDL and risk 
of ischaemic heart disease, (72) again independent of other factors. The 
Pravastatin Limitation of Atherosclerosis in Coronary Arteries Trial (PLAC-1) 
used the technique of Nuclear Magnetic Resonance (NMR) to examine LDL 
particle size in patients with cardiovascular disease. They revealed that small 
LDL particles and not large LDL particles predicted angiographically 
measured disease progression independent of other lipid levels (73). Liu et al 
investigated the association between LDL particle size and carotid artery 
intima thickness (IMT) as a measure of atherosclerosis in asymptomatic family 
members with familial combined hyperlipidaemia (FCHL). They found that on 
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multivariate analysis, smaller particle size was associated with increased 
IMT(74). A further study looking at patients with type II diabetes showed that 
LDL size was the strongest marker of CHD in a multivariate analysis(75). 
Thus, the association between small dense LDL and CHD is well established. 
 
Many theories have been suggested as to why small dense LDL is so 
atherogenic. It has been suggested that small dense LDL is more easily taken 
up by arterial tissue than larger LDL thereby leading to greater accumulation 
in atherosclerotic plaques (76). Another study suggested that the increased 
atherogenicity of small dense LDL was due to decreased hepatic clearance by 
the LDL receptor and enhanced binding to LDL receptor independent sites in 
extra-hepatic tissues such as the arterial wall (77). There is an increase in 
oxidative susceptibility and reduced antioxidant properties in small dense LDL 
further contributing to atherogenicity (78). 
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Figure 1.3 Typical LDL Subfractions in Different Populations 
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1.6 Normal Endothelial Function 
Endothelial dysfunction is thought to play an important role in the initiation and 
progression of atherosclerosis.  It is defined as alterations in the normal 
properties of the endothelium, which leads to impairment of organ function. 
Normal endothelium reduces vascular tone, regulates vascular permeability, 
limits platelet adhesion and aggregation, prevents activation of the 
coagulation cascade and restricts leucocyte adhesion.  Endothelial activation 
is the loss of endothelial anti-inflammatory properties through the increased 
expression of adhesive molecules such as e-selectin, ICAM and VCAM. Nitric 
oxide (NO) is one of the most important mediators released by the 
endothelium. It is a potent vasodilator that inhibits inflammation, growth of 
vascular smooth muscle and aggregation of platelets.  
 
Many different means of assessing endothelial dysfunction have been 
employed most of which usually measures an endothelial cell response to a 
stimulus. Endothelium dependant vasodilatation can be assessed in the 
coronary and peripheral circulation. Coronary angiography has been used to 
assess changes in vascular diameter in response to an infusion of an 
endothelium dependant vasodilator such as acetylcholine (Ach). In a healthy 
vessel, ACh causes a NO mediated vasodilatatory response, which is not 
observed in patients with endothelial dysfunction. Also, intracoronary Doppler 
can be used to measure coronary blood flow in response to stimuli (79). The 
degree of endothelial dysfunction in the peripheral circulation is proportionate 
to the degree of endothelial dysfunction occurring in the coronary arteries 
(80). Assessment of endothelial vasomotion in these peripheral arteries has 
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been shown to correlate with coronary dysfunction (81). Peripheral circulation 
endothelial function can be assessed in the forearm by intra-arterial infusion of 
endothelium dependent vasodilators such as acetylcholine (82). Flow 
mediated dilatation of the brachial artery using high resolution ultrasound is a 
less invasive approach(83). Further non-invasive methods of assessing 
endothelial function are currently emerging such as laser doppler imaging. 
This technique is described later. 
 
 
1.7 Cardiovascular Disease, Endothelial Function and Inflammation 
1.7.1 Endothelial Function 
It is now accepted that abnormalities of endothelial function and inflammation 
play a major role in the development of atherosclerosis. This is supported by 
both experimental and clinical data. Furthermore, there is significant evidence 
for the use of inflammatory markers both as predictors of coronary heart 
disease and prognostic factors for CHD(84-88). 
Normal endothelium does not usually support binding of leucocytes but in the 
presence of early atheromatous changes, patches of arterial endothelial cells 
express selective adhesion molecules on their surface, which bind to various 
classes of leucocytes. Vascular Cell Adhesion Molecule- 1 (VCAM-1) 
expression has found to be increased on endothelial cells overlying atheroma 
(89). This increase in adhesion molecules is found at sites prone to 
developing atheroma, such as branch points in the arterial tree, where there is 
disturbed flow and reduced shear stress, which reduces local production of 
NO. NO has anti-inflammatory properties and can reduce V-CAM 
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expression(90). This disturbed flow can also increase expression of 
intercellular adhesion molecule-1 (ICAM-1) (91). These leucocytes then 
penetrate the intima where they perpetuate a local inflammatory response 
with macrophages ingesting lipid and becoming foam cells. The activated 
leucocytes and arterial cells can release fibrogenic mediators that promote 
replication of smooth muscle cells leading to the development of an 
atherosclerotic plaque. Inflammatory processes also contribute to precipitating 
acute thrombotic complications of atheroma. The activated macrophages 
abundant in the atheroma can produce proteolytic enzymes capable of 
degrading the collagen within the fibrous plaque of the cap allowing it to 
rupture (Figure 1.4). 
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Fig 1.4 Participation of Inflammation in Atherosclerosis 
Reproduced with permission (92). 
A. Leucocyte recruitment to the atherosclerotic plaque. 
B. T-lymphocytes join macrophages in the intima during lesion evolution 
C. Thinning of the fibrous cap caused by alteration of the extracellular 
matrix induced by collagenases produced by foam cells leading to 
plaque rupture 
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1.7.2 Markers of Inflammation 
Elevated levels of several inflammatory markers have shown to be predictive 
of vascular events in several different populations. Prospective 
epidemiological studies have shown associations with increased levels of 
cytokines Interleukin-6 (IL-6) and Tumour Necrosis Factor-α (TNF-α) and 
increased vascular risk(85-87;93). This has also been observed with 
increased levels of acute phase reactants such as C-reactive protein (CRP), 
fibrinogen and serum amyloid A(84;85;94;95). 
The most relevant clinically of these markers is CRP. It is an acute phase 
protein, which is a member of the pentraxin family of innate immune response 
proteins (96). Measurement of highly sensitive CRP (hs-CRP) as a biomarker 
of inflammation and therefore atherosclerosis confers several advantages 
over the measurement of other novel biomarkers. CRP has a long half life and 
is stable without being affected by circadian variation (97). Furthermore, it is 
easily measured with a standardized high-sensitivity assay available.  
Several studies have indicated that increased levels of highly sensitive (hs) 
CRP are strong predictors of cardiovascular disease in healthy subjects(88) 
(Fig 1.5). These studies included men, women, middle-aged and elderly 
subjects. A large British study by Danesh et al showed that higher levels of 
baseline CRP predicted coronary heart disease after adjustment for other 
vascular risk factors (84). Thus, CRP is an important biomarker useful for the 
prediction of vascular risk in most populations of patients independent of other 
factors. 
A number of drugs used in the treatment of CHD have been observed to 
reduce CRP. In the Physicians‟ Health Study, aspirin has been shown to 
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reduce cardiovascular risk to a greater extent in subject with higher levels of 
CRP (95). A number of studies have shown that statins reduce CRP in 
patients with hyperlipidaemia. In the Air Force/ Texas Coronary 
Atherosclerosis Prevention Study (AFCAPS/ TexCAPS), lovastatin reduced 
CRP by almost 15%. In addition, not only was there a significant reduction in 
coronary events apparent in patients with increased total cholesterol to HDL 
ratio but a reduction was also present in patients with an increased CRP but 
no increase in cholesterol:HDL ratio(98).  
 
 
 
 
Fig 1.5 Prospective studies of hsCRP as a predictor for future vascular 
events 
(Reproduced with permission (88)) 
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1.8 Omega –3 Fatty acids 
The cardioprotective effects of omega-3 fatty acids were first noted following 
the observation that the Greenland Inuit had a low mortality from CHD despite 
a high incidence of smoking and obesity. In 1975, Dyerberg and Bang 
suggested that this was due to the high content of omega-3 fatty acids in the 
Inuit diet which comprised mainly of fish, seal and whale (99). 
Omega-3 fatty acids are polyunsaturated fatty acids. These omega-3 fatty 
acids are alpha linolenic acid (LNA), eicosapentenoic acid (EPA) and 
docosahexenoic acid (DHA) (Fig 1.6). LNA is a plant-based source of omega-
3 fatty acid while EPA and DHA are obtained from marine sources. They are 
essential fatty acids and so must be consumed in the diet. Omega- 3 fatty 
acids have a variety of potential cardioprotective properties including effects 
on lipoproteins, inflammation, thrombosis and endothelial function. 
 
1.8.1 Omega-3 Fatty Acids and CHD: Observational Studies 
The observation that the Greenland eskimos had lower mortality due to their 
high fish consumption has lead to several observational studies. A study 
examining middle aged men in the town of Zupthen in the Netherlands found 
that men who rarely or never ate fish had a higher rate of CHD than those 
who ate fish more than once a week(100). Similarly, the Chicago Western 
Electric Study also showed an inverse relationship between fish consumption 
and death from CHD (101) as did the Multiple Risk Factor Intervention Trial 
(MRFIT)(102). Zhang et al found that fish consumption was associated with 
reduced risk from all cause mortality, IHD and stroke across 36 countries 
(103). In women, the Nurses‟ Health Study found that CHD deaths were 50% 
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lower in those women who consumed fish five times a week (104;105). A 
subgroup of these women with diabetes showed a stronger relationship with a 
60% reduction in CHD death in those who ate fish five times a week(106).  
However, not all observational studies have yielded similar results, with some 
studies showing a lack of association. The Health Professional Follow-up 
study showed no association between dietary fish consumption and the risk of 
coronary disease (107). Also, the US Physicians Health study found no 
association between the risk of MI, non-sudden cardiac death or total CV 
mortality but fish consumption was associated with a reduction in total 
mortality (108). There was an inverse association between fish consumption 
and 25 year mortality in the Seven Countries Study but this was no longer 
significant once the effects of saturated fats, flavinoids and smoking were 
taken into account (109).  
Various theories behind the conflicting data have been postulated. End-point 
definitions, experimental design, study populations and type of fish consumed 
have all thought to influence the varying results.  However, a recent meta-
analysis of 13 published cohort studies found a consistent inverse association 
between fish consumption and CHD mortality rates(110).  
 
1.8.2 Randomised Controlled Trials of Omega-3 Fatty Acids 
Several trials have suggested favourable effects of omega-3 fatty acids in 
reducing the risk of CHD. The diet and reinfarction trial (DART) included 2033 
Welsh men(111). It found that patients who received dietary advice on fish 
had a relative reduction in mortality of 29% during the 2 year follow-up mainly 
because of reductions in deaths from CHD. The Physician‟s Health Study 
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(112) found a reduced risk of sudden cardiac death in subjects with increased 
blood  levels of omega- 3 fatty acids. The largest randomised controlled trial 
examining the efficacy of omega-3 fatty acids in secondary prevention of CHD 
was the Italian GISSI-Prevenzione trial, which examined 11, 324 patients with 
a recent myocardial infarction. Patients were randomised to either 300mg of 
vitamin E or 850mg of omega-3 fatty acids, both or neither. After 3.5 years, 
the omega 3 fatty acid group had a reduction in relative risk of 15% in the 
composite end-point of total mortality, non-fatal myocardial infarction and 
stroke with a 20% reduction in all cause mortality and 45% reduction in 
sudden death(113). The Study on Prevention of Coronary Atherosclerosis by 
Intervention with Marine Omega-3 fatty acids (SCIMO) Study demonstrated 
the positive effects of omega-3 fatty acid supplementation on coronary artery 
disease which was assessed angiographically (114). In spite of these large 
studies showing a beneficial effect from fish oil, a recent meta-analysis 
examining 48 randomised controlled trials found that omega-3 fatty acids had 
no effect on total mortality or combined CV events(115).  
 
1.8.3 Effect of Omega-3 Fatty Acids on Lipoproteins 
In a review of human studies, Harris et al reported that 4g daily of omega-3 
fatty acids reduced triglyceride levels by 25 to 30% with a decrease in HDL of 
1 to 3%. However, LDL cholesterol was found to increase by 5 to 10%. The 
triglyceride lowering effect was dose dependant (116). 
Human and animal studies have shown that omega-3 fatty acids inhibit 
hepatic triglyceride synthesis and secretion of VLDL from the liver (117-119). 
The primary mechanism of triglyceride lowering is thought to be via reduced 
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production rather than enhanced clearance of triglyceride rich lipoproteins as 
activity of either postheparin LPL or hepatic lipase has been shown not to be 
stimulated by omega-3 fatty acids (120-122).  
The LDL raising effect of omega-3 fatty acids is well recognised and has been 
observed in both healthy (123) and hyperlipidaemic subjects (124). This effect 
is rare at doses of 1g per day(125). At higher doses (3-5g), the LDL raising 
effect may be offset by a redistribution of LDL to larger sizes(126), thus 
potentially reducing its atherogenicity. The mechanisms behind the LDL 
raising effect of omega-3 fatty acids are unclear. It has been suggested that 
the fish oil down regulates the LDL receptor (127;128).  Changes in LDL 
particle size occur as omega-3 fatty acids suppresses CETP activity thus 
reducing the transfer of cholesteryl ester from HDL to VLDL and LDL thereby 
favouring large cholesterol rich LDL(129). 
Most studies show a beneficial effect of omega-3 fatty acids on HDL. The 
reduction in activity of CETP also affects HDL particles favouring large 
cholesterol rich HDL (HDL2) again through reducing transfer of cholesteryl 
esters from HDL to VLDL(129). 
Omega-3 fatty acids have also been shown to reduce triglyceride levels  
postprandially (130). This effect has been observed in healthy men (131) and 
patients with hypertriglyceridaemia (120). Moreover, they lower postprandial 
chylomicrons and chylomicron remnants (122;131).  
 
1.8.4 Effect of Omega-3 Fatty Acids on Thrombosis 
Omega-3 fatty acids are thought to reduce the risk of thrombosis by affecting 
platelet function and haemostasis. The observation that the Greenland 
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Eskimos had reduced platelet aggregation and prolonged bleeding times 
suggested an important mechanism relating to the reduction of CHD(132). 
They act by displacing arachidonic acid from platelet phospholipid stores, 
decreasing the available substrate for thromboxane A2 synthesis and so 
reducing the ability of thromboxane A2 to induce platelet aggregation, thereby 
resulting in prolongation of bleeding time(133). The results from studies 
examining the effect of omega-3 fatty acids on haemostatic and fibrinolytic 
factors are conflicting(134-137). Thus, omega-3 fatty acids have beneficial 
effect on platelet aggregation but their effect on thrombosis is yet to be 
established. 
 
1.8.5 Effect of Omega-3 fatty Acids on Arrhythmias 
The effect of omega-3 fatty acids on reducing CHD mortality may, in part, be 
attributable to their anti-dysrhythmic effects. Several studies have suggested 
that omega-3 fatty acids are useful in the prevention of atrial and ventricular 
dysrhythmias. These observations have arisen as a result of animal and cell 
culture studies and more recently clinical randomised controlled trials. Studies 
examining rats have revealed that pre-treatment with omega-3 fatty acids 
prevented the initiation and reduced the severity of arrhythmias in response to 
various stimuli (138). In cultured rat cardiac myocytes, omega-3 fatty acids 
inhibited induced tachyarrhythmias (139).  These properties may be as a 
result of incorporation of omega-3 fatty acids into myocardial membrane 
phospholipids affecting electrophysiological properties. In patients with 
implantable cardiac defibrillators, the effect of omega-3 fatty acids on 
arrhythmic events is uncertain but there is no reduction in mortality (140-142).  
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1.8.6 Omega-3 Fatty Acids and Inflammation 
Once again, it was first suggested that omega-3 fatty acids had anti-
inflammatory properties from the epidemiological observations of the low 
incidence of autoimmune and inflammatory disorders in the Greenland 
Eskimos (143). As discussed previously, inflammation plays a key role in the 
development of atherosclerosis and so the anti-inflammatory properties of 
omega-3 fatty acids are thought to contribute further to their cardioprotective 
effects. 
Consumption of omega-3 fatty acids increases EPA in the cell membrane, 
which competes with arachidonic acid as a substrate for cycloxygenase and 
lipoxygenase enzymes. Those derived from arachidonic acid are pro-
inflammatory whereas those derived from omega-3 fatty acids are anti-
inflammatory(144). Furthermore, they suppress the production of pro-
inflammatory cytokines and reduce expression of cell adhesion molecules 
such as I-CAM, V-CAM and e-selectin (145). 
The beneficial anti-inflammatory effects of omega-3 fatty acids have been 
seen in a number of conditions other than CHD. Studies have suggested 
benefits in patients with inflammatory bowel disease (146), rheumatoid 
arthritis (147) and asthma (148). 
 
1.8.7 Omega-3 Fatty Acids and Endothelial Function 
Evidence from in vitro and in vivo studies have shown that omega-3 fatty 
acids are thought to have a beneficial effect on vascular endothelium. Chin et 
al showed an improvement in endothelial function with omega-3 fatty acids 
using forearm venous occlusion plethysmography (149;150). Goodfellow 
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examined endothelial function using non-invasive ultrasonic vessel wall 
tracking of brachial artery flow mediated dilatation (151) and found an 
improvement in the group treated with fish oil. In vitro, Goode et al 
demonstrated an improvement in endothelial function with an in vitro study of 
small arteries from subcutaneous gluteal fat biopsies in hypercholesterolaemic 
patients treated with omega-3 fatty acids(152). 
The mechanism behind these improvements is unclear. It has been suggested 
that omega-3 fatty acids cause changes in the composition of the membrane 
bilipid layer. The in vitro study by Goode et al found that the greatest 
improvement in endothelial function occurred in patients with greater EPA and 
DHA levels in their red cell membrane. Therefore, changes in the membrane 
fluidity may promote increased release of endothelium derived NO in 
response to ACh(152). 
 
1.8.8 Omega-3 Fatty Acids and Hypertension 
As a result of clinical and animal studies, it has been postulated that omega-3 
fatty acids have hypotensive properties. They are thought to stimulate 
prostaglandins that control sodium and water excretion, inhibit thromboxane, 
which is a vasoconstrictor, and regulate renin release(153). A meta-analysis 
of 31 studies showed a significant reduction of 3.4 mmHg  systolic and 2.0 
mmHg diastolic pressure with a 5.6g consumption of omega-3 fatty 
acids(154). Similarly, a further meta-analysis of 17 trials found a 5.5 mmHg 
systolic and 3.5mmHg reduction in diastolic blood pressure with daily doses of 
greater than 3g(155).  
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1.8.9 Omega-3 Fatty Acids in the Treatment of IgA Nephropathy 
Trials of omega-3 fatty acids in the treatment of IgA nephropathy have shown 
conflicting results.  A trial from the Mayo clinic treated patients with 12g daily 
of omega-3 fatty acids. They found at 4 years that patients receiving the fish 
oil had a significantly lower incidence of doubling of serum creatinine and a 
lower incidence of death or end stage renal failure(156). Other studies have 
failed to confirm these results and a meta-analysis of five randomised 
controlled trials concluded that the variation in results were due to differences 
in the duration of follow-up and once this was adjusted for statistically, there 
was no benefit from fish oil treatment (157). A more recent trial by the 
Southwest Paediatric Nephrology Study elucidated no significant difference in 
renal progression observed at 3 years in the patients treated with 4g daily of 
fish oil(158). In summary, there is currently no clear evidence supporting the 
use of omega-3 fatty acids in IgA nephropathy. 
 
1.8.10 Tolerability of Omega-3 Fatty Acids 
The Food and Drug Administration has ruled that intakes of up to 3g daily of 
marine omega-3 fatty acids are generally recognized as safe for inclusion into 
the diet. This includes particular consideration of bleeding tendencies and 
their effect on LDL-C.  
Omega-3 fatty acids are generally well tolerated, with a fishy aftertaste as the 
most commonly reported side effect in most studies. In the GISSI Prevention 
study, when 0.85g of omega-3 fatty acids were given daily to subjects for 3.5 
years, gastrointestinal upset and nausea were the most commonly reported 
side effect (4.9% and 1.4% respectively)(113). In a study examining 275 
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patients given 6.9g daily of omega-3 fatty acids for 6 months, gastrointestinal 
upset was reported in 8% of patients (159).  
 
In summary, both observational and randomised controlled trials have 
suggested that omega-3 fatty acids have cardioprotective properties. In 
addition to their effect on lipids and lipoproteins, they have been shown to 
have anti-inflammatory, anti-thrombotic, anti-hypertensive, anti-arrhythmic 
properties and improve endothelial function as well as being well tolerated. 
However, it is difficult to compare the results of these studies due to differing 
doses and treatment duration. 
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Figure 1.6 Structures of Omega-3 Fatty Acids 
Reproduced with permission (160) 
Structures of the two classes of polyunsaturated fatty acids. The omega 3 
fatty acids have their first double bond at the third carbon molecule from the 
methyl (CH3) end of the fatty acid, whereas the omega 6 fatty acids have their 
first double bond at the sixth carbon molecule. The chemical names for each 
fatty acid are also given: the number of carbon atoms is given first, followed 
by the number of double bonds and the position of the first double bond. 
Omega-6 linoleic acid can be desaturated in certain plants to form omega-3 
linolenic acid. Whereas linoleic acid is mainly converted into arachidonic acid, 
linolenic is elongated and desaturated into eicosapentenoic acid and then 
docosahexenoic acid 
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1.9 Proteinuric Renal Disease 
1.9.1 Dyslipidaemia of Proteinuric Renal Disease 
The prevalence and extent of dyslipidaemia in proteinuric renal disease is 
variable depending on the aetiology of the renal dysfunction,  the degree of 
the renal impairment and level of proteinuria. The association between 
nephrotic syndrome and hyperlipidaemia was first reported in 1917(161).  
However, despite extensive clinical and animal work, the mechanism behind 
this has not yet been fully established. 
The development of nephrotic range proteinuria is associated with abnormal 
lipoprotein metabolism and both qualitative and quantitative changes in lipids 
and lipoproteins. Total cholesterol and LDL are invariably raised (162;163). 
Triglyceride levels may also be elevated (164) and VLDL is raised (162;163). 
Furthermore, it has been shown that patients with nephrotic range proteinuria 
have excess LDL III (165). 
This pattern of abnormalities is probably a result of a number of different 
mechanisms. Firstly, the increase in plasma LDL is thought to be due to 
increased LDL synthesis (166) and reduced catabolism of LDL. Indeed a 
previous study in our laboratory by Warwick et al showed that there was a 
significant reduction in the rate of catabolism of Apo B, which is the main 
constituent of LDL (167;168). Furthermore, Vaziri et al have suggested that 
not only does proteinuria lead to the up-regulation of 3-hydroxy-3-
methylglutaryl (HMG) CoA reductase (the rate-limiting enzyme required for 
cholesterol biosynthesis) but also leads to a deficiency in receptor mediated 
LDL clearance. This results in a limitation of hepatic cholesterol uptake and 
leads to an increase in cholesterol and LDL levels (169). Furthermore, it has 
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been shown that, in patients with nephrotic range proteinuria, there is an 
increase in HDL3 with a reduction in protective cholesterol rich HDL2 (170). 
Proteinuria is thought to lead to urinary losses of lecithin: cholesterol 
acyltransferase (LCAT) which has a similar molecular weight to albumin(171). 
This limits HDL mediated uptake of surplus cholesterol from extra hepatic 
tissues leading to HDL abnormalities and subsequent effect on VLDL and 
chylomicrons (172). The increase in triglyceride rich lipoproteins has been 
shown to be due to impaired chylomicron (173;174) and VLDL clearance 
(173). Deighan et al reported a deficiency of VLDL apolipoproteins in 
proteinuria and hypothesised that this deficiency resulted in its defective 
clearance (175). Impaired lipoprotein lipase activity has been observed in 
patients with proteinuria. LPL is the rate-limiting enzyme involved in lipolysis 
of chylomicrons and VLDL. LPL binds to heparan sulphate proteoglycans on 
the cell surface of the endothelium. Many studies have shown a reduction in 
LPL activity in both nephrotic humans and animals (169).  
 
Data from the Framingham heart study has shown that patients with 
proteinuria have RLP-C and RLP-TG concentrations 2-3 fold higher than the 
reference range for males(176). In patients with nephrotic range proteinuria, it 
has been demonstrated that there is an excess of remnant lipoproteins as well 
as LDL III thereby significantly increasing cardiovascular risk(177). In this 
study, plasma triglyceride level was the most important factor determining LDL 
III and remnant lipoprotein levels.  
The formation of LDL III requires excess triglycerides and hepatic lipase. 
Triglyceride transfers via CETP from VLDL1 to LDL in exchange for 
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cholesteryl ester. This produces a triglyceride enriched LDL particle, which is 
hydrolysed by hepatic lipase resulting in the formation of small dense LDLIII. 
This is also the suggested mechanism for small dense LDL formation in 
proteinurics due to higher levels of triglyceride and the strong correlation 
between triglyceride concentration and LDL III concentrations.  
 
1.9.2 Endothelial Function in Proteinuric Renal Disease 
It has been suggested that proteinuria itself, or pathophysiological changes 
associated with it, may cause endothelial dysfunction. There are a number of 
theories to explain the possible link between proteinuria and endothelial 
dysfunction. These include elevated blood pressure, dyslipidaemia, 
hypoalbuminaemia, disordered coagulation pathways, inflammation and 
oxidative stress that all may occur in proteinuric patients, particularly those 
with the nephrotic syndrome. Endothelial function has been shown to be 
abnormal by both venous occlusion plethysmography(178) and brachial artery 
ultrasound(179), in patients with proteinuria.  
 
3.5  Hypotheses and Aims 
1.10.1 Hypotheses 
The purpose of this project is to examine the ability of omega-3 fatty acids 
derived from fish oils to correct the dyslipidaemia observed in patients with 
nephrotic range proteinuria, thus reducing the risk of coronary heart disease 
(CHD), and to clarify the mechanism underlying this dyslipidaemia.   
It is important to establish a lipid lowering therapy that is effective, tailored to 
the specific problem in proteinuric patients but is also safe and well tolerated.  
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Fish oil derived fatty acids lower plasma triglyceride by reducing VLDL 
production and at the start of the study, Omacor, a therapeutic agent 
containing omega-3 fatty acids in a concentrated form had recently become 
available and seemed an ideal therapy for this population. 
Our main hypotheses are (i) Omacor will be well tolerated in subjects with 
nephrotic range proteinuria and will give adequate triglyceride lowering with 
consequent benefits on levels of small dense LDL and HDL.  (ii) VLDL and not 
chylomicrons (intestinally derived lipoproteins) possess structural 
abnormalities that delay clearance and result in hypertriglyceridaemia.  Fish 
oils will correct this.  (iii) Omacor will improve endothelial function in 
proteinuric patients. 
 
1.10.2 Aims 
The following questions summarise the rationale behind this research: 
In patients with nephrotic range proteinuria: 
1. Does treatment with omega-3 fatty acids give adequate triglyceride control 
with consequent benefits for levels of small dense LDL and remnant 
lipoproteins? 
2. Is postprandial lipaemia improved with omega-3 fatty acids? 
3. Do omega-3 fatty acids have an effect on chylomicron and VLDL1 structure 
and composition? 
4. Are HDL subfractions affected by treatment? 
5. What is the effect of treatment on endothelial function and inflammation? 
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Chapter 2: Methods 
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2.1 Study Population 
19 Subjects with primary glomerular disease, nephrotic range proteinuria 
(defined as either >3g of proteinuria or >2g of albuminuria per 24 hours) and 
serum creatinine <250µmol/l were recruited. Patients with diabetes mellitus or 
who were on steroids, other immunosuppressive agents or warfarin treatment 
were excluded.  Comparisons were made with age and sex matched controls. 
If used, lipid-lowering treatment was stopped 4 weeks prior to the study and 
restarted following the study. All patients and controls gave written consent 
prior to participating and Glasgow Royal Infirmary Research Ethics Committee 
approved the study. Patients and controls attended after an overnight fast. 
The laser Doppler scan was carried out as outlined in chapter 8. An 
intravenous cannula was inserted and fasting samples were taken. A fat load 
amounting to 90g of fat in the form of “Calogen” drink was given to the 
subject. Subsequent samples were taken at 2, 4, 6 and 8 hours following the 
fat load. This procedure was repeated after 8 weeks treatment with Omega-3 
fatty acids (Omacor) 2g twice daily.  
 
2.2 Statistical Power 
Sample size calculations are to give 80% power at α = 0.05. Omacor reduces 
triglyceride levels by 37% in subjects with hypertriglyceridaemia and 27% in 
familial combined hyperlipidaemia(180). To detect a 30% change in 
triglyceride concentration, 17 subjects will be required. 
Based on results from a previous study comparing VLDL apolipoprotein 
content in subjects with proteinuria and controls, each VLDL particle in 
controls contained 10 moles of apoCII, 30 moles of apoCIII and 0.5 moles of 
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apoE(175).  A meaningful difference in apoCII between proteinurics and 
controls would be 4 moles per lipoprotein particle. Using a standard deviation 
(SD) of 2.5 for this measurement, 8 subjects will be required in each group. 
For apoCIII, 17 subjects would be required for a meaningful change of 15 
moles/particle(SD 15). For apoE, 17 subjects would be required for a 
difference between proteinurics and controls of 0.3 moles/particle (SD of 0.3).  
The apolipoprotein content of patients and controls post treatment with 
Omacor will be compared by ANOVA. For apoCII to detect a difference of 4 
moles/particle (SD 2.5), 8 patients will be required.  For apoCIII, (difference of 
15 moles/particle, SD 15), sample size =17. For apoE (difference of 0.3 
moles/particle (SD 0.3), sample size =17.  
The sample size being studied is small and so if the standard deviation 
exceeded those predicted or if there is marked heterogeneity within the 
population, there will be a significant chance of a Type II error. Given that a 
number of variables studied are inter-related, formal statistical advice was that 
correction for multiple comparisons was not necessary. However, we 
acknowledge that multiple analyses could result in statistically significant 
results by chance and so therefore we have endeavoured to avoid over 
interpreting the data. 
 
2.3  Quantification of Lipoproteins 
VLDL cholesterol, LDL cholesterol and HDL cholesterol were measured 
according to the Lipid Research Clinics Program Manual of Laboratory 
Operations (1975)(12). VLDL (d 1.006g/ml) was isolated by ultracentrifugation 
at 35 000 rpm at 4 C for 18 hours in a Beckman Ti 50.2 rotor. LDL was 
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precipitated by adding an equal volume of 92mmol/l sodium heparin (5x105) / 
Mn Cl2(181). This was followed by centrifugation at 10,000 rpm at 4 C for 30 
minutes. HDL remained in solution. Cholesterol measurements were carried 
out on total plasma, VLDL and HDL. The HDL level was subtracted from the 
cholesterol content of the supernatant giving LDL cholesterol. All coefficients 
of variations (CV) were less than 2%. 
 
2.4 Preparation of Chylomicrons 
Chylomicrons were isolated by a short ultracentrifugation at a density of 
1.006g/ml. 2ml of plasma was overlayered with 4ml d=1.006g/ml solution and 
centrifuged in a Beckman Ti 40.3 rotor at 4 C for 30 minutes at 10,000rpm. 
The chylomicrons were removed carefully using a finely drawn glass Pasteur 
pipette in 2ml. The 2 ml removed were then overlayered with 4ml d=1.006g/ml 
solution and centrifuged in a Beckman Ti 40.3 rotor for 16 hours at 15 C at 
35,000rpm for 16 hours. The purified chylomicrons were removed using a 
finely drawn Pasteur glass pipette. 
 
2.5 Isolation of VLDL1 (Sf 60-400), VLDL2 (Sf 20-60), IDL (Sf 12-20) and LDL   
(Sf 0-12) 
VLDL1 (Sf  60-400), VLDL2 (Sf 20-60), IDL (Sf 12-20), LDL (Sf 0-12) were 
isolated from fresh plasma by modification of the cumulative gradient 
ultracentrifugation method (15). Stock solutions of density 1.006g/ml and 
1.182g/ml were prepared using NaCl, NaBr and Na2EDTA. These were used 
to make 6 density solutions, which ranged from 1.0588 to 1.0988g/ml. The 
density of 2mls of plasma (after removal of chylomicrons described above) 
66 
 
was adjusted to 1.118g/ml using 0.341g NaCl. The adjusted plasma was 
carefully overlayered by the density solutions as described in Table 2.1. 
Ultracentrifugation of the sample was performed as outlined in Table 2.2. 
Samples were carefully removed after each run using a finely drawn Pasteur 
pipette. 
VLDL1 was removed in 1ml, VLDL2 and IDL in 0.5ml, and LDL in 1ml. After 
removal of VLDL1, The sample was overlayered with 1ml of 1.0988g/ml 
density solution. 
 
 
 
Table 2.1 Density Gradients for Separation of VLDL1, VLDL2, IDL and 
LDL 
Solution    Density (mg/l)  Volume (mls) Position 
6   1.0588    2  Top 
5   1.0641    2    
4   1.0722    2 
3   1.0790    2 
2   1.0860    1 
1   1.0988    1 
Plasma  1.118 (adjusted)   2 
   1.182     0.5  Bottom 
 
(Adapted with permission(15)) 
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Table 2.2 Conditions for Preparation of VLDL1, VLDL2, IDL and LDL  
  Sf   Speed (rpm)   Time (h/min) 
______________________________________________________________ 
VLDL1  60-400  39,000    1.38 
VLDL2  20-60   18,500    15.41 
IDL  12-20   39,000    2.35 
LDL  0-12   30,000    21.10 
______________________________________________________________ 
(Adapted with permission(15)) 
 
2.6 LDL Subfraction Analysis 
Three LDL subfractions were separated directly from fresh plasma by 
nonequilibrium density gradient ultracentrifugation(59). Again, stock solutions 
of density 1.006g/ml and 1.182g/ml were prepared using NaCl, NaBr and 
Na2EDTA. These were used to make 6 density solutions, which ranged from 
1.060g/ml to 1.019g/ml. The density of plasma was adjusted to 1.09g/ml by 
using KBr. The adjusted plasma was carefully overlayered as described in 
Table 2.3 in an ultraclear Beckman SW 40 tube, which had been coated with 
polyvinyl alcohol. This was centrifuged for 24h at 40,000rpm at 23°C in a 
swinging bucket rotor with slow acceleration and no deceleration. The 
gradient containing separated LDL subfractions was displaced upwards by a 
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dense hydrophobic material (Maxidens 1.9g/ml), which was introduced using 
a constant infusion pump at a flow rate of 0.5ml/min. The presence of 3 
fractions (LDL I d 1.025-1.034 g/ml, LDL II d 1.034-1.044 g/ml and LDL III d 
1.044-1.063 g/ml) was detected by continuous monitoring at 280nm. The 
individual subfraction areas were quantified, corrected for previously 
calculated extinction coefficients and expressed as a percentage of total LDL. 
The lipoprotein mass of LDL (d 1.019 –1.063 g/ml) was determined and used 
to generate individual subfraction concentrations in mg lipoprotein per 100ml 
plasma. 
 
Table 2.3 Density Gradient for LDL Subfractions 
Solution        Density (mg/l)  Volume (ml)           Position 
______________________________________________________________ 
6    1.019         1   Top 
5    1.024         2   
4    1.034         2  
3    1.045         1 
2    1.056         1 
1    1.060         1 
Plasma   1.09 (adjusted)       3 
    1.182         0.5        Bottom 
______________________________________________________________ 
(Adapted with permission (15)).  
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2.7 Sequential preparation of HDL2 and HDL3 
HDL2 (d 1.063 – 1.125 g/ml) and HDL3 (d 1.125 – 1.215 g/ml) were separated  
using sequential density ultracentrifugation. The remaining 4ml of infranatant 
following LDL separation with a density of 1.019- 1.063 g/ml was adjusted 
to d 1.125 g/ml by the addition of NaBr solution at density 1.3104 g/ml. After 
 a 24 hour spin at 15°C at 35, 0000 rpm in a Beckman 50.4 fixed angle rotor in 
a Beckman L8-60M ultracentrifuge, during which the lighter particles floated to 
the top and heavier particles sank, the top 2 ml containing HDL2 at d 1.063-
1.125g/ml were removed carefully from the top. The infranatant was adjusted 
to d 1.215 g/ml by addition of NaBr solution at d 1.3104 g/ml. After a further 
24-hour spin again at 15°C and 35,000 rpm, the top 2 ml containing HDL3 at   
d 1.125- 1.215 g/ml were aspirated. 
   
2.8 Compositional Analysis: Cholesterol, Free Cholesterol, Triglyceride, 
Phospholipid and Protein 
Total lipoprotein composition of VLDL1, VLDL2, IDL, LDL d 1.019 – 1.063, 
HDL2 and HDL3 were quantified as follows. Total cholesterol was measured by 
enzymatic hydrolysis of cholesteryl esters to form free cholesterol followed by 
oxidation to give hydrogen peroxide. This is quantified by formation of a 
coloured product at 505nm (Roche Diagnostics, UK, Kit 11491458216). Free 
cholesterol was assayed by the same method omitting the enzyme cholesteryl 
esterase. (Wako Chemicals: Alpha Laboratories, UK Kit 279-47106). 
Cholesteryl ester was calculated as the total cholesterol minus the free 
cholesterol times 1.68 to correct for mass of esters.  Triglyceride was assayed 
by enzymatic hydrolysis followed by enzymatic determination of liberated 
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glycerol by colorimetry at 505nm (Roche Diagnostics, UK, Kit 12016648122). 
Phospholipid was determined by an enzymatic colorimetric assay method 
using absorbance at 500nm (Wako Chemicals through Alpha Laboratories, 
UK). Lipid analyses were performed on IL 600 clinical chemistry analyser 
(Instrument Laboratories, Cheshire, UK). Protein was analysed by 
modification of the method by Lowry et al(182). The free cholesterol, 
cholesteryl ester, triglyceride, phospholipid and protein content of the VLDL1, 
VLDL2, IDL and LDL collected were assayed and their lipoprotein 
concentration were calculated as the sum of these products. CVs for assays 
were: cholesterol 2.86%, triglyceride 3.83%, free cholesterol 2.15%, 
phospholipid 3.82% and protein 5.06%. 
 
2.9 Remnant Lipoprotein 
RLP-C was separated from plasma by an immunoaffinity mixed gel containing 
monoclonal antibodies to human apo B-100 and human apo A-1. (Japan 
Immunoresearch lab, Takasaki, Japan). The unbound fraction was measured 
after 2 hours incubation on automatic shaker cholesterol by an ultrasensitive 
enzymatic spectrophotometric assay using an I lab 600 clinical chemistry 
analyser. Interassay CV was 5.8%. 
 
2.10 Highly Sensitive CRP 
C reactive protein (CRP) was measured by an in house double antibody 
sandwich enzyme linked immunosorbent assay with rabbit anti-human CRP 
and peroxide conjugated rabbit anti-human CRP(183). Interassay CV was 
2.72%. 
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2.11 I-CAM and V-CAM 
ICAM was measured using a quantative sandwich enzyme immunoassay from 
R&D Systems (Abingdon, Oxfordshire) Quantikline Human Soluble ICAM-1 
Immunoassay Kit BBE 1B. VCAM was analysed using a quantative sandwich 
enzyme immunoassay commercially available kit from R&D Systems 
(Abington, Oxfordshire, UK). Interassay CV was less than 5%. 
 
2.12 Insulin and Glucose 
Insulin was measured using a solid phase two-site immunoassay purchased 
from Mercodia (Uppsala, Sweden). Glucose was analysed using a 
commercially available kit from Randox Laboratories, Crumlin, UK.  The 
principle of this assay is glucose-6-phosphate is oxidised in the presence of 
NADP and glucose-6-phosphate dehydrogenase.  The rate of NADPH 
formation during the reaction is directly proportional to the glucose 
concentration. Insulin CV was 4% and glucose 2%. 
 
2.13 Oxidised LDL 
Oxidised LDL was measured using a solid phase two-site antibody 
immunoassay in which two monoclonal antibodies are directed against 
separate antigenic determinants on the same oxidised LDL apoB molecule.  
This is commercially available from Mercodia (Uppsala, Sweden).Interassay 
CV 16.4%. 
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2.14 Apolipoprotein Measurements 
Apolipoprotein were analysed A1, B, CII, CIII and E were analysed on an 
IL600 clinical chemistry analyser (Instrument Laboratories, Warrington, 
Cheshire, UK) using Immunoturbidimetric commercially available kits from 
WAKO Chemicals through Alpha Laboratories, UK. CVs were as follows: AI 
5.23%, B 1.54%, CII 2.46%, CIII 7.31% and E 5.78%. 
 
2.15 HDL Gel Electrophoresis 
HDL sizes were determined using non-denaturing polyacrylamide gel 
electrophoresis using 2-30% linear gradient pre-poured slab gels from Alamo 
Gels, San Antonio, Texas. The gels were scanned by laser densitometry and 
particle size was determined using high molecular weight standards(184) 
[HDL2b 9.7- 12 nm; HDL2a 8.8- 9.7 nm; HDL3a 8.2- 8.8 nm, HDL3b 7.8- 8.2 nm; 
HDL3c 7.2- 7.8 nm]. HDL CVs less than 2%. 
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Chapter 3: Baseline Patient & 
Control Characteristics 
 
 
 
 
 
 
 
 
 
 
 
74 
 
3.1 Baseline Characteristics 
19 patients who fulfilled the inclusion criteria outlined in the methods section 
(Chapter 2) were recruited from the renal out-patient clinic of Glasgow Royal 
Infirmary. One patient withdrew prior to the first visit and one patient withdrew 
during the treatment period as he became intolerant of Omacor due to 
gastrointestinal upset (diarrhoea). Therefore data for 18 patients at baseline 
and 17 patients post treatment were analysed. In the patient group, median 
serum creatinine was 143μmol/l (IQR 118-163). This represented a median 
estimated glomerular filtration rate (eGFR) of 46ml/min (IQR 38-58) using 4 
variable MDRD formula(185). Mean 24 hour urinary protein excretion was 
4.3g (IQR 3.4-6.0) and mean serum albumin was 36g/dl (IQR 31- 40). Primary 
renal diagnoses were as follows: 8 idiopathic membranous nephropathy, 3 
focal segmental glomerulosclerosis, 2 mesangiocapillary glomerulonephritis, 2 
IgA nephropathy with a further 3 patients with chronic glomerulonephritis that 
was unable to be classified further on renal biopsy.   16 out of the 18 patients 
(84%) were on statin therapy prior to the study and all of the patients were on 
either an ACE inhibitor or Angiotensin receptor antagonist with 2 on dual 
therapy. 
Baseline data was compared with that obtained from 17 control patients who 
were age and sex matched (table 3.1). We attempted to match patients and 
controls for triglyceride. However, in view of the significant 
hypertriglyceridaemia observed in the patient population, it proved difficult to 
screen and recruit controls with higher triglyceride levels. This explains why 
the triglyceride levels in the control population were higher than expected in a 
normal population but still lower than the patient group. 
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3.2 Lipids and Lipoproteins 
The results for baseline lipids, lipoproteins, insulin and glucose are outlined in 
table 3.1. Plasma cholesterol was higher in the patient population (p=0.003). 
Plasma triglyceride was also increased in the patient population (p=0.01). 
However, with the initial attempts to match for triglyceride, the mean 
triglyceride observed for the control patients was higher than would be 
expected in a normal population. Total VLDL-C was higher in the patients 
(p=0.004) however, LDL-C and HDL-C did not differ significantly despite the 
mean LDL-C in the patient group being 0.5mmol/l higher than controls. 
Notably, fasting insulin and glucose levels were similar despite the observed 
difference in plasma triglyceride and there was no relationship between 
baseline triglyceride concentration and either insulin or fasting glucose in both 
patients and controls.  
 
3.3 Plasma Lipoprotein Concentrations  
Total VLDL concentration in the patients was increased due to an increase in 
both larger, lighter VLDL1 and smaller, denser VLDL2 subfractions although 
only the increase VLDL2 reached statistical significance (p=0.02). Despite 
similar LDL-C levels, total LDL lipoprotein concentration was higher in the 
patient group (p=0.03), however no difference in IDL concentration was 
observed (table 3.2).  
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3.4 LDL Subfractions and Remnant Lipoproteins  
The plasma concentration of small dense LDL (LDLIII) was increased 
threefold (p=0.03) in the patient population. LDL II was the major subfraction 
in controls whereas LDL III was the major subfraction in the patient population 
with its mean percentage being twice that in controls. The concentrations of, 
and relative percentages of LDL I and II did not differ significantly between the 
groups. 
 
Remnant-like lipoproteins were increased in patients with nephrotic range 
proteinuria. There was an almost three fold increase in the concentration of 
RLP-Cholesterol (RLP-C) in the patient group (p=0.03) and although the 
median RLP-Triglyceride (RLP-TG) concentration was doubled, this did not 
reach statistical significance (table 3.2). 
 
3.5 Factors associated with Baseline LDL III and Remnant Lipoproteins 
in Patients and Controls 
Tables 3.3 and 3.4 outline these relationships. In the patient group, LDL III 
concentration and LDLIII percentage correlated with plasma triglyceride 
concentrations, VLDL1, VLDL2 and remnant lipoproteins. There is a greater 
correlation between % LDL III and RLP than LDL III concentration as shown in 
table 3.3. No relationship was observed between LDL III and RLP baseline 
renal function, proteinuria, HDL-C, insulin or fasting glucose. 
When examining factors associated with LDL III and RLP across the two 
groups studied, similarities and differences were identified. In the control 
group, LDL III concentration and %LDLIII also correlated closely with plasma 
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triglyceride concentrations, VLDL1, VLDL2 and remnant lipoproteins. Also in 
the control group, there was a much closer correlation between LDL III 
concentration and remnant lipoproteins. In the control group, an inverse 
relationship between both LDL III concentration and RLP-TG with HDL was 
observed. This was not observed in the patient group however in multivariate 
analysis, subject group was not an independent predictor for LDL III 
concentration, %LDL III or RLP. 
 
3.6 Discussion 
Analysis of  quantification of lipids at baseline demonstrated that patients 
had higher levels of total cholesterol, triglyceride and VLDL-C and no 
difference in LDL-C or HDL-C. Detailed lipoprotein analysis demonstrated an 
increase in both VLDL subfractions with a 51% increase in VLDL2 but a non-
significant 39% increase in VLDL1 in patients with nephrotic range proteinuria. 
Higher levels of small, dense atherogenic LDL III were observed in the patient 
group in sufficient quantities that is likely to increase cardiovascular risk. 
Furthermore, a three-fold increase in remnant lipoprotein cholesterol was 
found in the patients with proteinuria.  No direct relationship was observed 
between either RLP or LDL III and urinary protein, plasma albumin or renal 
function.  
 
The results observed in our study are in keeping with previously published 
studies examining patients with nephrotic range proteinuria both in our 
laboratory and by other authors. The most commonly observed abnormality 
observed in patients with nephrotic range proteinuria is a raised plasma 
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cholesterol (162). Triglyceride levels are often raised but their range is more 
variable(164). These changes have been found to correlate inversely with 
serum albumin(186). Furthermore, previous studies have shown that LDL-C 
levels are invariably raised in these patients(163) and VLDL levels are 
frequently increased. A previous study from our laboratory has demonstrated 
that patients with nephrotic range proteinuria possessed excess remnant 
lipoproteins as well as raised LDL III in quantities significantly increasing CV 
risk. Plasma triglyceride levels have been shown to be the most important 
factor determining both LDLIII and remnant lipoprotein levels(187) . Data from 
the Framingham heart study has shown that patients with urinary dipstick 
analysis positive for protein have RLP-C and RLP-TG concentrations 2-3 fold 
higher than the reference range for males(176). In contrast to previous work 
from our laboratory, the 63% rise in median VLDL1 concentration we observed 
in patients compared with controls was not significant. It is recognized that the 
VLDL1 subfraction predominates in patients with hypertriglyceridaemia. In 
keeping with this, plasma triglycerides were elevated in the patient group. 
However marked heterogeneity was seen in the control group. We suspect 
that this results from the higher than normal triglyceride concentration 
obtained in our control population and accounts for the lack of difference 
observed in the VLDL1 results. We did not observe any difference in HDL-C 
concentration. This is a frequent finding with a number of authors not 
identifying any difference in HDL levels in patients with nephrotic range 
proteinuria without renal failure(170;186;188). Thus, our baseline results are 
in keeping with previously published work in patients with nephrotic range 
proteinuria.  
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We did not find subject group to be an independent factor predicting LDL III 
concentration, % LDL III or remnant lipoproteins suggesting that the 
differences observed between the two populations are due to differing 
baseline parameters, and almost certainly, the increased plasma triglyceride 
levels seen in the patients. Correlations between LDL III concentration, 
remnant lipoproteins and plasma triglyceride concentration were tighter in the 
control population. Plasma triglyceride is the most important determinant of 
LDL III formation followed by hepatic lipase activity. Increased triglyceride 
levels lead to triglyceride enrichment of LDL II. Hepatic lipase hydrolyses the 
triglyceride thereby shrinking it to LDL III(65). This may explain why we 
observed a weaker correlation between LDL III and triglyceride in the patient 
group as it is likely that due to the hypertriglyceridaemia, hepatic lipase was 
not rate-limiting.  
Increasing number of studies has shown that higher LDL III concentrations are 
associated with increased cardiovascular risk. LDL III concentration 
>100mg/dl confers a seven-fold increase in risk of myocardial infarction (61). 
Moreover, there is evidence to suggest that remnant lipoproteins are 
atherogenic and an independent risk factor for coronary heart disease (34;35). 
In summary, this combination of increases in total cholesterol, triglyceride, 
VLDL, LDL III and remnant lipoproteins are all likely to contribute to the 
significantly increased risk of cardiovascular disease observed in patients with 
proteinuria. 
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______________________________________________________________ 
     Patients       Controls 
     n= 18          n=17 
                                                         (All median & IQR) 
______________________________________________________________ 
Age (years)    63.0 (55.8- 71.0)  61 (47.0-70.5) 
Sex (M:F)    15:3    14: 3 
Cholesterol (mmol/l)  6.2 (5.5- 7.5)   5.5 (4.7 – 5.9)* 
Triglyceride (mmol/l)  2.1 (1.8- 2.6)   1.4(1.1 – 2.0) ** 
VLDL-C (mmol/l)   0.7 (0.6 -1.2)   0.5(0.3- 0.7) † 
LDL-C  (mmol/l)   4.2 (3.3- 5.4)   3.7 (3.0- 4.3) 
HDL-C (mmol/l)   1.0 (0.90 -1.1)  1.1 (0.9- 1.4) 
Insulin (mmo/l)   10.4 (7.9 -16.8)  8.4 (3.8- 15.8) 
Glucose (mmol/l)   5.3 (4.8 -6.2)   5.3 (4.4- 5.9) 
 
 
Table 3.1 Baseline Patient and Control Characteristics 
Baseline patient characteristics compared with controls. Prior to statistical 
analysis, any parameter which was not normally distributed was normalised 
by log transformation. All data were compared using unpaired t-tests. 
Statistical differences are indicated (* p=0.003, **p=0.01, †p=0.004). 
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______________________________________________________________ 
 
   Patient   Control   p 
      
(n=18 )    (n=17) 
       
   (All median & IQR) 
______________________________________________________________ 
 
Total VLDL  182 (122- 240)  107 (78- 175)           ns 
 
 
VLDL1 (mg/dl) 106 (62-138)   65(35- 115)                      ns 
 
  
VLDL2 (mg/dl) 88 (44-106)   43 (35- 61)                0.02 
 
 
IDL (mg/dl)  59 (44- 82)   53 (43- 64)            ns 
 
 
LDL I conc(mg/dl) 43 (21- 62)   29 (15-57)           ns 
 
 
LDL II conc(mg/dl) 198 (112- 246)  167 (73-261)             ns 
 
 
LDL III conc(mg/dl) 195 (64-237)   53 (30-182)                   0.03       
 
 
T-LDL conc(mg/dl) 411 (278-492)  315 (254-374)                    0.03 
 
 
% LDL I  8.9(5.5-15.8)   8.1 (3.8-16.1)            ns 
 
 
%LDL II  41.1 (34.3-61.6)                 65.2 (27.3-68.3)          ns
           
    
%LDL III  48.4 (17.8-60.3)  24.7 (12.0-63.9)           0.07 
 
 
RLP- C (mg/dl) 14.8 (6.0- 20.5)  5.6 (4.1- 12.7)           0.03 
 
 
RLP-TG (mg/dl) 46.5 (22.2- 51.3)  23.8 (20.8 – 49.2)            ns 
 
 
Table 3.2 Patient and Control Lipoproteins at Baseline 
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   LDL III conc        LDL III%            RLP-C   RLP-TG 
 
   (r2%)         (r2%)              (r2%)     (r2%) 
 
 
 
Triglyceride  32.7 c         53.5 a  64.1 a   71.5 a  
 
 
VLDL1 conc  30.5
 c          50.4 a             72.4 a   79.7 a 
 
 
VLDL2 conc  52.7
 a        56.0 a  36.8 b  30.7 c 
 
 
RLP-C  19.8 d        40.5 d   _  _ 
 
 
RLP-TG  20.4 d        45.7 b  _  _ 
 
 
HDL-C  0.0        0.0  0.0  0.0 
 
 
 
 
Table 3.3 Factors associated with LDL III and Remnant Lipoprotein 
Concentration in Patients at Baseline 
 
Linear regression analysis of baseline LDL III and remnant lipoproteins with 
baseline triglyceride, VLDL1, VLDL2, remnant lipoproteins and HDL in patient 
group. r2% = coefficient of determination and level of statistical significance is 
indicated: a p<0.001, b p<0.005, c p<0.01, d p<0.05. 
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     LDL III conc   LDL III%          RLP-C             RLP-TG 
 
          (r2%)     (r2%)          (r2%)   (r2%) 
 
 
 
Triglyceride  70.0 a     49.4 a  80.1 a  77.6 a  
 
 
VLDL1 conc  64.5
 a      37.8 b  68.5 a   60.7 a 
 
 
VLDL2 conc  59.4
 a    32.4 d  44.3 b  19.4 d 
 
 
RLP-C  67.2 a     59.0 a   _   _ 
  
 
RLP-TG  49.1a     39.5 b   _   _ 
 
 
HDL-C  30.8 d     6.5   16.8  27.7 d 
 
 
 
 
 
Table 3.4 Factors associated with LDL III and Remnant Lipoprotein 
Concentration in Controls at Baseline 
   
Linear regression analysis of baseline LDL III and remnant lipoproteins with 
baseline triglyceride, VLDL1, VLDL2, remnant lipoproteins and HDL in controls 
group. r2% = coefficient of determination and level of statistical significance is 
indicated: a p<0.001, b p<0.005, c p<0.01, d p<0.05. 
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4.1 Introduction 
It is known that patients with nephrotic range proteinuria posses the 
atherogenic lipoprotein phenotype characterised by hypertriglyceridaemia, 
small dense LDL and low HDL-C(187). These abnormalities are 
proatherogenic conferring an increase in cardiovascular risk with an LDL III 
concentration of > 100 mg/dl which has been associated with a seven-fold 
increase in the risk of myocardial infarction (61). Remnant lipoproteins and 
remnant lipoprotein cholesterol (RLP-C) are also known to be 
proatherogenic(189) and an independent risk factor for coronary artery 
disease (190). Their presence is characteristically observed in patients with 
hypertriglyceridaemia. Deighan et al have previously shown that excess levels 
of both LDLIII and RLP-C were present in patients with nephrotic range 
proteinuria and these levels were closely correlated with triglyceride 
concentration (187). 
Omega-3 fatty acids have cardioprotective effects through a number of 
mechanisms. These have been discussed in chapter 1 and include triglyceride 
reduction. Theoretically therefore, they would appear to be an ideal treatment 
to reduce the hypertriglyceridaemia present in patients with proteinuria and as 
a result, have beneficial effects on both small dense LDL and remnant 
lipoproteins.  
Our aim, therefore, was to examine the effect of high dose omega-3 fatty 
acids on atherogenic triglyceride rich lipoproteins in patients with nephrotic 
range proteinuria and also in age and sex matched controls. In particular we 
aimed to assess changes in small dense LDL and remnant lipoproteins. 
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4.2 Subjects and Methods 
18 patients with nephrotic range proteinuria and 17 controls were recruited as 
described in chapter 3. One patient did not tolerate omega-3 fatty acids and 
so 17 patients and 17 controls were analysed. Samples following a ten hour 
fast were taken at baseline and after an eight-week treatment period with 4g 
of omega-3 fatty acids daily (Omacor –Solvay). Patients receiving lipid-
lowering therapy had their treatment stopped for a period of four weeks prior 
to inclusion into the study. 
 
4.3 Statistics 
Statistical analyses were carried out using MINITAB 13.1 for Windows 
(Minitab inc). Results are shown as median and interquartile ranges (IQR). 
Prior to statistical analysis, any factor that was not normally distributed was 
normalised by log transformation. Patient and control results were compared 
using unpaired t-tests. Results pre and post treatment were compared using 
paired t-tests. Linear regression analysis was performed to identify significant 
correlations.  Multivariate analysis was performed using stepwise regression 
and a general linear model. 
 
4.4 Results 
4.4.1 Lipids and Lipoproteins 
Changes in lipids and lipoproteins in patients following treatment with omega-
3 fatty acids are outlined in table 4.1. In proteinuric patients we found that 4g 
daily of omega-3 fatty acids reduced plasma triglyceride (TG) concentration by 
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a mean of 0.45mmol/l (95%CI:  0.16 to 0.74, p=0.005). Plasma VLDL-C also 
fell following treatment (mean decrease 0.38mmol/l 95% CI:  0.01 to 0.75, 
p=0.04). This was mainly due to a decrease in larger TG rich VLDL1 rather 
than VLDL2 with a mean reduction of VLDL1 33.2mg/dl (95% CI 4.2 to 62.2, 
p=0.03). It is noteworthy that total plasma cholesterol increased by a mean of 
0.25mmol/l (95% CI: 0.0 to 0.5, p=0.05) with an increase in LDL-C in 
proteinuric patients following treatment with omega-3 fatty acids with a mean 
increase of 0.6 mmol/l (95% CI 0.2 to 1.1, p=0.06). Plasma concentration of 
HDL-C did not differ following treatment in the proteinuric patients. In the 
control group, no significant change in plasma concentration of total 
cholesterol, triglyceride, VLDL-C, LDL-C, or HDL-C was observed following 
treatment with omega-3 fatty acids (table 4.2).  
 
4.4.2 LDL Subfractions 
In the patient population, there was a significant reduction in the proportion 
(percent LDL III) and concentration of LDL III. The overall percentage of LDL 
that was in the form of LDLIII (LDLIII %) fell by a mean of 8.6 (95% CI: 0.8 to 
16.4 p=0.01) and LDL III concentration fell by a mean of 26.4 mg/dl (95% CI –
14.5 to 67.4, p=0.05). In the patient group, the percentage and concentration 
of large, light, cholesterol-rich LDLI increased following treatment, with a 
mean increase in LDLI% of 2.6 (95%CI 0.8 to 4.3 p=0.03 and a mean 
increase in LDL I concentration of 13.4mg/dl (95%CI 5.2 to 21.6), p=0.001. No 
change in LDL II concentration or percentage was observed. Total LDL 
lipoprotein concentration only rose marginally not reaching statistical 
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significance despite an increase in LDL-C following treatment with omega-3 
fatty acids. 
Changes in the LDL subfraction profile of the controls were less marked, with 
no observed difference in LDL III concentration or LDL III %. There was, 
however, an increase in larger, lighter, less atherogenic LDL with an increase 
in LDL II concentration of 33.6mg/dl (95% CI 2.1 to 65.0, p=0.02). A significant 
increase in total LDL concentration was also observed in the controls (31.9 
mg/dl: 95% CI 0.6 to 63.2, p=0.04)  
Of the patients who completed the study, 13 out of 17 patients (72%) 
possessed LDL III concentrations above 100mg/dl at baseline falling to 7 out 
of 17 (41%) after treatment with omega-3 fatty acids. 8 out of 17 controls 
(47%) had LDL III concentration above 100mg/dl prior to treatment falling to 6 
(35%) following treatment. 
The effect of omega-3 fatty acids on LDL subfractions was very 
heterogeneous in both the patient and control populations, ranging from a 
reduction of 164 mg/dl to an increase of 150 mg/dl in LDL III concentration in 
the patients group and from a reduction of 78mg/dl to an increase of 92mg/dl 
in the control group. Figure 4.1 illustrates the effect on LDL subfraction profile 
before and after treatment with omega-3 fatty acids in one individual patient 
with a marked reduction in the % LDL III. 
 
4.4.3 Remnant Lipoproteins 
Following treatment with omega-3 fatty acids, RLP-C concentration fell in 
patients by a mean of 3.5mg/dl (95% CI 0.1 to 6.9), p=0.05. Similarly RLP-TG 
concentration fell by a mean of 12.4mg/dl (95% CI 2.6 to 22.2), p=0.03. In the 
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control group, RLP-C and RLP-TG were unchanged following treatment with 
omega-3 fatty acids.  
 
 
 
 
Fig 4.1 Effect on LDL profile in one Patient 
Shift in LDL Subfraction profile in an individual patient before and following 
treatment with Omega-3 fatty acids. Profile changes form predominantly LDL 
III to LDL II. 
 
 
 
 
- Pre Treatment 
- Post Treatment 
LDL I 
LDL II 
LDL III 
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4.4.4 Factors determining change in LDLIII and Remnant Lipoproteins 
In the patient group, there was no association between either the change in 
LDL III concentration or the proportion of LDL III (expressed as a percentage) 
with change in triglyceride, VLDL1, VLDL2, RLP-C or RLP-TG (table 4.5 & 
figure 4.2). In contrast, a correlation was demonstrated in the control group 
between the change in both LDL III concentration and LDLIII% and the 
change in plasma triglyceride, VLDL2 and RLP-TG. As a result of these 
contrasting results, we proceeded to further statistical analysis using the 
subject group as an independent variable. This did not show patient group to 
be an independent predictor of the change in LDLIII concentration or LDLIII% 
following treatment.  
The relationship between remnant lipoprotein reduction and reduction in TG 
and TG rich lipoproteins were similar in the two groups studied. In the 
patients, the reduction in RLP-C was associated with the reduction in 
triglyceride and VLDL1 (r
2 47.5, p=0.001 and r2=40.2, p=0.004). Whilst the 
change in RLP-TG correlated with change in VLDL1 (r
2=27.6, p=0.02) but not 
triglyceride concentration. In the controls, the change in RLP-C and RLP-TG 
strongly correlated with change in triglyceride, VLDL1 and VLDL2 (table 4.6 & 
figure 4.3). Again, when subject group was included as an independent 
variable in multivariate analysis, it was not found to be an independent 
predictor of change in remnant lipoproteins. 
 
4.5 Discussion 
In this study, we have demonstrated that treatment with omega-3 fatty acids in 
patients with nephrotic range proteinuria has a beneficial effect on atherogenic 
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lipoproteins. Treatment significantly reduced LDL III concentration and caused 
a reduction in remnant lipoproteins. Furthermore, they decreased plasma 
triglyceride and VLDL levels particularly VLDL1. We also observed an 
increase in plasma LDL- C with omega-3 fatty acid treatment although this 
was potentially offset by a redistribution to larger, lighter, less atherogenic LDL 
These effects were not observed in the control group as omega-3 fatty acids 
neither significantly affected the proportion of, or concentration of LDL III nor 
did treatment influence plasma triglyceride or VLDL concentration.  
The cardioprotective effects of omega-3 fatty acids were first noted following 
the observation that the Greenland Inuit had a low mortality from CHD despite 
a high incidence of smoking and obesity. A number of epidemiological and 
population studies have since demonstrated the cardioprotective effects of 
omega-3 fatty acids. The Nurses‟ Health Study found that CHD deaths were 
50% lower in those women who consumed fish five times a week. A subgroup 
of these women with diabetes showed a stronger relationship with a 60% 
reduction in CHD death (106).  The diet and reinfarction trial (DART) (111) 
found that patients who received dietary advice on increasing fish intake had a 
relative reduction in mortality of 29% during the 2 year follow-up mainly 
because of reductions in deaths from CHD. The Physician‟s Health Study 
(112) found a reduced risk of sudden cardiac death in subjects with increased 
levels of omega- 3 fatty acids. Furthermore, the Italian GISSI-Prevenzione trial 
found that patients randomised to a daily capsule of omega 3 fatty acid (1g) 
had a reduction in relative risk of 15% in the composite end-point of total 
mortality, non-fatal myocardial infarction and stroke (113). As a result of these 
studies, the American Heart Association now recommends that high risk 
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patients or patients with cardiovascular disease eat fish (particularly fatty fish) 
at least twice a week. 
 
The cardioprotective effects of omega-3 fatty acids may be as a result of 
various different mechanisms. These include their effects on atherogenic 
lipoproteins. In normal controls, omega-3 fatty acids are known to exert a 
number of effects on plasma lipoproteins. They reduce plasma triglyceride 
concentration in a dose dependant manner with doses of 4g causing a 
reduction of 25-30% (191).  This is thought to be through suppression of 
hepatic VLDL and triglyceride production. It has also been suggested that 
there is increased catabolism of VLDL to LDL through enhanced binding of 
omega-3 fatty acid enriched VLDL to lipoprotein lipase (192). A review by 
Harris of human trials concluded that omega-3 fatty acids had no clinically 
significant effect on total cholesterol with an increase in LDL-C which was 
more marked in hypertriglyceridaemic patients and a minimal, inconsistent 
effect on HDL levels(191). At higher doses (3-5g) the LDL-C raising effect of 
omega-3 fatty acids are well recognized with a redistribution of LDL 
phenotype to one that is larger, lighter and potentially less atherogenic 
particles(126).  
 
We observed a fall in LDL III proportion and concentration following treatment 
with omega-3 fatty acids in the patients with nephrotic range proteinuria. This 
was not observed in the normal controls. In that context, the mean reduction 
of triglyceride concentration was 17.5% in the patient group and 5.9% in the 
control group. However, there was a strong relationship between change in 
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plasma triglyceride and change in LDL III reduction in the control group, which 
was not observed in the nephrotic group. We did not find subject group to be 
an independent factor responsible for these observed differences and so it is 
likely that these differences are due to a difference in baseline parameters, 
particularly the baseline levels of plasma triglyceride. It has been 
hypothesised that in males, in order to produce atherogenic levels of LDL III, 
adequate hepatic lipase activity and a plasma triglyceride level of >1.5 mmol/l 
is required. In this study, the majority of the patient group were male (82%) 
and in 15 out of the 17 patients who completed the study, triglyceride 
concentration was >1.5 mmol/l at baseline. This fell to 10 out of 17 at the end 
of treatment. We propose that this explains the lack of relationship between 
triglyceride reduction and LDL III reduction in the patients group, as the 
triglyceride reduction was not enough to make plasma triglyceride a rate-
limiting factor in the production of small dense LDL with the mean triglyceride 
in the patients following treatment remaining elevated at 1.8mmol/l. In 
contrast, 8 out of 17 controls had a baseline triglyceride concentration of >1.5 
mmol/l falling to 6 at the end of treatment with a mean triglyceride of 
1.5mmol/l. Thus, we suggest the difference in effect of omega-3 fatty acids on 
LDL III concentration in the 2 populations is due to the difference in baseline 
triglyceride levels rather than the 2 groups responding differently to treatment. 
 
Remnant lipoproteins were significantly reduced by omega-3 fatty acids in the 
patient group but not in the control group. Once again, we did not find this to 
be a group effect and this might be due to the higher baseline levels of 
triglyceride and VLDL1 in the patient group. We know that triglyceride is a 
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major determinant of remnant lipoprotein production and we have already 
shown that they are strongly related to plasma triglyceride and VLDL1 levels. 
Therefore, both groups display a similar response to the omega-3 fatty acids 
but as there are higher baseline levels of triglyceride, remnant lipoproteins 
and a significant triglyceride reduction in the patient group, this results in a 
marked fall in remnant lipoproteins. 
 
A concerning effect of omega-3 fatty acids was the observed increase in LDL-
C in the patient group. This LDL raising effect is a well recognized effect of 
omega-3 fatty acids (123;191) but is poorly understood. Possible mechanisms 
include down regulation of the LDL apolipoprotein B/E receptor or a 
preferential conversion of synthesized VLDL to LDL. This effect on LDL 
represents one of the controversial aspects of omega-3 fatty acids. Several 
epidemiological and clinical trials (193-195) have established that the 
relationship between LDL-C and relative risk for CHD is log-linear. Thus, at 
any level of LDL-C, for any given mg/dl change in LDL-C level, the change in 
relative risk is the same (196). This reduction of LDL-C levels, irrespective of 
how, has been shown to reduce the risk of CHD (197). As discussed in 
chapter 1, patients with nephrotic range proteinuria have an increased 
cardiovascular risk, and so increasing levels of LDL-C in these patients could 
potentially increase this risk. However, it is not known whether the increase in 
LDL-C caused by omega-3 fatty acids coupled with the redistribution to larger, 
lighter and therefore potentially less atherogenic LDL would result in an 
increased cardiovascular risk or whether the other beneficial effects of omega-
3 fatty acids (discussed in chapter 1) outweigh this. It has been shown that 
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cerivastatin reduces LDL III concentrations by 27% in patients with nephrotic 
range proteinuria(198), therefore it may be useful to combine a statin with 
omega-3 fatty acids to offset the LDL raising effect. 
 
Omega-3 fatty acids in the form of Omacor were generally well tolerated by 
both patients and controls. One patient withdrew during the study as he 
suffered gastrointestinal upset in the form of abdominal pain and diarrhoea. 
Other reported minor effects were a fishy after taste. Anecdotally, several 
patients reported that their arthritis had improved on treatment with one 
patient requesting to continue on treatment after completion of the study. 
 
In conclusion, in patients with nephrotic range proteinuria omega-3 fatty acids 
reduce LDL III remnant lipoproteins and triglyceride rich lipoproteins thereby 
reducing cardiovascular risk. However these beneficial effects are offset by an 
increase in LDL-C. It is not clear whether this increase in LDL-C with 
redistribution in LDL size confers an increase in cardiovascular risk. One 
potential role for omega-3 fatty acids could be in conjunction with a statin in 
order to combine LDL-C lowering with a reduction in atherogenic triglyceride 
rich lipoproteins. Further work is required in this area to clarify this. 
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Patients 
(n=17) 
Baseline Post Treatment p 
Cholesterol (mmol/l) 6.2 (5.5- 7.3) 6.4 (5.5- 7.5) 0.05 
Triglyceride (mmo/l) 2.2 (1.7- 2.6) 1.8 (1.2- 2.2) 0.005 
VLDL-C (mmol/l) 0.7 (0.6- 1.3) 0.6 (0.4- 0.9) 0.04 
LDL-C (mmol/l) 4.1 (3.2- 5.4) 4.6 (4.0- 5.8) 0.06 
HDL-C (mmol/l) 1.10 (0.9- 1.2) 1.2 (0.9- 2.4) ns 
IDL-C (mg/dl) 58.2 (43.0- 79.2) 62.3 (48.0- 130.3) ns 
VLDL1 concentration (mg/dl) 106.1 (60.8- 141.1) 70.9 (35.8- 108.0) 0.03 
VLDL2 concentration (mg/dl) 87.1 (43.4- 107.9) 73.2 (47.7- 95.2) ns 
RLP-C (mg/dl) 14.6 (5.9- 22.0) 8.8 (6.1- 16.9) 0.05 
RLP-TG (mg/dl) 46.0 (21.8- 52.2) 26.4 (19.6- 46.9) 0.03 
 
Table 4.1 The Effect of Omega-3 Fatty Acids on Lipoproteins in Patients 
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Controls 
(n=17) 
Baseline Post Treatment p 
Cholesterol (mmol/l) 5.6 (4.7- 5.9) 5.4 (5.0- 6.2) ns 
Triglyceride (mmol/l) 1.5 (1.1- 2.0) 1.3 (1.0- 1.8) ns 
VLDL-C (mmol/l) 0.6 (0.3- 0.7) 0.4 (0.3- 0.7) ns 
LDL- C (mmol/l) 3.8 (3.0- 4.3) 3.9 (3.4- 4.4) 0.07 
HDL- C (mmol/l) 1.1(0.9- 1.4) 1.2 (1.0- 1.5) ns 
IDL (mg/dl) 52.7 (43.4- 63.6) 53.8 (43.8- 62.7) ns 
VLDL1 concentration (mg/dl) 64.6 (35.2- 114.8) 59.6 (25.4- 96.1) ns 
VLDL2 concentration (mg/dl) 43.4 (34.8- 60.6) 43.2 (31.7- 100.0) ns 
RLP-C (mg/dl) 5.6 (4.1- 12.7) 5.2 (3.7- 12.4) ns 
RLP-TG (mg/dl) 23.8 (20.8- 49.2) 22.0 (19.4- 40.6) ns 
 
Table 4.2 The Effect of Omega-3 Fatty Acids on Lipoproteins in Controls 
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Patients Baseline Post Treatment p 
LDL I % 8.4 (5.4- 17.2) 11.5 (6.5- 19.3) 0.03 
LDL II% 40.4 (33.6- 62.4) 55.2 (34.2- 64.8) ns 
LDL III % 49.9 (17.4- 61.2) 29.8 (14.9- 58.5) 0.01 
LDL I conc (mg/dl) 41.3 (20.6- 59.4) 54.9 (24.9-  81.2) 0.001 
LDL II conc (mg/dl) 184.8 (104.9- 248.4) 215.9 (138.2- 309.2) ns 
LDL III conc (mg/dl) 178.8 (61.6- 231.0) 96.1 (49.3- 204.5) 0.05 
Total LDL conc (mg/dl) 370.5 (270.8- 480.7) 397.8 (313.8- 527.3) ns 
 
Table 4.3 The Effect of Omega-3 Fatty Acids on LDL Subfractions in Patients 
 
 
 
Controls Baseline Post Treatment p 
LDL I % 8.1 (3.8- 16.1) 13.2 (7.5- 54.6) 0.07 
LDL II% 65.2 (27.3- 68.3) 66.1 (39.4- 72.0) ns 
LDL III % 24.7 (12.0- 68.4) 16.9 (11.6- 38.8) ns 
LDL I conc (mg/dl) 28.9 (14.8- 57.3) 41.0 (25.2- 62.2) ns 
LDL II conc (mg/dl) 167.0 (72.8- 260.6) 213.7(132.5- 258.3) 0.02 
LDL III conc (mg/dl) 53.3 (29.8- 182.0) 50.3 (36.9- 142.6) ns 
Total LDL conc (mg/dl) 317.5 (253.9- 374.2) 338.0 (299.1- 400.8) 0.04 
 
Table 4.4 The Effect of Omega-3 Fatty Acids on Lipoproteins in Controls 
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  ∆LDL III conc   ∆LDL III%  ∆RLP-C ∆RLP-TG 
 
      (r2%) 
 
 
∆Triglyceride       0.7  11.9   47.5a      0 
  
 
∆VLDL1 conc      0   2.3   40.2
b     27.6c
  
 
∆VLDL2 conc      5.1   12.4   0     8.9 
 
 
 
∆RLP-C               0   13   -    -     
     
 
∆RLP-TG      0   3.5   0    - 
     
 
 
 
 
 
 
 
Table 4.5 Factors Associated with Change in LDL III and Remnant 
Lipoprotein Concentration in Patients  
 
Linear regression analysis of change in LDL III and remnant lipoproteins with 
change in triglyceride, VLDL1, VLDL2 and remnant lipoproteins in the patient 
group. r2% = coefficient of determination. Level of statistical significance is 
indicated: a p=0.001, bp=0.004, cp=0.02. 
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   ∆LDL III conc     ∆LDL III%       ∆RLP-C  ∆RLP-TG 
 
      (r2%) 
 
 
∆Triglyceride  50.2b       38.5c             74.9a                  80.7a 
 
 
∆VLDL1 conc  4.6       9.4   69.7
a                 56.0a
  
 
∆VLDL2 conc  41.1
b      41.5b  35.3c       51.3a
   
 
∆RLP-C  17.1      16.3   -         - 
        
 
∆RLP-TG  30.7d      41.4b  83.5a         - 
  
 
   
 
 
 
Table 4.6 Factors associated with Change in LDL III and Remnant 
Lipoprotein Concentration in Controls  
 
Linear regression analysis of change in LDL III and remnant lipoproteins with 
change in triglyceride, VLDL1, VLDL2 and remnant lipoproteins in the control 
group. r2% = coefficient of determination. Level of statistical significance is 
indicated: 
a p<0.001, b p<0.005, c p<0.01, d p<0.05. 
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Figure 4.2 Change in LDL III concentration vs Change in Triglyceride 
 
Linear Regression analysis of change in LDL III concentration with change in 
triglyceride concentration in patients and controls as indicated.  
(Patients r2=0.7%, p=ns & Controls r2=50.2%, p<0.005) 
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 Figure 4.3 Change in RLP-C vs Change in Triglyceride Concentration 
 
Linear Regression analysis of change in RLP-C with change in triglyceride 
concentration in patients and controls as indicated.  
(Patients r2= 47.5%, p=0.001 & Controls r2= 74.9, p<0.001) 
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Chapter 5: Omega-3 Fatty 
Acids and Postprandial 
Lipaemia 
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5.1 Introduction 
The importance of postprandial lipid metabolism in the development of 
coronary artery disease is well established. 
Chylomicrons are the largest and lightest triglyceride-rich lipoproteins. They 
are plentiful postprandially but almost absent when fasted. They are 
synthesised in response to dietary lipid intake and are responsible for 
transporting dietary triglyceride and cholesterol. They are composed mainly of 
triglyceride with apo B48 as the structural protein. VLDL are also triglyceride- 
rich but have apo B100 as the structural protein. They are responsible for the 
transport of endogenously synthesised triglyceride. VLDL particles can be 
subdivided into two subfractions according to their flotation coefficients using 
cumulative gradient centrifugation (described in chapter 2). VLDL1 (Sf 60-400) 
is larger, lighter and more triglyceride-rich. VLDL2 (Sf 20-60) is smaller, denser 
and more enriched in cholesteryl ester. These two subfractions appear to be 
independently regulated. VLDL1 is associated with raised plasma triglyceride 
and overproduced in patients with insulin resistance (199). VLDL2 is 
overproduced in patients with raised LDL cholesterol. VLDL1 is inefficiently 
converted to LDL in contrast to VLDL2 which is rapidly metabolised to LDL. 
Patients with nephrotic range proteinuria have been found to have an 
increase in plasma concentrations of both these VLDL subfractions (162;163). 
The effects of omega-3 fatty acids on postprandial lipaemia is not completely 
understood but they are known to decrease hepatic VLDL production, 
increase VLDL to LDL conversion, reduce the magnitude of the postprandial 
triglyceride response (119;200;201) and increase chylomicron clearance.  We 
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aimed to examine: (1) chylomicron and VLDL1 metabolism in patients with 
nephrotic range proteinuria compared with controls (2) The effect of omega-3 
fatty acids on chylomicron and VLDL1 metabolism in patients compared with 
controls. 
 
5.2 Methods 
The same study population described in the methods section were used for 
this study. Patients and controls were treated with 4 g daily of omega-3 fatty 
acids (Omacor) for a period of eight weeks and attended on 2 occasions: once 
prior to treatment and also at the end of the treatment period. They ingested a 
90g fat load in the form of a calogen drink. Chylomicrons and VLDL1 were 
isolated by density ultracentrifugation from EDTA plasma (as described in 
chapter 2) in fasting and at 2 hour, 4 hour, 6 hour and 8 hour samples after 
the fat load. Separation of lipoproteins was performed immediately after 
sampling to prevent degradation of the chylomicrons. Chylomicron and VLDL1 
concentrations were measured also as described in chapter 2. Incremental 
area under the curve (AUC) was calculated by standard methods to quantify 
postprandial lipoprotein concentrations. 
 
5.3 Statistics 
Statistical analyses were performed using MINITAB 14X for Windows. Any 
factors that were not normally distributed were subject to log transformation. 
These included chylomicron incremental area under the curve. Results are 
shown as median and interquartile range (IQR). Paired data were compared 
using a paired t-tests and comparison between patients and controls were 
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carried out using 2 sample t-tests. Simple regression analyses were 
performed to elucidate associations. A General Linear Model was used to 
perform multivariate analysis if a categorical variable was included. 
 
5.4 Results 
5.4.1 Postprandial Chylomicron Concentration 
 
AUC (mmol/l.h) Baseline Post Treatment p 
Patients 18.5 (8.9- 32.6)* 13.5 (7.4-22.9) 0.05 
        Controls 9.2 (4.8- 14.4) 7.2 (4.6- 14.5) ns 
 
Table 5.1 Chylomicron AUC in Patients and Controls at baseline and   
following treatment 
*p=0.05 when compared with controls 
 
 
At baseline, postprandial chylomicron AUC was greater in patients compared 
with controls (Median 18.5mmol/l.h: IQR 8.9-32.6 vs 9.2 mmol/l.h:4.8-14.4) 
p=0.05. Following treatment we observed a fall in patient chylomicron AUC 
with a mean reduction of 6.8mmol/l.h (95% CI 0.1-13.6, p=0.05). However, in 
the control population, the reduction in chylomicron AUC was not significant 
with a mean decrease of 3.9mmol/l.h (95% CI –3.6 to 11.5, p=ns). As a result 
of the decrease in patient chylomicron AUC, at the end of 8 weeks treatment, 
patient and control chylomicron AUC concentrations were no longer 
significantly different (Table 5.1). Figure 5.1 shows chylomicron triglyceride 
107 
 
concentration in patients and controls before and after treatment with omega-
3 fatty acids. 
In patients, peak postprandial chylomicron triglyceride concentration fell 
following treatment with omega-3 fatty acids from 5.5mmol/l (95% CI 2.5- 7.4) 
to 3.8mmol/l (95% CI 1.7- 5.3, p=0.04). This reduction was not observed in 
the control group 3.7mmol/l (95% CI 1.0- 4.1) at baseline to 2.7 (95% CI 1.2-
4.1), p=ns. 
 
 
 
Figure 5.1 Postprandial Chylomicron Triglyceride Concentration 
Mean chylomicron triglyceride concentration over 8 hours following a fat load 
in patients and controls at baseline and following treatment 
(Pv1: patients at baseline, Pv2: patients post treatment, Cv1: controls at 
baseline Cv2: controls post treatment) 
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5.4.2 Relationship Between Chylomicron AUC and Baseline Parameters 
The relationship between baseline chylomicron AUC and baseline parameters 
are shown in table 5.2. There was no relationship between baseline 
chylomicron AUC and baseline urinary proteinuria or renal function in patients. 
In the patient group, chylomicron AUC correlated with baseline triglyceride, 
VLDL1, VLDL2, remnant lipoproteins and LDL III concentrations. Similar 
associations were observed in the control group with tighter correlations. 
 
5.4.3 Relationship Between Change in Chylomicron AUC 
No association was identified between any of the baseline parameters and the 
change in chylomicron AUC in the patient group. In the control population only 
the baseline levels of remnant lipoproteins correlated with change in 
chylomicron AUC (RLP-C  r2 27.2, p=0.02 and RLP-TG r2 20.6, p=0.04) 
(figures 5.3 and 5.4).   
 
Associations between change in chylomicron AUC and change in other lipid 
and lipoprotein parameters following treatment with omega-3 fatty acids are 
outlined in table 5.3. The only factors, which were associated with the change 
in chylomicron AUC in the patient group, were the change in LDL III 
concentration and the change in LDL III %. However, in the control group, 
extensive associations were seen with change in chylomicron AUC related to 
change in triglyceride, VLDL1, VLDL2, LDL III%, LDL III concentration, RLP-C 
and RLP-TG (figures 5.5 and 5.6). 
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In view of the apparent differences between the two groups, we proceeded to 
multivariate analysis using patient group as an independent categorical 
variable. This demonstrated that the difference between the 2 groups was not 
related to differences in either baseline chylomicron AUC or baseline 
triglyceride, but that the categorical variable of patient group appeared to be 
an independent predictor of the change in chylomicron AUC following 
treatment with omega-3 fatty acids (p=0.03).
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Baseline Parameters  All               Patients                        Controls 
    r2       p     r2  p        r2      p 
________________________________________________________________________________________________________ 
Triglyceride   35.7  <0.001   20.8  0.04                                     74.4  <0.001 
                                  
VLDL1    37.0  <0.001   40.6  0.004     76.2  <0.001 
 
VLDL2    9.9  0.04    25.3  0.02     77.6  <0.001 
 
RLP-C   39.2  <0.001   31.2  0.01     61.3  <0.001 
 
RLP-TG   37.9  <0.001   27.8  0.02               37.3          0.005 
           
LDLIII conc   31.0  <0.001    19.9  0.04      65.6  <0.00 
 
Table 5.2: Association Between Baseline Chylomicron AUC and Baseline Parameters 
Linear regression analysis of baseline chylomicron AUC with baseline parameters in all subjects as a whole, patients and controls. 
(r2= coefficient of determination).
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Parameters    All            Patients         Controls 
    r2  p   r2  p     r2  p 
________________________________________________________________________________________________________ 
∆ Triglyceride  2.7  ns   0  0     49.7  0.001 
 
∆ VLDL1   1.3  ns   0  0     30.3  0.01 
 
∆ VLDL2   0  ns   0  0     41.6  0.003 
 
∆ LDL III conc  0.3  ns   28.1  0.02     28.4  0.02 
 
∆ LDL III %   0  ns   21.9  0.03     41.7  0.03 
 
∆ RLP-C   0.7  ns   0  0     43.3  0.002  
 
∆ RLP-TG   0  ns   0  0     59.7  <0.001 
 
Table 5.3: Association Between Change in Chylomicron AUC and Change in Parameters 
Linear regression analysis of change in chylomicron AUC with change in parameters in all subjects as a whole, patients and 
controls. (r2= coefficient of determination).
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5.4.4 Postprandial VLDL Concentration 
 
AUC (mmol/l.h) Baseline Post Treatment p 
       Patients 7.4 (4.2- 11.8) 5.6 (4.2- 10.1) ns 
      Controls 4.6 (1.1- 9.8) 3.2 (1.5- 5.9) ns 
 
Table 5.4 VLDL1 AUC in Patients and Controls at Baseline and Following 
Treatment 
 
At baseline, postprandial VLDL1 AUC did not differ between patients and 
controls [Median 7.4mmol/l.h (IQR 4.2- 11.8) vs 4.6mmol/l.h (1.1- 9.8), p=ns]. 
Following treatment with omega-3 fatty acids, there was a mean reduction of 
1.7mmol/l.h (95% CI -1.0 to 3.4) in patients and 1.5mmol/l.h (95% CI -1.9 to 
3.2) in control, both p=ns.  
At the end of treatment, patients and control postprandial VLDL1 AUC 
remained similar (Median 5.6mmol/l.h (4.2- 10.1) vs 3.2mmol/l.h (1.5- 5.9), 
p=ns). Figure 5.2 shows VLDL1 triglyceride concentration in patients and 
controls before and after treatment with omega-3 fatty acids. Patient peak 
postprandial VLDL1 triglyceride concentration fell from 3.3mmol/l (IQR 2.0- 
4.2) to 2.4mmol/l (1.5- 3.4), p=0.04. Similarly, in the control group, peak 
postprandial VLDL1 triglyceride concentration fell from 2.7mmol/l (IQR 1.1- 
3.5) to 1.7mmol/l (0.8- 2.7), p=0.03.  
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5.4.5 Relationship Between VLDL1 AUC and Baseline Parameters 
The association between baseline VLDL1 AUC and baseline parameters in 
patients and controls are shown in table 5.5. Baseline VLDL1 AUC did not 
correlate with baseline serum creatinine, eGFR or urinary proteinuria in the 
patient group. In the patient group, the lack of relationship between baseline 
VLDL1 AUC and baseline triglyceride is noteworthy. A clear outlier who is 
behaving differently from the other patients can explain this. Once this outlier 
is removed, a strong correlation is present (r2=31%, p=0.015). On multivariate 
analysis, subject group was not an independent predictor of baseline VLDL1 
AUC.  
Change in VLDL1 AUC did not correlate with any baseline parameter or 
change in triglyceride, VLDL1, VLDL2, LDL III%, LDL III concentration, RLP-C 
and RLP-TG in either patients or controls. 
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Figure 5.2 Postprandial VLDL1 Triglyceride Concentration 
Mean VLDL1 triglyceride concentration over 8 hours following a fat load in 
patients and controls at baseline and following treatment 
(Pv1: patients at baseline, Pv2: patients post treatment, Cv1: controls at 
baseline Cv2: controls post treatment). 
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Baseline Parameters           Patients            Controls 
        r2  p     r2  p 
_______________________________________________________________________________________________________ 
Triglyceride       14.6  0.07     82.9  <0.001 
                                        
VLDL1        36.7  0.006     91.6  <0.001 
        
VLDL2        30.3  0.01     74.0  <0.001 
       
RLP-C       15.0  0.07     65.0   <0.001 
        
RLP-TG       16.8  0.06     49.4   0.001 
                  
LDLIII %       10.9  0.1     39.1   0.004  
     
LDLIII mass       23.7  0.03     67.0   <0.001 
 
 
Table 5.5: Association Between VLDL1 AUC and Baseline Parameters 
Linear regression analysis of VLDL1 AUC with baseline parameters in patients and controls, r
2= coefficient of determination. 
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5.5 Discussion 
The aim of this study was to investigate chylomicron and VLDL1 metabolism in 
patients with nephrotic range proteinuria, compare them to normal controls 
and to examine the effect of treatment with omega-3 fatty acids on their 
metabolism. By separating chylomicrons and VLDL1 from plasma through 
density gradient ultracentrifugation, we have shown that postprandial 
chylomicron concentration is significantly greater in patients with nephrotic 
range proteinuria compared to normal controls. We demonstrated that 
baseline triglyceride and triglyceride rich lipoproteins were associated with 
baseline chylomicron concentration and that treatment with omega-3 fatty 
acids led to a significant reduction in chylomicron AUC in the patient group but 
not the controls. In patients, change in chylomicron concentration was 
associated with change in LDL III proportion and concentration. There was no 
association between change in chylomicron concentration and change in 
triglyceride, VLDL1, VLDL2 and remnant lipoproteins in the patient group. 
However, in the control group there was a strong association with all these 
parameters.  
VLDL1 AUC did not differ at baseline between patients and controls. 
Furthermore, there was no significant effect on VLDL1 AUC following 
treatment in patients or controls. However, peak postprandial VLDL1 
triglyceride concentration was significantly lowered by treatment with omega-3 
fatty acids in all subjects. Baseline VLDL1 AUC correlated with baseline 
VLDL1, VLDL2 and LDL III mass in patients. In controls, there was a strong 
correlation between VLDL1 AUC and triglyceride-rich lipoproteins. 
 
 117 
 
There is little information in the literature on chylomicron metabolism in 
humans with nephrotic syndrome. Animal studies have shown changes in 
chylomicron synthesis and catabolism as well as qualitative compositional 
changes (202;203). Warwick et al examined chylomicron metabolism in 9 
patients with nephrotic range proteinuria by measuring changes in triglyceride 
and retinyl palmitate concentration in the d<1.006g/ml fraction of plasma 
following Vitamin A loaded standard fat meal. They found no significant 
difference in the time course of the lipaemic response, which was confirmed 
by comparing AUC curves for controls and patients. They concluded that 
chylomicron metabolism did not differ between patients and controls (204). 
This was a small study, which has not been confirmed.  
As discussed earlier, the effects of omega-3 fatty acids on lipid metabolism is 
not completely understood. There is evidence to suggest that omega-3 fatty 
acids reduce triglyceride levels after a postprandial challenge(130) and they 
have also been shown to lower postprandial chylomicron and chylomicron 
remnants (122). This is thought to be through acceleration of chylomicron lipid 
clearance by facilitation of lipoprotein lipase-mediated lipolysis (120). We 
observed a reduction in chylomicron AUC in the patient group but not the 
controls and found this reduction was independent of change in triglyceride 
(figures 5.5 & 5.6) and baseline chylomicron AUC. Multivariate analysis 
showed that subject group was an independent predictor of change in 
chylomicron AUC following treatment with omega-3 fatty acids. The reasons 
behind this are unclear but may be related to structural or compositional 
change in the chylomicrons of patients with nephrotic range proteinuria. 
Westphal et al examined the effect of 4g of omega-3 fatty acids (Omacor) on 
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hypertriglyceridaemic men following a fat load. They found chylomicron 
concentration to fall by 49-64% over 4-8 hours(205). Thus, the effect of 
omega-3 fatty acids on chylomicrons is more marked at higher baseline 
triglyceride levels.  
Treatment with omega-3 fatty acids has been shown to reduce VLDL by 
reducing their synthesis and secretion. They inhibit 1,2-diacylglycerol-sterol O-
acyltransferase(206) or phosphatidate phosphatase (207) thereby resulting in 
a substantial reduction in synthesis of VLDL. This reduced synthesis would be 
in keeping with our finding that peak postprandial VLDL1 was reduced but 
VLDL1 AUC was unchanged by treatment with omega-3 fatty acids.  
 
Zilversmit described atherosclerosis as a „postprandial phenomenon‟ over 20 
years ago (42). Since then, a number of studies have linked disturbed 
metabolism of postprandial lipoproteins with increased cardiovascular risk. A 
meta-analysis of 17 prospective studies found that a 1 mmol/l rise in fasting 
plasma triglyceride was associated with a 30% risk of total CVD in man and 
75% increase in women (208). Postprandial lipaemia is defined as the 
physiological transitory alteration in lipoprotein metabolism lasting from 6 to 12 
hours after ingesting a fatty meal.  Fasting plasma triglycerides are known to 
predict the duration and magnitude of postprandial lipaemia (119). The 
hypertriglyceridaemia, which occurs following a meal, reflects the 
accumulation of triglyceride rich lipoproteins such as chylomicrons and their 
remnants (early response) plus VLDL and its remnants (late response). These 
triglyceride rich lipoproteins are important in the pathogenesis of 
atherosclerosis as they allow the accumulation of lipids within the arterial wall 
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through the generation of small dense LDL and reduction in HDL(209). 
Patients with nephrotic range proteinuria are known have an increased 
cardiovascular risk. They are known to have higher levels of fasting 
triglycerides at baseline than normal controls(164) therefore it would follow 
that they would have higher levels of postprandial  triglyceride rich lipoproteins 
contributing to their higher cardiovascular risk. The recognition of these 
abnormalities is important as it allows us to target treatment thereby reducing 
this excess cardiovascular risk in this population. 
 
The effect of omega-3 fatty acids on postprandial lipaemia in patients with 
nephrotic range proteinuria has not, to our knowledge, been studied before. 
Statins are currently the mainstay of treatment for these patients as they 
reduce cholesterol and LDL-C concentration. Fibrates are effective in reducing 
triglyceride levels particularly in hypertriglyceridaemic patients but are poorly 
tolerated in patients with renal disease. Monotherapy with statins alone may 
not be sufficient in this group of patients to have an adequate effect on both 
cholesterol and postprandial lipaemia. We have shown that omega-3 fatty 
acids are effective in reducing postprandial lipaemia in patients with nephrotic 
syndrome. This effect is not related to the change in triglyceride level but is 
related to higher baseline triglyceride levels in these patients.  
 
In summary, we have shown that there is increased postprandial lipaemic 
response in patients with nephrotic range proteinuria and that this is reduced 
by treatment with omega-3 fatty acids. These differences may be due to 
structural and compositional differences in chylomicrons and VLDL in patients 
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with nephrotic range proteinuria compared with the controls. Further analysis 
of the composition and structure of these particles may provide us with more 
information on how to interpret these results. 
 
 
Baseline Patient TG (mmol/l)
C
h
a
n
g
e
 i
n
 P
a
ti
e
n
t 
C
h
y
lo
 A
U
C
 (
m
m
o
l/
l.
h
)
54321
20
10
0
-10
-20
-30
-40
p=ns
 
Figure 5.3:  Patient Change in Chylomicron AUC vs Baseline Triglyceride 
Concentration 
 
Linear regression analysis of change in chylomicron concentration with 
baseline triglyceride concentration in patients. 
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Figure 5.4: Control Change in Chylomicron AUC vs Baseline Triglyceride 
Concentration 
Linear regression analysis of change in chylomicron concentration with 
baseline triglyceride concentration in controls. 
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Figure 5.5: Patient Change in Chylomicron AUC vs Patient Change in 
Triglyceride Concentration 
Linear regression analysis of change in chylomicron concentration with 
change in triglyceride concentration in patients. 
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Figure 5.6: Control Change in Chylomicron AUC vs Control Change in 
Triglyceride Concentration 
 
Linear regression analysis of change in chylomicron concentration with 
change in triglyceride concentration in controls, r2= 49.7%, p=0.001. 
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Chapter 6: The Effect of 
Omega-3 Fatty Acids on 
Structure and Composition of     
Chylomicron and VLDL1 
Particles 
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6.1 Introduction 
Patients with nephrotic range proteinuria have an excess of triglyceride rich 
lipoproteins such as chylomicrons and VLDL. In the previous chapter, we 
have demonstrated that there is delayed postprandial chylomicron clearance 
in patients with proteinuria. Several studies have shown that the increase in 
the VLDL1 subgroup of VLDL in patients with nephrotic range proteinuria is as 
a result of delayed lipoprotein clearance and increased hepatic production 
although our data from chapter 5 did not confirm the presence of impaired 
clearance(162;165;168;210).  
Our laboratory has previously shown abnormalities in the structure of VLDL1 
in patients with nephrotic range proteinuria (175) with a smaller more 
crystalline structure and we postulated that this abnormal structure contributed 
to the impaired clearance of VLDL particles. The evidence regarding the 
structure of chylomicrons in humans is sparse. 
Therefore, the aim of our study was firstly to examine the apolipoprotein and 
lipid components of chylomicrons and VLDL1 in patients with nephrotic range 
proteinuria thereby establishing the structure of these particles in both patient 
and control populations. Thereafter, we examined the effect of omega-3 fatty 
acids on the structure of these lipoproteins in patients and controls. 
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6.2 Subjects and Methods 
 
The patients and controls described in the method section were studied in this 
chapter. Chylomicrons and VLDL1 fractions were separated as described 
previously. Apolipoproteins B, AI, CII, CIII and E were measured on fasting 
EDTA plasma samples from patients before and following treatment with 
omega-3 fatty acids. Apolipoproteins B, CII, CIII and E were measured on 
fasting VLDL and peak chylomicrons in both patient and control groups pre 
and post treatment.  
 
 
6.3 Results 
 
6.3.1 Baseline Plasma Apolipoproteins 
 
The plasma content of apolipoproteins is shown in table 6.1. There was 
significantly less apolipoprotein CIII in the controls with a trend towards less 
apolipoprotein B and CII.  
Each VLDL, IDL and LDL particle carries one moiety of apo B therefore, using 
this as a reference, a crude estimate of the amount of apo CII, CIII and E 
moieties per lipoprotein particle in the plasma was obtained. As a result, we 
found no difference between the amount of CII, CIII and E per lipoprotein 
particle (table 6.1). 
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Apolipoprotein  Patients   Controls      p 
______________________________________________________________ 
 
B (mg/dl)  122.5 (100.9- 139.2) 112.1 (96-0- 119.4)          ns 
 
AI (mg/dl)  125.6 (115.0- 138.9) 137.4 (116.0- 167.9)         ns 
 
CII (mg/dl)  5.6 (4.4- 7.1)   4.29 (3.3- 5.5)                ns
            
CIII (mg/dl)  15.1 (13.1- 18.2)  12.6 (10.1- 14.3)          0.02 
 
E (mg/dl)  4.7 (4.1- 5.6)   4.0 (3.5- 5.0)            ns 
 
Apo CII/B*  4.4 (3.5- 5.9)   4.2 (2.9- 4.8)            ns
   
Apo CIII/B*            12.2 (10.6- 15.5)  11.7 (9.6- 12.8)           ns 
 
Apo E/B*  3.8 (3.0- 5.1)   3.8 (3.3- 4.4)            ns 
 
* (mg/mg x 10-2) 
 
Table 6.1: Plasma Apolipoproteins (n=17) 
Plasma apolipoproteins in patients compared with controls. Prior to statistical 
analysis, any parameter which was not normally distributed was normalised 
by log transformation. All data were compared using unpaired t-tests. 
 
 
 
6.3.2 The Effect of Treatment on Plasma Apolipoproteins 
Tables 6.2 and 6.3 represent the effect of treatment with omega-3 fatty acids 
on plasma apolipoprotein concentration in patients and controls. The plasma 
apolipoproteins of patient and controls were not affected by treatment with 
omega-3 fatty acids. There was, however, a significant reduction of CII per 
lipoprotein particle in the patient group. This was not seen in the control 
population 
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Apolipoprotein  Baseline     Post Treatment  p 
_____________________________________________________________ 
 
B (mg/dl)  122.5 (100.9- 139.2) 123.7 (114.8- 154.8)           ns
     
AI (mg/dl)  125.6 (115.0- 138.9) 124.2 (113.5- 138.9)           ns 
 
CII (mg/dl)  5.6 (4.4- 7.1)   5.0 (4.1- 6.9)             ns
   
CIIII (mg/dl)  15.1 (13.1-18.2)  14.4 (13.2- 18.8)            ns 
 
E (mg/dl)  4.7 (4.1- 5.6)   5.0 (4.3- 5.6)             ns 
 
Apo CII/B*  4.4 (3.5- 5.9)   4.1 (3.1- 5.3)                    0.01 
 
Apo CIII/B*  12.2 (10.6- 15.5)  11.6 (10.0- 12.6)            ns 
  
Apo E/B*  3.8 (3.0- 5.1)       3.7 (3.3- 4.5)             ns 
 
 
All values median & IQR 
* (mg/mg x 10-2) 
 
 
Table 6.2: Effect of Treatment on Patient Plasma Apolipoproteins (n=17) 
 
The effect of treatment on plasma apolipoproteins in patients. Prior to 
statistical analysis, any parameter which was not normally distributed was 
normalised by log transformation. All data were compared using paired t-tests. 
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Apolipoprotein  Baseline     Post Treatment   p 
______________________________________________________________ 
 
B (mg/dl)  112.1 (96.0- 119.4)  110.0 (96.2- 122.1)            ns 
     
AI (mg/dl)  137.4 (116.0- 167.9) 138.8 (114.6- 172.0)           ns 
 
CII (mg/dl)  4.3 (3.3- 5.5)   4.3 (3.1- 5.6)              ns 
   
CIIII (mg/dl)  12.6 (10.1- 14.3)  12.7 (9.1- 13.9)             ns 
 
E (mg/dl)  4.0 (3.5- 5.0)   4.3 (3.6- 5.4)             ns 
 
Apo CII/B*  4.2 (2.9- 4.8)   4.1 (2.9- 4.7)              ns 
 
Apo CIII/B*  11.7 (9.6- 12.8)  11.2 (9.0- 13.3)       ns 
 
Apo E/B*  3.8 (3.3- 4.4)   3.8 (3.4- 4.5)           ns
    
 
 
Table 6.3: Effect of treatment on Control Plasma Apolipoproteins (n=17) 
The effect of treatment on plasma apolipoproteins in controls.  All values 
expressed as median & IQR. * (mg/mg x 10-2) 
 
  
 
6.3.3 Chylomicron Apolipoproteins & Compositions: Patients vs 
Controls 
The concentration of chylomicron apolipoproteins in both patient and control 
groups are shown in table 6.4. The analysis of the chylomicron 
apolipoproteins was performed in 10 patients and 6 controls as the 
concentration of chylomicrons were too low in some patients and controls to 
allow accurate measurement of either apo CII, CIII or E. If one of the 
chylomicron apolipoproteins was undetectable, then all of the apolipoprotein 
and composition results for that subject were disregarded to avoid biasing the 
result.  There was twice as much apo B present in the control chylomicrons 
(p=0.03) compared with patients, but the quantities of other chylomicron 
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apolipoproteins did not differ significantly. The molar ratio of apolipoprotein 
CII, CIII and E to apolipoprotein B was calculated in order to assess the 
quantity of apolipoprotein CII, CIII and E on each chylomicron particle (table 
6.5). This showed that the patient group had significantly higher levels of apo 
CII, III and E per lipoprotein particle. In addition, the patients‟ chylomicron 
particles contained greater quantities of triglyceride, total cholesterol, free 
cholesterol and phospholipids compared to the controls. Given that the 
triglyceride is the greatest constituent of chylomicron particles, the 3 fold 
increase in chylomicron triglyceride strongly suggests that larger chylomicron 
particles are present in the patients with proteinuria. However, surface 
structure of chylomicrons did not differ between the patient and control group 
as outlined in table 6.6. In the control group, we observed a strong 
relationship between chylomicron size and baseline fasting plasma triglyceride 
(r2 85.9%, p=0.005). This was not observed in the patient group (r2 0, p=0.6). 
On multivariate analysis, subject group was not an independent predictor of 
particle size. 
Apolipoprotein  Patients     Controls  p 
    (n=10)        (n=6) 
______________________________________________________________ 
 
 
B (mg/dl)  0.25 (0.20- 0.39)  0.51 (0.45- 0.83)         0.04 
   
CII (mg/dl)  0.34 (0.26- 0.62)  0.19 (0.13- 0.74)           ns 
   
CIIII (mg/dl)  0.90 (0.52- 1.82)  0.32 (0.18- 1.83)           ns 
   
E (mg/dl)  0.13 (0.09- 0.28)  0.09 (0.05- 0.34)           ns 
 
 
Table 6.4: Plasma Concentration of Chylomicron Apolipoproteins: 
Patients vs Controls 
 
(All values median & IQR) 
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Moles per Particle  Patients       Controls     p 
    (n=10)         (n=6) 
______________________________________________________________ 
 
 
Apo CII           68.3 (56.9- 95.2) 24.6 (13.8- 60.4)  0.03 
  
Apo CIII           179 (145- 248) 58.3 (16.4- 134.8)          0.03     
      
Apo E             7.3 (5.7- 9.8)      2.8 (1.7- 6.6)                 0.02       
            
Triglyceride*   491000 (406000-740000)   156000 (89000-312000)           0.008 
 
Total Cholesterol* 58000 (42000- 85000) 19000 (9500- 40000)        0.01 
  
Free Cholesterol* 29000 (21000- 44000) 10000 (4000- 25000)      0.03 
 
Phospholipid* 46000 (36000- 79000)     19000 (9000- 39000)     0.02 
     
 
 
Table 6.5: Apolipoproteins and Lipid Content per Chylomicron Particle: 
Patients vs controls 
 
Prior to statistical analysis, any parameter which was not normally distributed 
was normalised by log transformation. All data were compared using unpaired 
t-tests. * Expressed to the nearest 1000. 
(All median & IQR) 
 
 
 
Patients     Controls   p 
mg/mg  (n=10)        (n=6) 
______________________________________________________________ 
 
 
FC:PL   0.58 ± 0.13       0.50 ± 0.15   ns 
 
CII:PL           1.5 x 10-3 ± 0.6 x 10-3  1.4 x 10-3 ± 0.3 x 10-3               ns 
  
CIII:PL         3.6 x 10-3 ± 1.5 x 10-3  2.7 x 10-3 ± 1.1 x 10-3               ns 
 
E:PL         0.15 x 10-3 ± 0.07 x 10-3    0.18 x 10-3 ± 0.08 x 10-3       ns 
      
 
Table 6.6 Surface Structure of Chylomicrons 
(All mean & SD)  
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6.3.4 Chylomicron Apolipoproteins & Compositions: Treatment Effect in 
Patients & Controls 
 
 
The effect of treatment with 4 g daily of omega-3 fatty acids on chylomicron 
apolipoproteins and compositions in both patients and controls is shown in 
tables 6.7 and 6.8. No significant change in chylomicron apolipoprotein 
content or chylomicron lipid composition was observed in either population 
following treatment. 
 
 
Moles per particle  Baseline  Post Treatment  p 
                  
______________________________________________________________ 
 
 
Apo CII  68.3 (56.9- 95.2)  87.5 (41.7- 158.3)      ns 
             
Apo CIII  179 (145- 248)  184 (122- 326)                ns
                  
Apo E   7.3 (5.7- 9.8)    8.7 (6.2- 16.2)      ns
                      
Triglyceride*  491000 (406000-740000)   455000(196000-701000)  ns 
   
Total Cholesterol* 58000 (42000- 85000) 53000 (24000- 89000)       ns 
  
Free Cholesterol* 29000 (21000- 44000)  22000 (15000- 39000)        ns 
  
Phospholipid * 46000 (36000- 79000) 44000( 20000- 98000)       ns 
 
 
 
Table 6.7: Apolipoproteins and Lipid content per chylomicron particle: 
Treatment Effect in Patients (n=10) 
 
Prior to statistical analysis, any parameter which was not normally distributed 
was normalised by log transformation. All data were compared using unpaired 
t-tests. * Expressed to the nearest 1000. 
(All median & IQR) 
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Moles per particle  Baseline    Post Treatment  p 
                  
______________________________________________________________ 
 
Apo CII   24.6 (13.8-60.4) 40.0(6.6-146.7)           ns 
              
Apo CIII   58.3(16.4-134.8) 222(18-848)    ns 
                    
Apo E    2.8 (1.7-6.6)  5.3 (2.7-13.5)   ns 
                        
Triglyceride*  156000 (89000-312000) 157000(43000-684000)  ns 
      
Total Cholesterol* 19000 (9500-40000) 9000(4000-98000)           ns
   
Free Cholesterol* 10000(4000-25000)  15000(1000-41000)             ns
  
Phospholipid *    19000 (9000-39000) 18000 (7000-83000)  ns
  
 
Table 6.8: Apolipoproteins and Lipid Content per Chylomicron Particle: 
Treatment Effect in Controls (n=6) 
 
* Expressed to the nearest 1000. (All values median & IQR)  
 
 
 
6.3.5 VLDL1 Apolipoproteins & Compositions: Patients vs Controls 
The concentration of VLDL1 apolipoproteins are shown in table 6.9. Once 
again as with the chylomicrons, complete data was only available for 15 
patients and 13 controls therefore only these subjects were included in the 
analysis. No difference in apolipoprotein concentration of VLDL1 between 
patients and controls was seen. 
Furthermore, after calculating the molar ratio of apolipoprotein CII, CIII and E 
to apo B, there was no difference identified between patients and controls 
(table 6.10). The triglyceride, cholesterol and phospholipids content of the 
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VLDL1 particles were also similar. In addition, surface structure did not differ 
between patients and controls (table 6.11). 
 
Apolipoprotein  Patients     Controls   p 
    (n=15)       (n=13) 
______________________________________________________________ 
 
 
B (mg/dl)   3.33(1.79-5.12) 2.82 (1.15-3.71)                  ns
       
CII (mg/dl)   1.14 (0.50-1.77) 0.78 (0.34-2.0)                    ns 
     
CIIII (mg/dl)   3.10 (1.68-4.50) 1.65 (1.04-3.54)                  ns 
    
E (mg/dl)   0.12 (0.09-0.34) 0.17 (0.11-0.29)                  ns
  
 
Table 6.9: Plasma Concentration of VLDL1 Apolipoproteins: Patients vs 
Controls 
(All values median & IQR) 
 
 
 
 
 
Moles per particle  Patients     Controls            p 
    (n=15)                (n=13) 
______________________________________________________________ 
 
 
Apo CII  17.8 (12.9-23.6)  24.7 (15.6-36.3)           ns 
             
Apo CIII  46.4 (39.3-67.0)  47.7 (30.7-81.1)           ns
  
Apo E   0.87 (0.54-1.63)  1.00 (0.77-1.63)           ns
    
Triglyceride*  23000 (20000-2000) 26000 (22000-40000)        ns 
 
Total Cholesterol* 9000 (8000-10000)  10000 (8000-13000)          ns 
  
Free Cholesterol* 5000 (4000-6000)  5000 (4000-7000)            ns
           
Phospholipid * 7000 (6000-8000)  7000 (6000-11000)            ns         
        
 
Table 6.10: Apolipoproteins and Lipid Content per VLDL1 Particle: 
Patients vs controls 
* Expressed to nearest 1000. (All values median & IQR) 
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mg/mg   Patients     Controls  p 
    (n=15)        (n=13) 
______________________________________________________________ 
 
 
FC:PL    0.7 ± 0.08        0.7 ± 0.07  ns 
 
CII:PL    2.6. x 10-3 ± 1.1       2.9 x 10-3 ± 1.2  ns 
  
CIII:PL   7.0 x 10-3 ± 2.4       6.0. x 10-3 ± 1.3  ns 
 
E:PL           0.14 x 10-3 ± 0.08       0.16 x 10-3 ± 0.02 ns 
      
 
Table 6.11: Surface Structure of VLDL1 
 
(All mean & SD) 
 
 
 
6.3.6 VLDL1 Apolipoproteins & Compositions: Treatment Effect in 
Patients and Controls 
Tables 6.12 and 6.13 display the apolipoprotein and lipid content per VLDL1 
particle following treatment with omega-3 fatty acids in patients and controls. 
Treatment with omega-3 fatty acids did not alter the apolipoprotein or lipid 
content of VLDL1 particles in either patients or controls. 
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Moles per particle  Baseline  Post Treatment  p 
                  
______________________________________________________________ 
 
Apo CII  17.8 (12.9-23.6)  20.4 (13.3-30.7)  ns
   
Apo CIII  46.4 (39.3-67.0)  50.0 (40.3-58.2)  ns 
 
Apo E   0.87 (0.54-1.63)  0.71 (0.44-1.62)  ns
                         
Triglyceride*         23000 (20000-27000)    25000 (24000-30000) ns
    
Total Cholesterol* 9000 (8000-10000)  10000 (8000-11000) ns 
  
Free Cholesterol* 5000 (4000 -6000)  5000 (4000 -6000)  ns 
   
Phospholipid * 7000 (6000-8000)  8000(6000-8000)  ns 
 
Table 6.12: Apolipoproteins and Lipid Content per VLDL particle: 
Treatment Effect in Patients (n=15) 
*Expressed to nearest 1000. (All values median& IQR)  
 
 
 
 
Moles per particle       Baseline   Post Treatment  p 
                  
______________________________________________________________ 
 
 
Apo CII  24.7 (15.6-36.3)  18.2 (8.8-31.8)  ns 
   
Apo CIII  47.7 (30.7-81.1)  42.3 (24.5- 62.0)  ns 
   
Apo E   1.00 (0.77-1.63)  1.2 (0.68-2.88)  ns 
 
Triglyceride  26000 (22000-40000) 27000 (19000-341000) ns
  
Total Cholesterol 10000 (8000-13000) 10000 (8000-11000) ns
     
Free Cholesterol 5000 (4000-7000)  5000 (4000-6000)  ns
    
Phospholipid  7000 (6000-12000)  7000 (6000-8000)  ns 
 
Table 6.13: Apolipoproteins and Lipid Content per VLDL Particle: 
Treatment Effect in Controls (n=13) 
*Expressed to nearest 1000. (All values median & IQR) 
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6.4 Discussion 
In this study, we have demonstrated that chylomicrons in patients with 
nephrotic range proteinuria differ in structure and composition compared with 
normal controls. Patients had significantly higher levels of apolipoprotein CII, 
CIII and E per chylomicron particle with greater quantities of triglyceride, total 
cholesterol, free cholesterol and phospholipids. The quantity of triglyceride per 
chylomicron particle can be used as a marker of particle size and so this 
strongly suggests that patient chylomicron particles are significantly larger 
than the control population. Treatment with omega-3 fatty acids did not alter 
the structure or composition of chylomicrons in patients or controls. In contrast 
to previous data, however, we found no difference in the structure or 
composition of VLDL1 particles when comparing patients and controls(175). 
Once again, treatment with omega-3 fatty acids did not alter the composition 
or structure of VLDL1 particles in neither patients nor controls. 
There is little in the literature regarding the structure of chylomicrons in human 
nephrotics. Levy et al examined chylomicron structure in nephrotic rats. They 
concluded that chylomicrons of nephrotic rats were larger in size with a higher 
triacyglycerol to protein ratio(202). A further study by this group once again 
showed that chylomicrons of nephrotic rats were larger, deficient in apo E and 
apo AI, rich in triacylglycerol and cholesterol but poor in phospholipid (203).  
To our knowledge, there are no human studies examining chylomicron 
structure in nephrotic humans. 
Our data suggests that patients with nephrotic range proteinuria have larger 
chylomicrons than the control group with decreased apolipoprotein to 
triglyceride ratio. This size discrepancy may be responsible for less efficient 
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lipolysis and therefore clearance of these larger particles. In the previous 
chapter, we demonstrated that treatment with omega-3 fatty acids improved 
chylomicron clearance in patients with nephrotic range proteinuria. However, 
treatment did not alter the structure of chylomicrons in the patient or control 
group. Thus, the better clearance observed is not related to structural 
changes. In the control group, we observed a strong relationship between 
chylomicron size and baseline fasting plasma triglyceride. This was not 
observed in the patient group with no correlation between particle size and 
baseline triglyceride.  Therefore differences in baseline triglyceride levels 
cannot account for the difference in structure of the chylomicron particles. On 
multivariate analysis, subject group was not an independent predictor of 
particle size. However, in view of the small numbers, these results must be 
interpreted with caution. 
We did not show any difference in structure or composition of VLDL1 between 
patients with nephrotic range proteinuria compared with controls. In addition, 
treatment with omega-3 fatty acids did not alter the structure of these particles 
in both groups. There are very few studies examining the structure of VLDL1 in 
nephrotic humans but, in contrast to our findings, data from our laboratory has 
previously shown that VLDL1 from nephrotic patients were deficient in apo CII, 
CIII and E. The particles were smaller, with increased triglyceride content per 
particle with higher free cholesterol to phospholipid ratio(175).  
These differences in results can be explained in a number of ways. Firstly, 
patients with nephrotic range proteinuria are a very heterogeneous group with 
a range of lipoprotein abnormalities and so the numbers may be too small to 
be representative of the group as a whole. The apo B assay used in the 
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laboratory is currently more sensitive at detecting lower levels than the older 
assay used in the previous study. Also, the triglyceride levels in our control 
population are higher than the previous study as we attempted to triglyceride 
match our control group.  
Thus, we have demonstrated that chylomicron particles in patients with 
nephrotic range proteinuria are larger than in normal controls. This structural 
abnormality may be why their clearance is reduced. We did not observe any 
difference in VLDL1 structure. Although treatment with omega-3 fatty acids 
improves chylomicron clearance in patients with nephrotic range proteinuria, 
they do not seem to do this through altering their structure. Therefore, it is 
possible that omega-3 fatty acids reduce synthesis of chylomicrons.  
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Chapter 7: Omega-3 Fatty Acids 
and HDL Subfractions in Patients 
with Nephrotic Range Proteinuria 
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7.1 Introduction 
 
Prospective epidemiological studies have demonstrated that reduced levels of 
plasma HDL-C are an independent risk factor for coronary heart disease and 
that increasing HDL-C reduces this risk. This is has been reviewed in detail in 
chapter 1. Plasma high density lipoprotein (HDL) is heterogeneous, 
comprising of a number of particles of differing size and composition. There 
are several ways of separating HDL subfractions. Ultracentrifugation 
separates HDL into 2 subclasses: HDL2 and HDL3. HDL2 is larger and 
cholesterol-rich and HDL3 is smaller and denser. Electrophoretic methods 
separate HDL on the basis of their charge and size. Blanche et al described 5 
subclasses: HDL2a, HDL2b, HDL3a, HDL3b and HDL3c (see chapter 2). It is 
generally thought that larger cholesterol rich HDL2 is cardioprotective while 
smaller dense HDL3 is associated with an increased risk of CHD. However, 
there is conflicting data regarding the atherogenicity of these subfractions. 
In most studies examining patients with nephrotic syndrome or nephrotic 
range proteinuria, HDL-C levels have been reported as normal or 
low(167;170;186;211). Reduced HDL2 levels and normal HDL3 levels are also 
reported(170;212;213). Most of the data regarding the effect of treatment with 
omega-3 fatty acids on HDL metabolism is favourable. 
The aim of this study was two fold. 1. To compare the distribution of HDL 
subfractions in subjects with nephrotic range proteinuria (patients) and in age 
and sex matched controls (controls). 2. To study the effect of omega-3 fatty 
acids on HDL subfraction distribution. 
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7.2 Subjects & Methods 
 
17 patients and 17 controls as described earlier took part in this study. Fasting 
EDTA plasma prior to and following an eight week treatment period with 
omega-3 fatty acids were taken. Analysis was carried out on fresh samples 
within 5 days of drawing the samples. Samples were kept refrigerated at -4°C. 
HDL2 and HDL3 subfractions were isolated by density gradient 
ultracentrifugation as described in the methods section. The sizes of HDL2 and 
HDL3 were quantified using gradient gel electrophoresis as described in 
chapter 2.  
 
7.3 Statistics 
 
 
Statistical analyses were carried out using MINITAB 13.1 for Windows 
(Minitab inc). Results are shown as mean and standard deviation (SD), or 
where data were not normally distributed as median and interquartile ranges 
(IQR). Prior to statistical analysis, any factor that was not normally distributed 
was normalised by log transformation. Patient and control results were 
compared using unpaired t-tests. Results pre and post treatment were 
compared using paired t-tests. Linear regression analysis was performed to 
identify significant correlations with a „p‟ value less than 0.05 considered 
significant. 
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7.3 Results 
 
 
7.3.1 Baseline HDL Concentrations 
 
At baseline, HDL-C, total HDL concentration and HDL2 did not differ 
significantly between patients and controls (table 7.1). HDL3 concentration 
displayed a trend towards being higher in the patient population but this did 
not reach statistical significance (p=0.059). Other baseline parameters in 
patients compared with controls are presented in chapter 3. 
 
 
 
 
Patients   Controls   p 
 
_____________________________________________________________ 
 
HDL-C    1.0 (0.9-1.1)   1.1 (0.9-1.4)   ns 
(mmol/l) 
 
Total HDL    196.3 (172.2-231.6)  177.1 (159.3-216.8)  ns 
(mg/dl) 
 
HDL2       66.5 (52.4 –83.5)      80.9 (38.4 –117.4)  ns 
(mg/dl)  
 
HDL3       132.6 (110.3-143.0)    116.7 (93.3-130.1)          0.059 
(mg/dl) 
 
  
Table 7.1: Baseline HDL Concentrations in Patients vs Controls (n=17) 
 
 
7.3.2 Treatment Effect in Patients and Controls 
The effect of treatment with omega-3 fatty acids on HDL2 concentrations in 
patients and controls is outlined in table 7.2. In the patient group, HDL2 
concentration increased by a mean of 11.3 mg/dl (95% CI 0.6 – 22.0, p=0.05). 
In controls, HDL2 increased by a mean of 17.2 mg/dl (95% CI 1.4- 33.0, 
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p=0.02). Although the medians appear similar, the mean results are shown 
below and statistically differ. 
The effect of treatment on HDL3 and total HDL concentration in patients and 
controls is shown in tables 7.3 and 7.4. Treatment with omega-3 fatty acids 
did not alter HDL3 or total HDL concentration in patients or controls.    
 
 
HDL2 (mg/dl)  Baseline     Post Treatment              p 
 
______________________________________________________________ 
 
 
Patients   66.5 (52.4-83.5) 71.0 (52.6-118.2)  0.05 
 
 
Controls      80.9 (38.4-117.4)* 80.1 (58.6-127.6) **           0.02 
 
 
 
Table 7.2: The Effect of Treatment on Patient and Control HDL2 
Concentrations 
 
(All median & IQR)  
In controls, although the medians quoted above appear similar, the mean 
results statistically differ (*mean 84.5 ± 59.4 vs **mean 101.7± 70.3). 
 
 
 
 
 
HDL3 (mg/dl)  Baseline  Post Treatment   p 
 
______________________________________________________________ 
 
 
Patients   132.63(110.3-143.0) 124.9 (117.1-140.1)  ns 
 
 
Controls   116.7 (93.3-130.1)  109.8 (103.1-118.7)  ns 
 
 
Table 7.3: The Effect of Treatment on Patients and Control HDL3 
Concentrations 
(All median & IQR) 
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Total HDL (mg/dl)  Baseline  Post Treatment  p 
______________________________________________________________ 
 
 
Patients   196.3 (172.2- 231.6) 214.8 (195.3-246.0)  ns 
 
 
Controls   177.1 (159.3- 216.8) 197.8 (168.9- 222.5)           ns
   
 
 
Table 7.4 The Effect of Treatment on Total HDL Lipoprotein 
Concentrations 
(All median & IQR) 
 
 
7.3.3 Association Between Baseline HDL2 and Baseline Parameters 
Table 7.5 displays the relationship between baseline HDL2 concentration and 
baseline parameters for patients and control groups individually and 
collectively.  
For patients and controls collectively, there were strong negative correlations 
between baseline HDL2 and baseline triglyceride, LDL III, VLDL1 and RLP-C 
(table 7.5 and figures 7.1 & 7.2).  In patients, there was no association 
between baseline HDL2 concentration and baseline renal function and 
proteinuria. Baseline triglyceride correlated with baseline HDL2 in patients and 
controls (r2  -24.4%, p=0.02 and r2- 29.5%, p=0.01). Baseline VLDL1 and 
VLDL2 correlated with baseline HDL2 in both patients and control with a tighter 
association in the patient group. When entering the subject group into a 
general linear model as a variable, it was not an independent predictor. 
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7.3.4 Association Between HDL3 and Baseline Parameters 
 
Table 7.6 displays the relationship between baseline HDL3 concentration and 
baseline parameters for patients and control groups individually and 
collectively. For patients and controls as a whole, there were strong 
correlations between baseline HDL3 and baseline triglyceride, LDL III, VLDL1 
and RLP-C (table 7.6 and figures 7.3 & 7.4). In the patient group there was no 
association between baseline HDL3 or baseline parameters including renal 
function and urinary proteinuria. This is likely to be due to a clear outlier. On 
removing this outlier, there is a strong correlation between baseline HDL3 and 
baseline triglyceride (r2 36.6%, p=0.008) but the other correlations are not 
affected. However, in the control group, several baseline parameters 
correlated with baseline HDL3. These included cholesterol (r
2 22.5%, p=0.03), 
triglyceride (r2 31.8%, p=0.01), LDLIII% (r2 32.6%, p=0.01), LDLIII mass (r2 
34.2%, p=0.008), VLDL1 (r
2 41.3%, p=0.003), VLDL2 (r
2 26.7%, p=0.02) and 
RLP-C (r2 44.2, p=0.002). Once again, when examining the population as a 
whole, subject group was not an independent predictor. 
 
 
7.3.5 Change in HDL2 and HDL3 Concentrations 
 
There was no association between change in HDL2 concentration and change 
in triglyceride, LDL III, VLDL1, VLDL2, RLP-C and RLP-TG in patients and 
controls. 
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Similarly, with regards to change in HDL3 concentration, there was no 
association with change in triglyceride, LDL III, VLDL1, VLDL2, RLP-C and 
RLP-TG in patients. In controls, only a decrease in VLDL1 concentration 
correlated with an increase in HDL3 (r
2 23.9%, p=0.03).  
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    All           Patients          Controls 
 
   r2  p    r2  p    r2  p 
 
________________________________________________________________________________________________________ 
 
Triglyceride  22.7  0.003    24.4  0.025    29.5  0.014 
 
  
LDL III %  13.0  0.02    20.8  0.038    6.7  ns  
 
 
LDL III conc  24.8  0.002    27.9  0.017    28.7  0.016 
 
 
VLDL1   42.1  0.000    46.8  0.001    41.0  0.003 
 
 
RLP-C  16.7  0.01    14.1  0.076    22.9  0.03 
 
 
 
Table 7.5: Association Between Baseline HDL2 and Baseline Parameters in Patients and Controls 
Linear regression analysis of baseline HDL2 concentration with baseline parameters in all the subjects as a whole, patients and 
controls. (All correlations negative) 
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    All           Patients          Controls 
 
   r2  p    r2  p    r2    p 
 
________________________________________________________________________________________________________ 
 
Triglyceride  17.6  0.008    0  ns    31.8  0.01   
  
 
LDL III %  16.7  0.009    0  ns    32.6  0.01 
 
 
LDL III conc  23.8  0.002    0  ns    34.2  0.008 
 
 
VLDL1   12.5  0.023    0  ns    41.3  0.003 
 
 
RLP-C  18.6  0.006    0  ns    44.2  0.002 
 
 
Table 7.6: Association Between Baseline HDL3 and Baseline Parameters in Patients and Controls 
 
Linear regression analysis of baseline HDL3 concentration with baseline parameters in all the subjects as a whole, patients and 
controls. 
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Figure 7.1 Baseline HDL2 vs Baseline Triglyceride in Patients & Controls 
 
Linear regression analysis of baseline HDL2 with baseline triglyceride in all 
subjects (r2 = -22.7%, p=0.003). 
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Figure 7.2 Baseline HDL2 vs Baseline VLDL1 in Patients & Controls 
 
Linear regression analysis of baseline HDL2 with baseline VLDL1 in all 
subjects (r2 = -46.8%, p<0.001).
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Figure 7.3 Baseline HDL3 vs Baseline Triglyceride in Patients & Controls 
 
Linear regression analysis of baseline HDL3 with baseline triglyceride in all 
subjects (r2= 17.6%, p=0.008). 
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Figure 7.4 Baseline HDL3 vs Baseline RLP-C in Patients & Controls 
 
Linear regression analysis of baseline HDL3 with baseline RLP-C in all 
subjects (r2= 18.6%, p= 0.006). 
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HDL Subclass              Patients                Controls             p 
         (%) 
______________________________________________________________ 
 
2a                              24.4 (23.1- 28.4)         25.5 (21.6- 27.9)            ns 
 
2b                              24.1 (21.8- 26.1)         24.8 (21.3- 29.1)            ns 
 
3a                              25.9 (24.4- 27.2)            26.4 (23.9- 28.4)            ns 
  
3b                              15.8 (13.2- 16.7)         14.3 (11.7- 18.3)            ns 
 
3c                               9.2 (5.7 - 0.7)           7.7 (6.2- 10.2)            ns
  
 
Table 7.7: Baseline Patient and Control HDL Subclasses by Gel 
Electrophoresis 
 
 
 
7.3.6 Baseline Subclasses- Gel Electrophoresis 
 
Patient and control baseline distribution of HDL subclasses are shown in table 
7.7. There was no significant difference in all the subclasses between patients 
and controls. 
 
7.3.7 Treatment Effect on HDL subclasses- Gel electrophoresis 
Table 7.8 outlines the effect of treatment with omega-3 fatty acids on % of 
each HDL subclass as measured by gel electrophoresis in patients and 
controls. 
Omega-3 fatty acids did not affect HDL2a in patients or controls however the 
percentage of HDL2b was increased in patients and controls (mean increase 
patient group 3.98 (95%CI 1.58 to 6.39), controls 3.7 (95%CI 2.0 to 5.3). Both 
percentages of HDL3a and HDL3b subclasses were reduced by treatment 
with omega-3 fatty acids in patients and controls: HDL3a- patients 2.0 (95%CI 
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0.6 to 3.4), controls: 1.8 (95%CI 1.1 to 2.6), HDL3b- patients: 1.5 (95%CI 0.4 
to 2.6), controls: 1.7 (95%CI 0.9 to 2.6). 
The percentage of HDL3c was not significantly affected in patients but in 
controls fell by mean of 0.8 (95%CI 0.1 to 1.7). Mean HDL particle diameter 
increased in both patients and controls following treatment with omega-3 fatty 
acids: patients 9.39nm (IQR 9.34- 9.54) to 9.51nm (9.40- 9.80) p=0.03, 
controls 9.42nm (IQR 9.36- 9.53) to 9.50nm (9.40- 9.82) p=0.001.
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HDL subclass    Patients                    Controls 
 
      (%)               Baseline      Post Treatment      p      Baseline        Post Treatment            p 
________________________________________________________________________________________________________ 
 
2a                     24.4 (23.1- 28.4)          26.6 (23.2 -27.9)    ns            25.5 (21.6 – 27.9)    25.4 (23.7- 28.4)      ns 
 
2b                     24.1 (21.8- 26.1)            26.7 (23.9- 35.0)  0.003            24.8 (21.3- 29.1)     26.9 (22.9- 36.6)       <0.001 
 
3a                     25.9 (24.4- 27.2)            23.7 (19.5- 27.5)    0.009         26.4 (23.9- 28.4)  24.7 (21.1- 27.4)       <0.001       
 
3b                     15.8 (13.2- 16.7)           13.5 (10.9- 15.6)      0.009            14.3 (11.7- 18.3)  14.1 (8.6- 16.2)   <0.001 
 
3c                      9.2 (5.7- 10.7)            7.3 (5.9- 10.2)            ns             7.7 (6.2- 10.2)   8.2 (4.6- 9.9)     0.03                      
 
 
 
Table 7.8: Effect of Treatment on HDL Subclasses Measured by Gel Electrophoresis 
 
Percentage of each HDL subclass in patients and controls at baseline and following treatment. 
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7.5 Discussion 
 
 
In this study we have identified no difference in the plasma concentration of 
HDL subfractions in patients with nephrotic range proteinuria compared with 
age and sex matched controls analysed either by density ultracentrifugation or 
gradient gel electrophoresis. There was however a trend towards increased 
levels of the smaller denser HDL3 and as mentioned previously, there is a 
clear outlier in the patient group and once this outlier is omitted, HDL3 levels 
are significantly higher in the patient group compared with the controls. 
Omega-3 fatty acids significantly increased HDL2 concentration in patients 
and controls but HDL3 concentration remained unchanged. On gel 
electrophoresis, HDL subclass 2a was unaffected by treatment but %2b 
increased in both patients and controls. Percentage of HDL subclasses 3a 
and 3b were reduced by treatment but only 3c was reduced in controls. 
However, mean particle diameter was increased by omega-3 fatty acids in 
both patients and controls. Baseline lipoprotein concentration of HDL2 was 
inversely associated with atherogenic triglyceride rich lipoproteins in patients 
and controls, whereas lipoprotein concentration of HDL3 correlated with 
atherogenic triglyceride rich lipoprotein, at baseline, in the control group only. 
Subject group was not an independent predictor of baseline HDL2 or HDL3 
concentrations or change in levels following treatment with Omega-3 fatty 
acids.  
As discussed in the introduction, it is widely recognised that high HDL-C levels 
are associated with reduced cardiovascular risk and that raising HDL further 
reduces this risk(29;30;32;33). However, there is conflicting data regarding the 
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atherogenicity of HDL subfractions. Several studies have suggested a strong 
inverse relationship between HDL2 and coronary atherosclerosis. Salonen at 
al examined HDL subfractions in Finnish men. They found HDL-C and HDL2 to 
be inversely related to the risk of myocardial infarction (214). There was also 
an inverse relationship between HDL3 and ischaemic heart disease risk but 
statistical significance was lost when adjusted for HDL2. Furthermore, data 
from the VA-HIT study  showed that levels of small HDL predicted CHD 
events suggesting that the larger HDL (HDL2) particles were more 
protective(215). 
 In contrast, data from the Physicians‟ Health Study (216) and the Caerphilly 
and Speedwell Collaborative Heart Disease Studies found HDL3 to be the 
strongest inverse predictor of IHD(217). While density ultracentrifugation 
separates HDL into 2 subfractions, gradient gel electrophoresis methods have 
reported from 5 to 14 subclasses(184;218). Several studies have suggested 
that reduction in large HDL2b particles are associated with an increased in 
CHD risk(219;220).The variety of results from studies examining HDL 
subclasses reflects the heterogeneity of HDL particles. Quantification of these 
subclasses is useful but the available methods are time consuming and 
difficult as well as lacking in uniformity and validation.  
In patients with nephrotic syndrome, HDL-C levels are usually normal or 
reduced, often with a reduced HDL2 subfraction. The mechanism behind this 
is unclear. It has been shown that levels of cholesteryl ester transfer protein 
(CETP) are increased in this population. This protein mediates transfer of 
esterified cholesterol from HDL2 to VLDL. This increase in CETP activity is 
likely to be driven by increased levels of triglyceride rich lipoproteins prevalent 
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in nephrotic range proteinuria thereby leading to decreased HDL2 and 
increased HDL3. Also, reduced activity of another enzyme, Lecithin cholesterol 
acyltransferase (LCAT) has been documented in human and nephrotic rats. 
LCAT is the enzyme responsible for the esterification of cholesterol within the 
plasma maintaining a concentration gradient for unesterified cholesterol 
between peripheral cells and plasma. The reduced activity of LCAT may be 
due to hypoalbuminaemia as albumin normally binds lysolecithin (a product of 
LCAT reaction) and accumulation of unbound lysolecithin impairs enzyme 
activity (169), or LCAT may be lost in the urine of these patients. The resulting 
reduced levels of LCAT would impair cholesteryl esterification within the HDL 
particle and so inhibit conversion of HDL3 to HDL2.  
 
Omega-3 fatty acids have been shown to have a favourable effect on HDL. 
Doses of 3.5 to 4g have been shown to consistently increase HDL-C primarily 
by increasing HDL2 (221). They are thought to increase larger HDL (HDL2) at 
the expense of HDL3(129) mediated by a reduction in cholesteryl ester 
transfer protein activity thereby favouring large cholesterol-rich HDL formation. 
Using the method of ultracentrifugation to separate HDL, we found that 
treatment with omega-3 fatty acids increased concentration of HDL2 but did 
not affect HDL3. However, using gradient gel electrophoresis, we found that 
%HDL2b increased percentages of HDL3a and 3b fell and mean particle 
diameter of HDL particle increased with treatment in keeping with the above 
mechanism.  
Although we showed that baseline HDL2 concentration was associated with 
baseline triglyceride concentration, we did not find any association between 
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change in HDL 2 concentration and change in triglyceride concentration. This 
may be explained by the fact that treatment did not actually reduce total HDL 
or HDL-C but caused redistribution to larger HDL2. We also did not show a 
group effect, implying that the mechanism in patients and controls is similar 
and the differences are related to differences in baseline characteristics. 
 
Other than omega-3 fatty acids, a number of other agents are known to 
increase HDL-C, primarily statins and fibrates. Treatment with statins has a 
moderate effect on HDL raising it by about 5% (222). The mechanism behind 
the HDL raising effect of statins is not fully understood. They increase HDL 
apo AI production by approximately 15% in the liver (223) thereby increasing 
HDL2 production. In addition, they increase expression of LDL receptors 
causing a reduction in the numbers of potentially atherogenic lipoprotein 
acceptors of cholesteryl ester via the CETP mechanism from HDL.  Fibrates 
have a greater effect on HDL and can raise HDL concentration by up to 25% 
through a number of mechanisms but their use is limited in patients with 
nephrotic range proteinuria as they are poorly tolerated.  
 
In summary, therefore, we have demonstrated that omega-3 fatty acids have 
a favourable effect on HDL subclasses in both patients and controls which 
contributes further to their cardioprotective properties.  
. 
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8.1 Introduction 
As discussed previously, patients with nephrotic range proteinuria have a 
marked increase in cardiovascular risk. However, the lipid and lipoprotein 
abnormalities described earlier cannot alone account for the large burden of 
cardiovascular disease observed in this population.  
The endothelium is thought to play a central role in the early development of 
atherosclerosis(224). The pathological changes associated with proteinuria 
are believed to cause endothelial dysfunction. Both inflammation and 
oxidative stress are important mechanisms in the development of an 
atherosclerotic plaque.  
Omega-3 fatty acids have been shown to have beneficial effects on 
endothelial function and anti-inflammatory properties in the general population 
as discussed in chapter 1.Therefore, the aim of this study was three-fold. 
Firstly to examine endothelial function using the non-invasive technique of 
laser doppler imaging in patients with nephrotic range proteinuria and 
compare with a control population. This technique is based on the 
iontophoretic transdermal delivery of acetylcholine (Ach) and sodium 
nitroprusside (SNP) which are vasodilators(225). Ach induced vasodilatation 
is „endothelium-dependent‟ as it requires an intact endothelium with binding to 
muscarinic receptors and the generation of nitric oxide. SNP induced 
vasodilatation is termed „endothelium- independent‟. Nitric oxide acts on 
vascular smooth muscle leading to vasodilatation therefore, as SNP is a nitric 
oxide donor, it acts as an „endothelium independent‟ control. Laser Doppler 
imaging measures skin perfusion under the influence of these drugs. 
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Secondly, to assess whether omega-3 fatty acids improve endothelial function 
in this population. Finally, we aimed to examine novel markers of endothelial 
function and inflammation in this population both pre and post treatment with 
omega-3 fatty acids. 
 
8.2 Subjects and Methods 
 
 
8.2.1 Subjects 
 
The patients and controls described in the methods section were studied in 
this chapter. Patients and controls attended on 2 occasions as previously 
described: once at the start of the study prior to commencing omega-3 fatty 
acids and once following 8 weeks of treatment with 4g daily of Omacor. 
Endothelial function was measured using the technique of laser doppler 
imaging described below on both occasions prior to venesection. Fasting 
EDTA samples were drawn and plasma isolated as previously described on 
these 2 occasions. Samples were divided into 0.5ml aliquots and frozen at      
-80°C.Highly sensitive CRP (hsCRP), I-CAM, V-CAM, oxidised LDL and PLA2 
assays were performed as described in the methods section on all patients 
and controls completing the study. 
 
 
8.2.2 Iontophoresis Protocol 
 
This LDI protocol is based on one developed in Glasgow(225). We carried out 
the measurements in a temperature-controlled room at 23oC (±2oC) after 
allowing the patients and controls to acclimatise for 30 minutes before the 
procedure. A battery-powered constant current iontophoresis controller (MIC-
le; Moor Instruments Ltd. Axminster, UK) allowed drug delivery with Perspex 
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chambers (internal diameter 22 mm, area 3.8 cm2) and an internal platinum 
wire electrode were used for iontophoresis (ION 6; Moor Instruments Ltd.). 
Doubled-sided adhesive disks were used to attach the two chambers to the 
skin of the volar aspect of the forearm avoiding hair, broken skin, and 
superficial veins, Figure 8.1. The chambers were connected to the anode and 
cathode connections on the iontophoresis controller.  
 
 
 
  
 
 
 
 
Figure 8.1 Drug Delivery Chambers 
Perspex drug delivery chambers with overlying coverslips with a temperature probe 
attached to the skin. 
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Figure 8.2 LDI Experimental Setup 
 
Block Diagram of the experimental setup. The anodal and cathodal chambers 
contained acetylcholine (ACh) and sodium, nitroprusside (SNP) respectively.  
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The laser doppler imager software was programmed in order to control current 
delivery. The current was switched on at the beginning of a scan and 
remained on until the start of the next scan after which the current was then 
either left on for the next scan or was switched off after the total charge had 
been delivered. The duration of the current was the time taken to complete 
each scan (50 s) multiplied by the total number of scans programmed. Low 
currents were used to limit the iontophoresis dose. The procedure involved 
incremental current delivery with four scans at 5 µA, four at 10 µA, four at 15 
µA, and two at 20 µA amounting to a total charge of 8 mC.  2.5 ml of 1% ACh 
(Sigma Chemical Co., St. Louis, MO, U.S.A.) was placed into the anodal 
chamber and 2.5 ml of 1% SNP (Sigma) was placed in the cathodal chamber 
therefore both agents were delivered simultaneously during the delivery of 
current. 0.5% NaCl was used as the vehicle for these agents. Circular 
coverslips (32mm) over the chambers prevented the leakage of fluid.  
 
8.2.3 Perfusion Measurements 
Measurement of skin perfusion was carried out using a laser doppler imager 
(Moor Instruments Ltd.) with a red laser (wavelength, 633 nm; power, 1 mW; 
beam diameter, 1 mm). This non-invasive technique is based on the doppler 
shift imparted by moving blood cells in the underlying tissue to the 
backscattered light. The laser is scanned over both chambers through the 
coverslips and so backscattered light is collected by photodetectors which is 
converted into a signal proportional to perfusion. This is expressed as 
ACh 
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arbitrary perfusion (flux) units (PU). The signal is then displayed as a colour-
coded image on a monitor. The imager manufacturer's image analysis 
software allowed perfusion measurements by outlining a region of interest 
(ROI) around the internal circumference of the chamber. The median flux 
value across approximately 700 measurement points was calculated through 
statistical analysis of the ROI. Twenty scans were carried out. The first was a 
control prior to current administration followed by 14 scans of the incremental 
current protocol outlined earlier (14 scans) and five further scans without 
current administration. (Figure 8.4) Skin temperature close to the 
iontophoresis chambers was monitored continuously throughout. No 
significant temperature change occurred between the beginning and the end 
of perfusion measurements, indicating stable conditions. 
8.3 Statistics 
Analysis was performed using MINITAB 13.1 for Windows (Minitab Inc). 
Differences in measures of endothelial function (VCAM and ICAM) and other 
parameters between patients and controls were tested by the Mann-Whitney 
U test or Students‟ t-test as appropriate. For measurement of skin perfusion 
responses an assessment of the overall response to drugs (or vehicle) was 
obtained by taking the area under the perfusion-current curve (AUC), with 
comparisons made using the Mann-Whitney U test. All data is expressed as 
mean ±SD or SEM. A p value of <0.05 was considered as statistically 
significant throughout. 
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Figure 8.3 LDI Scan Pictures 
 
The photo image is generated by back scattered light and the flux image is the 
doppler shifted component. Flux is colour-coded with lowest perfusion in dark 
blue (0 PU) and highest in dark red (500 PU).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.4 LDI Scan Pictures with Incremental Current Administration 
 
Sodium nitroprusside (SNP) is in the upper chamber and acetylcholine (ACh) 
in the lower chamber. Current was incrementally applied as described in the 
text. The time courses of the drug-induced vasodilator responses differ.  
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8.4 Results 
8.4.1 Laser Doppler Assessment of Microvascular Endothelial Function 
 
At baseline, the vascular response to both SNP and acetylcholine did not 
differ significantly between patients and controls: SNP AUC , 1755 ± 490 vs 
1372 ± 755, Acetylcholine AUC, 1633 ± 411 vs 1654 ± 436 PU, p=ns). This is 
portrayed in figures 8.5 and 8.6. 
Treatment with omega-3 fatty acids did not improve vascular response to 
either SNP or acetylcholine in patients or controls. This is outlined in figures 
8.7, 8.8, 8.9 and 8.10. 
 
 
Figure 8.5 Comparison of ACh Responses Between Patients & Controls 
Comparison of vascular responses to ACh between patients and controls 
represented as arbitrary perfusion units under the perfusion current curve. No 
difference is observed, p=ns. 
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Figure 8.6 Comparison of SNP Response between Patients & Controls 
 
Comparison of vascular responses to SNP between patients and controls 
represented as arbitrary perfusion units under the perfusion current curve. No 
difference is observed, p=ns. 
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Figure 8.7 Acetylcholine Response in Patients Pre and Post Treatment 
 
Vascular response to ACh in patients pre (v1) and post (v2) treatment with 
omega-3 fatty acids. Bars represent standard error of mean, p=ns (two way 
ANOVA). 
 
 
 
 
Figure 8.8 SNP Response in Patients Pre and Post Treatment 
 
Vascular response to SNP in patients pre (v1) and post (v2) treatment with 
omega-3 fatty acids. Bars represent standard error of mean, p=ns (two way 
ANOVA). 
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Figure 8.9 Acetylcholine Response in Controls Pre and Post Treatment 
 
Vascular response to ACh in controls pre (v1) and post (v2) treatment with 
omega-3 fatty acids. Bars represent standard error of mean, p=ns (two way 
ANOVA). 
 
 
Figure 8.10 SNP Response in Controls Pre and Post Treatment 
 
Vascular response to SNP in controls pre (v1) and post (v2) treatment with 
omega-3 fatty acids. Bars represent standard error of mean, p=ns (two way 
ANOVA). 
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8.4.2 Baseline Cardiovascular Risk Markers 
Baseline levels of hsCRP, oxidised LDL, I-CAM, V-CAM and PLA2 in patients 
and controls are portrayed in table 8.1.Plasma V-CAM and PLA2 levels were 
significantly higher in the patient group at baseline (p<0.001 and p=0.04). No 
difference in baseline hsCRP, oxidized LDL and I-CAM was observed.  
 
                                        Patients   Controls   p 
                                         (n=17)               (n=17) 
______________________________________________________________ 
 
hsCRP (mg/l)                2.2 (0.8-6.2)           1.4 (0.9-8.0)  ns 
 
Ox LDL (mU/l)               83.6 (62.2-100.8)  79.4 (54.9-85.6) ns 
 
I-CAM (ng/ml)                257 (196 -308)              262 (218 -294)   ns 
 
V-CAM (ng/ml)               879 (739-1103)           621 (428-701)    <0.001 
 
PLA2 (ng/ml)                  228 (186-241)           185 (170-217)        0.04 
 
Table 8.1 Cardiovascular Risk Markers in Patients and Controls 
(All median & IQR) 
 
8.4.3 The Effect of Treatment on Cardiovascular Risk Markers in Patients 
& Controls 
In the patient group, treatment with omega-3 fatty acids did not significantly 
affect levels of hsCRP, oxidised LDL, I-CAM, V-CAM or PLA2 (table 8.2). 
In the controls, the only observed difference was in V-CAM concentration with 
a mean increase of 80 ng/ml (95% CI: 23 -138) (table 8.3). As in the patient 
group, hsCRP, oxidised LDL, I-CAM and PLA2 were unchanged. 
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Patients                              Baseline     Post Treatment  p 
  (n=17)    (n=17) 
______________________________________________________________ 
 
hsCRP (mg/l) 2.2 (0.8- 6.2)  1.6 (0.7-6.2)  ns 
 
Ox LDL (mU/l) 84 (63 -101)  95 (70 -107)  ns 
 
I-CAM (ng/ml) 257 (196-308)  247 (207-340) ns 
 
V-CAM (ng/ml) 879 (739-1103)  912 (1179-2541) ns 
 
PLA2 (ng/ml) 228 (186-241)  247 (186-271) ns 
 
 
Table 8.2 The Effect of Omega-3 Fatty Acids on Cardiovascular Risk 
Markers in Patients 
 
(All median & IQR) 
 
 
 
 
 
 
Controls                              Baseline       Post Treatment  p 
  (n=17)             (n=17) 
______________________________________________________________ 
 
hsCRP (mg/l) 1.4 (0.9- 8.0)  1.6 (0.8-3.4)  ns
  
Ox LDL (mU/l) 79 (55 - 86)   78 (56 -86)  ns 
 
I-CAM(ng/ml) 262 (218- 294)  276 (229-301) ns 
    
V-CAM (ng/ml) 621 (428- 701)  630 (539- 732)       0.01 
 
PLA2 (ng/ml) 185 (170-217)  175 (168- 217) ns 
 
 
 
Table 8.3 The Effect of Omega-3 Fatty Acids on Cardiovascular Risk 
Markers in Controls 
 
(All median & IQR) 
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8.5 Discussion 
 
This study has shown no difference between microvascular endothelial 
function assessed by the technique of laser doppler imaging in patients with 
nephrotic range proteinuria compared with controls. Furthermore, we showed 
that omega-3 fatty acids had no demonstrable effect on endothelial function 
measured directly using LDI or through the measurement of soluble markers 
of endothelial activation in either population. We demonstrated that patients 
had higher baseline levels of V-CAM and PLA2 than controls; however the 
only change that was observed following treatment with omega-3 fatty acids 
was an increase in V-CAM levels in the control group. 
There have been two studies examining endothelial function using the 
technique of laser doppler iontophoresis in proteinuric patients. The first failed 
to show any difference in vascular response between patients and controls. 
They examined 21 otherwise healthy patients with asymptomatic proteinuria 
(226). The second examined 39 patients with glomerulonephritis and a mean 
albumin: creatinine ratio (ACR) of 191mg/mmol. Patients with co-existing 
vascular disease were excluded. They stopped ACE inhibitors and 
angiotensin receptor antagonists prior to the study. They demonstrated that 
the patients with proteinuria had significantly abnormal microvascular 
endothelial function compared with the controls. The vascular response to 
both SNP and ACh was impaired in the proteinuric group (227). Other 
techniques of assessing endothelial function have yielded similar results. 
Stroes et al demonstrated endothelial dysfunction in nine patients with 
nephrotic range proteinuria by venous occlusion plethysmography(178) and 
an Australian group found abnormal „endothelium- dependent‟ response but 
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preserved „endothelium- independent‟ response in patients with nephrotic 
syndrome using brachial artery ultrasound(179). 
 
There are many factors which can affect endothelial function such as age, 
gender and smoking status. Drugs such as ACE inhibitors, angiotensin 
receptor antagonists and statins have all been shown to improve endothelial 
function(228;229). In this study, all statins were stopped for 4 weeks prior to 
enrolment, however we did not feel it was ethical to stop either ACE inhibitors 
or angiotensin receptor blockers in the patients with nephrotic range 
proteinuria and so all the patients were on either agent with two on both. 
Clearly, this may have influenced our results and account for some of the 
differences compared with previously published data. In addition, as we 
attempted to triglyceride match our controls, these subjects may not have 
been representative of a normal control population. Furthermore, the numbers 
in our study were small and the heterogeneous nature of the group may have 
contributed to the lack of observed difference between the patients with 
proteinuria and the control population.  
Studies have shown a beneficial effect of omega-3 fatty acids on endothelial 
function. Supplementation with 4g daily of omega-3 fatty acids improved 
endothelial function measured by brachial artery ultrasound in  a group of 15 
hypercholesterolaemic subjects compared with controls(151). Using laser 
doppler imaging, supplementation with omega-3 fatty acids improved ACh 
mediated vascular response but not SNP response in healthy subjects(230).  
However, their effect on endothelial function in patients with nephrotic range 
proteinuria has not, to our knowledge, been studied. 
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Lipoprotein associated phospholipase A2 (Lp-PLA 2) is a member of the 
phospholipase A2 family of enzymes produced by macrophages, T 
lymphocytes and mast cells. Lp-PLA2 is present in atherosclerotic plaques 
(231). It hydrolyses oxidised phospholipids resulting in pro-inflammatory 
particles(232). This is an emerging marker for vascular events with 
epidemiological studies suggesting an association between increased Lp-
PLA2 levels and CHD (183;233-235). In addition, increased Lp-PLA2  levels 
have been demonstrated in patients with subclinical coronary disease and 
coronary calcifications(236). More recently, Lp-PLA2 has been implicated in 
endothelial dysfunction(232;237) . To our knowledge, no studies have 
examined the effect of omega-3 fatty acids on PLA2 levels in patients with 
nephrotic range proteinuria. There have been a number of studies examining 
markers of endothelial function in patients with chronic renal failure but few 
have looked at the association between endothelial markers and the level of 
proteinuria. Elevated levels of I-CAM and V-CAM have been shown in patients 
with mild renal impairment(238), advanced renal impairment(239) and those 
on dialysis(240). MacKinnon et al demonstrated that patients with urinary 
protein levels greater than 2g in 24 hours had higher levels of I-CAM, V-CAM 
and CRP(241). Our study showed that patients with nephrotic range 
proteinuria had higher levels of V-CAM but I-CAM and CRP did not differ. The 
numbers in our study were small and as described above there were a 
number of confounding factors. 
 
Omega-3 fatty acids are known to have established ant-inflammatory 
properties (242). However, the interventional data is inconsistent (243-246). A 
 175 
 
recent meta-analysis of four prospective randomised studies showed that 
omega-3 fatty acids did not affect hs-CRP (247). Similarly, studies examining 
the effect of omega-3 fatty acids on markers of endothelial activation have 
displayed varying results. In a study of sixty healthy volunteers, 
supplementation with 6.6g omega-3 fatty acids had no effect on I-CAM or V-
CAM levels(248). However, a study of 563 hyperlipidaemic men showed that 
I-CAM fell but V-CAM was unchanged following treatment (249). This was a 
large, long-term study with a treatment duration of 3 years. The data regarding 
the effect of omega-3 fatty acids on oxidised LDL levels is sparse. There was 
no change in oxidised LDL levels in a study of hypercholesterolaemic  
subjects supplemented with alpha-linolenic acid for 2 years(250).  
It is difficult to draw conclusions from our data in view of the small numbers 
and short treatment duration. 
In summary, we were unable to demonstrate a difference in endothelial 
function between patients with nephrotic range proteinuria compared with 
normal controls. However, to our knowledge, we are the first to observe higher 
levels of Lp-PLA2 in this population. Moreover, treatment with omega-3 fatty 
acids had no beneficial effect in either population. 
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and Conclusions 
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9.1 Nephrotic Syndrome and Lipoprotein Abnormalities 
The dyslipidaemia associated with nephrotic syndrome is characterized by 
increased levels of cholesterol, triglyceride, VLDL-C, excess small dense LDL 
and low HDL-C(162-165). This work confirms these abnormalities. 
The mechanism leading to this dyslipidaemia is unclear. Several studies have 
suggested that there is reduced catabolism of Apo B containing lipoproteins 
(TG, VLDL, IDL and LDL) rather than increased hepatic synthesis. Demant et 
al examined metabolism of Apo B containing lipoproteins using radiotracer 
kinetic studies. They found impaired delipidation of VLDL2 and IDL with 
reduced LDL catabolism(251). In addition, a further study of 
hypercholesterolaemic patients with nephrotic syndrome showed that these 
patients had lower catabolic rates of LDL Apo B but no overproduction of LDL 
Apo B (252). Impaired triglyceride metabolism rather than increased synthesis 
is responsible for the increased triglyceride levels observed in these patients. 
Animal work has shown higher triglyceride levels in nephrotic rats than in rats 
with analbuminaemia despite similar rates of triglyceride production(253) .  
Total HDL levels are usually normal even although HDL2 to HDL3 ratio in 
patients with nephrotic syndrome are often low. Levels of LCAT (the enzyme 
responsible for the conversion of HDL3 to HDL2) have been found to be low 
due to urinary losses(254). Hepatic mRNA levels were unaffected suggesting 
increased excretion of LCAT rather than decreased production resulting in 
increased levels of HDL2. 
Increased levels of remnant lipoproteins and small dense LDL have previously 
been described in this population (255). Again, our observations have 
confirmed these abnormalities. Plasma triglycerides were the most important 
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factor influencing LDL phenotype and remnant lipoprotein concentration in our 
study. Once again, confirming previous observations. The increase in 
cholesterol, triglyceride, LDL-C, remnant lipoproteins and small dense LDL all 
contribute to increasing CV risk.   
 
9.2 Postprandial Lipaemia 
There is little published human work examining chylomicron and VLDL 
metabolism in patients with nephrotic range proteinuria. The existing evidence 
in this area is conflicting. Studies in nephrotic rats have found changes in the 
catabolism and composition of chylomicrons(202;203). These studies have 
been difficult to perform due to technical difficulties in separating the 
chylomicrons from VLDL. Warwick et al measured TG and retinyl palmitate in 
the d1.006g/ml fraction of plasma following a vitamin A loaded standard fat 
meal in nephrotic subjects. They found no difference in the time course of the 
postprandial response suggesting that chylomicron metabolism did not differ 
between nephrotic subjects and normal control (204). However, differences 
were observed between individuals in their postprandial response. This 
emphasizes the heterogeneity of the population being studied. The same 
group demonstrated a reduction in clearance of VLDL in nephrotic subjects 
but others have failed to demonstrate this (256). It is likely that the 
discrepancy in results is multifactorial with the heterogeneity of this 
population, the difficulty in separating and measuring chylomicrons and 
differences in fat load administration all contributing. 
There are very few studies examining the structure and composition of 
chylomicrons and VLDL. Chylomicrons from nephrotic rats have been shown 
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to be larger and rich in triacylgycerol(202). To our knowledge, there have 
been no human studies examining this. Our work is in keeping with the animal 
studies. We observed larger chylomicrons in the patients with nephrotic range 
proteinuria. These structural abnormalities may account for their less efficient 
lipolysis that we observed in chapter 5. 
Work from our laboratory previously reported abnormalities in the structure of 
VLDL particles with a smaller more crystalline particle deficient in apo CII, III 
and E(175). We were unable to replicate these findings in our population. 
Again, the heterogeneity of the population being studied along with the small 
numbers involved and advances in the apoB assay may, in part, account for 
this. However, our findings are in keeping with our results from chapter 5 
where we showed delayed postprandial chylomicron clearance but unaltered 
postprandial VLDL metabolism in the patients with nephrotic range 
proteinuria. Further studies are required to clarify this. 
 
9.3 Endothelial Function and Inflammation 
Proteinuria is increasingly being thought of as a marker of vascular disease. 
Microalbuminuria has been linked with endothelial dysfunction (10) .However; 
studies using the technique of laser doppler iontophoresis to assess 
endothelial function in patients with proteinuria are conflicting. A study of 21 
asymptomatic proteinuric patients failed to show any difference in vascular 
response(226). A further study examined 29 patients with a mean ACR of 
191mg/mmol found both impaired SNP (endothelium-independent) and Ach 
(endothelium independent) response in the patients with proteinuria(241). We 
failed to replicate this in our population of 17 patients with nephrotic range 
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proteinuria. Potential confounding factors that may have influenced our results 
included the small number of patients studied and the continued use ACE 
inhibitors and Angiotensin receptor blockers throughout  the study due to 
ethical concerns regarding discontinuing these preparations. 
 
Inflammation is known to play an important role in atherosclerosis. A number 
of biomarkers for endothelial dysfunction and inflammation are emerging 
which have been shown to be useful for the prediction of coronary heart 
disease.  Several studies have indicated that increased levels of hs CRP are 
predictive of cardiovascular events in healthy subjects(88). Increased levels of 
hsCRP have also been observed in patients with proteinuria(241).  Expression 
of adhesion molecules (I-CAM and V-CAM) are increased on endothelial cells 
overlying atheroma and elevated levels of these molecules have been found 
in patients with all levels of renal impairment from mild to end stage renal 
failure and also in patients with proteinuria(238-240). PLA2 is an emerging 
marker for vascular events. It is present in atherosclerotic plaques and 
associated with endothelial dysfunction(232;237). In our study we observed 
increased levels of PLA2 and V-CAM but no difference in I-CAM and CRP. We 
acknowledge that our study was not adequately powered to detect a 
difference in these parameters and there are a number of confounding factors 
as mentioned earlier. However, the increase in PLA2 and V-CAM are 
noteworthy but further more detailed investigation in a large study population 
is required to clarify this. 
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9.4 Omega- 3 Fatty Acids and Nephrotic Syndrome 
Prospective randomised controlled trial evidence has demonstrated the 
benefit of omega-3 fatty acids in different populations. Men without clinical 
heart disease, patients with angiographic evidence of CHD, patients with 
recent myocardial infarctions, adults over  65 years old and 
hypercholesterolaemic subjects are among the groups where the benefit of 
omega-3 fatty acids have been demonstrated(114;125;257-259). However, 
there has been little work examining their effect on dyslipidaemia in patients 
with nephrotic range proteinuria. 
The major effect of omega-3 fatty acids on lipids and lipoproteins is a 
reduction in plasma TG and TRLs. Studies have shown that they inhibit TG 
synthesis and secretion of VLDL from the liver(118;119;191). They are 
thought to reduce production of triglyceride rich lipoproteins rather than 
enhancing their clearance(52;120;121). They are also known to increase LDL-
C. The mechanism behind this is unclear but it has been suggested that they 
down regulate the LDL Apo B/E receptor as well as preferentially converting 
VLDL to LDL(127;128). This increase in LDL-C is potentially offset by a 
redistribution to larger less atherogenic LDL but remains a concern to some 
clinicians. This is thought to be caused by suppression of CETP activity thus 
reducing the transfer of cholesteryl ester from HDL to VLDL and LDL(129) 
resulting in triglyceride enrichment of HDL and LDL. 
We have shown in chapters 3 and 4 that patients with nephrotic range 
proteinuria had increased levels of triglyceride rich lipoproteins and excess 
small dense LDL. We found that treatment with omega-3 fatty acids reduced 
triglyceride rich lipoproteins and levels of small dense LDL concentration in 
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the patients with nephrotic range proteinuria but no reduction was observed in 
the control group. The differing effects are likely to be due to the higher 
baseline TG levels in patients with nephrotic range proteinuria compared with 
the controls. These benefits are similar to those seen in hypertriglyceridaemic 
subject but no underlying renal disease. 
Treatment with omega-3 fatty acids have been shown to reduce postprandial 
lipaemia in the normal population and hypertriglyceridaemic subjects with a 
greater benefit displayed with higher baseline TG levels(120;130;131). It is 
thought that they accelerate chylomicron clearance by facilitation of lipoprotein 
lipase mediated lipolysis(120). However, their effect on postprandial lipaemia 
has not been studied in nephrotic patients. In our study, we observed a 
reduction in chylomicron AUC following treatment with omega-3 fatty acids in 
the patients with nephrotic range proteinuria but not in the control population. 
We postulated that the differences again were related to the higher levels of 
baseline triglyceride in the patient group however on multivariate analysis 
subject group rather than baseline triglyceride concentration was found to be 
an independent predictor of change in chylomicron AUC. This suggests that 
the chylomicrons of patients with nephrotic range proteinuria may differ in 
structure or composition. 
 
Omega-3 fatty acids are thought to reduce VLDL synthesis and secretion 
(118;119;191). We found a reduction in peak postprandial VLDL1 AUC 
following treatment. Once again, this has not been previously studied in this 
population but is in keeping with previous studies suggesting a reduction in 
synthesis. The effect of omega-3 fatty acids on the structure or composition of 
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chylomicrons or VLDL has not been studied in any population. We observed 
no difference in the structure or composition of chylomicron or VLDL particles 
in patients or controls following treatment. This suggests that the effect we 
observed of omega-3 fatty acids on postprandial lipaemia is through either 
increased clearance or reduced the synthesis of chylomicrons and VLDL 
rather than an alteration in their structure. 
 
Omega-3 fatty acids have been shown to have a beneficial effect on HDL. 
They are thought to increase HDL2 at the expense of HDL3 by reducing CETP 
activity(129). In keeping with this suggested mechanism, we found that 
treatment increased levels of HDL2 with an increase in mean particle diameter 
of HDL in both patients and controls but HDL-C was unaltered. We did not 
show a group effect implying a similar mechanism in both groups. Increasing 
levels of HDL-C reduce CV risk(29-33) but the atherogenicity of the HDL 
subfractions is less clear. Quantification and measurement of these 
subclasses is difficult and time-consuming. Thus, the clinical significance of 
the effect of omega-3 fatty acids on HDL in this population is uncertain. 
The evidence regarding the effect of omega-3 fatty acids on endothelial 
function is conflicting. They have been shown to improve endothelial function 
in healthy patients when measured by both brachial artery ultrasound and 
laser doppler imaging(151;230) but their effect on endothelial function in 
patients with nephrotic range proteinuria has not previously been studied. We 
were unable to demonstrate an improvement in endothelial function of 
patients or controls following treatment. It has been suggested that omega-3 
fatty acids exert their effect on the endothelium by causing changes in the 
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composition of the membrane bilipid layer thereby promoting increased 
release of endothelium derived NO in response to Ach(152). As discussed 
earlier, our study was limited by a number of confounding factors such as 
renal dysfunction, co-existing vascular disease, the use of ACE inhibitors and 
Angiotensin receptor blockers and the short duration of treatment.  Further 
work with larger numbers of patients may help clarify the effect of omega-3 
fatty acids but studies may be limited due to the widespread use of ACE 
inhibitors and angiotensin receptor antagonists. They‟re proven efficacy in 
reducing the rate of renal progression makes stopping these preparations 
difficult to justify.  
 
9.5 Clinical Implications 
We observed increased levels of total cholesterol, triglyceride, VLDL-C, sd 
LDL and remnant lipoproteins in the patients with nephrotic range proteinuria 
compared with the controls. These abnormalities are associated with 
increased CV risk and so our data has a number of implications.  
Randomised controlled trials have demonstrated the benefit of omega-3 fatty 
acids. In the Diet and Reinfarction Trial (DART), there was a 29 % reduction in 
mortality in the patients who received dietary advice on fish consumption. 
However, no change in cholesterol levels were observed(111). The GISSI-
Prevenzione trial showed a 10 % reduction in the relative risk for the primary 
end-point of total mortality, non-fatal myocardial infarction and stroke with a 
0.9% reduction in triglyceride in the patients treated with 850mg of omega-3 
fatty acids at 6 months(113). The Study on Prevention of Coronary 
Atherosclerosis by Intervention with Marine Omega-3 fatty acids (SCIMO) also 
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showed a significant reduction in TG (10%) at 6 months with significantly less 
progression of coronary artery disease assessed angiographically(114). 
In our study, we observed a 17.5% fall in triglyceride concentration in the 
patients with nephrotic range proteinuria compared with a 5.9% fall in the 
control group therefore if we extrapolate from these studies, a significant 
reduction in CV risk should be evident. However, even although studies have 
suggested that hypertriglyceridaemia is a risk factor for CHD independent of 
other risk factors(260), the evidence regarding the benefit of triglyceride 
lowering on mortality is less robust. Since we commenced this study, there 
have been further studies examining fibrates, which have also addressed 
previous concerns that fibrates increase serum creatinine levels. The FIELD 
(Fenofibrate Intervention and Event Lowering in Diabetes) trial showed a 29% 
reduction in plasma triglyceride and 12% reduction in LDL-C in patients with 
diabetes but the reduction in the primary end-point of cardiovascular disease 
was not significant. They observed a 15% higher increase in serum creatinine 
in the fibrate group but this was no longer evident following discontinuation 
suggesting that this was due to a functional rather than a structural 
change(261). The JELIS (Japan EPA Lipid Intervention Study) randomised 18 
645 patients with total cholesterol of 6.5mmol/l or greater to 1800mg of EPA 
and statin or statin alone with a 5 year follow-up. They showed a 19% relative 
reduction in coronary events in the EPA treated group with a 9% reduction in 
triglyceride in this group compared with 4% reduction in the statin alone arm 
(p<0.0001). Both treatments produced only small changes in HDL-C(259). 
A recent study examining the effect of Torcetrapib (a potent CETP inhibitor) 
showed a 72% increase in HDL-C and 25% reduction in LDL-C but treatment 
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was shown to increase mortality and CV events and so was terminated 
prematurely(262). The mechanism behind this is unclear. The role of HDL 
subfractions may play an important role in the protective effect of HDL-C. This 
may, in part, account for the results observed in this study. Further work 
examining the effect of Torcetrapib on HDL subfractions may clarify this. The 
previously mentioned fish oil studies showed a reduction in CV risk with 
smaller reductions in TG levels. This implies that the action of omega-3 fatty 
acids on lipids and lipoproteins is not solely responsible for the effect they 
have on reducing CV risk. As discussed in chapter 2, in contrast to fibrates, 
omega-3 fatty acids act in a number of different ways. It is likely that the 
combination of these different mechanisms act to lower CV risk in this 
population of patients. In addition to triglyceride lowering, we observed 
significant reductions in remnant lipoprotein, small dense LDL and 
postprandial lipaemia. However, the effect we observed on LDL is concerning 
therefore we would suggest that monotherapy with omega-3 fatty acids is 
unadvisable in this population of patients.  
 
Our study was not designed to examine the effect of omega-3 fatty acids on 
renal progression and proteinuria. Studies have suggested that omega-3 fatty 
acids slow renal progression in patients with IgA nephropathy(156;263). 
Investigators from the Mayo clinic showed that treatment with omega-3 fatty 
acids reduced renal progression in patients with idiopathic IgA nephropathy 
and persistent proteinuria over a period of 2 years(156). The same 
investigators examined these patients over a mean follow-up of 6.4 years. 
Once again, they demonstrated reduced rates of renal progression in the fish 
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oil treated patients. However, levels of proteinuria did not differ between the 
two groups(263) and lipid parameters were not measured in these patients. 
Treatment with HMG Co reductase inhibitors has also been shown to reduce 
renal progression. A meta-analysis of 27 randomised controlled trials 
examined the effects of statins on change in eGFR (264). They showed that 
patients treated with statins had 1.2 ml/min per year slower decline in GFR 
than controls and a reduction in proteinuria. Thus, the combination of omega-
3 fatty acids and statins may reduce renal progression further particularly in a 
population with a high risk of progressive renal failure due to the presence of 
significant proteinuria. 
 
In this thesis, we have demonstrated that omega-3 fatty acids were well 
tolerated with beneficial effects on triglyceride-rich lipoproteins, postprandial 
lipaemia and HDL metabolism in patients with nephrotic range proteinuria. 
However, we have also shown that omega-3 fatty acids increase LDL-C in 
these patients which may offset these benefits.  
 
9.6 Further Work 
Further work is required to clarify certain areas which we have studied. We 
plan to carry out electron microscopy of the chylomicrons and VLDL1 in order 
to determine their size and whether they differ between the two populations. 
Kinetic studies examining chylomicron and VLDL1 metabolism in patients with 
nephrotic range proteinuria compared with controls may clarify the differences 
observed between our work and previously published work.  
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In terms of future treatment options, a study examining the effect of 
combination therapy with  HMG Co A reductase inhibitors together with  
omega-3 fatty acids  looking at their effect on lipids and lipoproteins, in 
particular,  postprandial lipaemia and their effect on LDL-C. Furthermore, their 
combined effect on renal progression and proteinuria would also be of interest 
in this population of patients. These further studies would allow us to 
effectively tailor lipid therapy in this high-risk population of patients. However, 
such large scale prospective studies examining CV or renal progression end-
points may prove difficult to undertake due to the low incidence of this 
condition and the large numbers that would be required to be recruited. 
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